ENANTIOSELECTIVE TOTAL SYNTHESIS OF DIKETOPIPERAZINE-CONTAINING NATURAL PRODUCTS: (–)-LANSAI B, (+)-NOCARDIOAZINES A AND B, AND (–)-ACETYLAPOARANOTIN

Thesis by

Haoxuan Wang

In Partial Fulfillment of the Requirements

for the Degree of

Doctor of Philosophy

CALIFORNIA INSTITUTE OF TECHNOLOGY

Pasadena, California

2015

(Defended on May 28th, 2015)

© 2015

Haoxuan Wang

All Rights Reserved

To My Mom, Dad and Grandma 献给我的家人

ACKOWNLEDGEMENTS

My greatest thank-you goes to my advisor Professor Sarah Reisman for her guidance and support. During the course of five years, I have grown up and learned so much, and none of which is possible without her. She is smart and passionate about chemistry, and she has always been encouraging and keeping me going, especially at the toughest time during my total synthesis projects. Besides interaction with her about chemistry, she is easily approachable and a fun person. I still remembered good time playing Frisbee with her, and I naively challenged her to a swimming race, which I lost unsurprisingly.

I am grateful for having Professor Brian Stoltz as my graduate committee chair, who is knowledgeable and super friendly. I would also like to thank Professor Jonas Peters and Professor Robert Grubbs for being in my committee. Even though we don't have a lot of chances to talk, I still benefits a lot from our conversation about chemistry and career.

I would also like to thank Dr. Scott Virgil for being a great person, who keeps the catalyst center running. He can fix all the instruments in the 3CS center, which is incredible. He is also full of knowledge, especially known for experimental tricks. I still recall that he helped me to grow an X-ray quality crystal from only 2 miligrams of material, which I thought was impossible. I would not be here if I had not the chance to join the wonderful summer research program in the laboratory of Professor Neil Garg. His enthusiasm about organic chemistry led me to apply for graduate school. Also, Dr. Alexander Huters taught me all the experimental techniques, which I still applied in lab nowadays.

The Reisman group is full of great people. I would like to thank all of them for making the lab a great place to work in. I would not successfully start my research without all the help from Dr. Roger Nani and Dr. Sergiy Levin. I am grateful for all the people that I collaborated with. It has been great fun working with them; I learn from them and we push the project forward together. The pyrroloindoline team includes Dr. Linsday Repka and Dr. Jane Ni, who developed the enantioselective (3 + 2) formal cycloaddition methodology. The ETP team includes Dr. Julian Codelli, Clint Regan and Dr. Paola Romanato. They established the early synthetic strategy. Also Amy McCarthy and Joe Qiu helped material throughput. The acutumine project was initiated by Dr. Raul Navarro and Dr. John Butler, which is now carried forward by Denise Grünenfelder.

Graduate school is not easy and I am lucky to know a few great friends who help me balance between inside and outside the lab. Dr. Geanna Min is a great bay mate and friend, who I can talk to about anything. Kangway Chuang is amazing, who is hardworking and incredibly smart. He has inspired me in many ways. Dr. Anton Dubrovskiy is the most positive person I've ever met and he could always cheer me up and let me know there is always a bright side in the life. I enjoyed the basketball playtime with Guy Edouard, Victor Mak, Kangway Chuang and John Butler. Cooking was more fun with Lauren Chapman. I am also lucky to friends that I can hangout with, including Dr. Chen Xu, Dr. Xiangyou Xing, Dr. Wenbo Liu, Dr. Bin Zhang, Dr. Na Hu, Dr. Qijun Hong, Fan Liu, Dr. Raul Navarro, Dr. Zack Wichens, Nick O'Connor, Nick Cowper, Alice Wong, Matthieu Richter, Julie Hofstra, Jordan Beck and Kelsey Poremba.

Finally, I would like to thank my parents and my grandparents for their continuing support of me. Without them, I would not have gotten this far.

ABSTRACT

Diketopiperazine (DKP) motif is found in a wide range of biologically active natural products. This work details our efforts toward two classes of DKP-containing natural products.

Class one features the pyrroloindoline structure, derived from tryptophans. Our group developed a highly enantioselective (3 + 2) formal cycloaddition between indoles and acrylates to provide pyrroloindoline products possessing three stereocenters. Utilizing this methodology, we accomplished asymmetric total synthesis of three natural products: (–)-lansai B, (+)-nocardioazines A and B. Total synthesis of (–)-lansai B was realized in six steps, and featured an amino acid dimerization strategy. The total synthesis of (+)-nocardioazine B was also successfully completed in ten steps. Challenges were met in approaching (+)-nocardioazine A, where a seemingly easy last-step epoxidization did not prove successful. After re-examining our synthetic strategy, an early-stage epoxidation strategy was pursued, which eventually yielded a nine-step total synthesis of (+)-nocardioazine A.

Class two is the epidithiodiketopiperazine (ETP) natural products, which possesses an additional episulfide bridge in the DKP core. With the goal of accessing ETPs with different peripheral structures for structure-activity relationship studies, a highly divergent route was successfully developed, which was showcased in the formal synthesis of (–)-emethallicin E and (–)-haematocin, and the first asymmetric synthesis of (–)-acetylapoaranotin.

TABLE OF CONTENTS

CHAPTER 1	1
Asymmetric Dearomatization via Cycloaddition Reaction	
1.1 INTRODUCTION	1
1.2 (2 + 1) CYCLOADDITION	2
1.2.1 Asymmetric Buchner Reaction	2
1.2.2 Cyclopropanation of Heterocyclic Compounds	4
1.3 (3 + 2) CYCLOADDITION	7
1.4 (3 + 3) CYCLOADDITION	12
1.5 (4 + 2) CYCLOADDITION	13
1.6 (4 + 3) CYCLOADDITION	21
1.7 CONCLUDING REMARKS	24
1.8 REFERENCES	25
CHAPTER 2	27
Direct Application of Enantioselective (3 + 2) Formal Cycloaddition: Concise Enantioselective Total Synthesis of (–)-Lansai B	
2.1 INTRODUCTION	27
2.1.1 Cyclization of Tryptophans Accessing C3-Substituted Pyrroloindoline Alkaloids via Transient Functional Groups	29
2.1.2 Direct Alkylation/Cyclization Strategies of Tryptophans	33
2.1.3 Enantioselective Synthesis of Pyrroloindolines	34
2.2 FIRST TOTAL SYNTHESIS OF (-)-LANSAI B	

	viii
2.3 LANSAI B-ETP DERIVATIVES PREPARATION	
2.4 CONCLUDING REMARKS	
2.5 EXPERIMENTAL SECTION	
2.5.1 Materials and Methods	
2.5.2 Preparative Procedures and Spectroscopic Data	
2.6 NOTES AND REFERENCES	
APPENDIX 1 Spectra Relevant to Chapter 2	65
CHAPTER 3 Enantioselective Total Synthesis of (+)-Nocardioazines A and B	96
3.1 INTRODUCTION	96
3.1 INTRODUCTION3.1.1 Proposed Biosynthesis of Nocardioazines A and B	96 97
 3.1 INTRODUCTION 3.1.1 Proposed Biosynthesis of Nocardioazines A and B 3.1.2 The Total Synthesis of (-)-Nocardioazine B by Ye 	96 97 98
 3.1 INTRODUCTION	
 3.1 INTRODUCTION 3.1.1 Proposed Biosynthesis of Nocardioazines A and B 3.1.2 The Total Synthesis of (-)-Nocardioazine B by Ye 3.1.3 Retrosynthetic Analysis 3.2 TOTAL SYNTHESIS OF (+)-NOCARDIOAZINE B 3.3 TOTAL SYNTHESIS OF (+)-NOCARDIOAZINE A 3.3.1 A Late-stage Epoxidation Strategy 3.3.2 An Early-stage Epoxide Installation Approach 3.4 CONCLUDING REMARKS 3.5 EXPERIMENTAL SECTION 3.5.1 Materials and Methods 	

	ix
3.6 NOTES AND REFERENCES	155
APPENDIX 2	156
Spectra Relevant to Chapter 3	
APPENDIX 3	215
X-Ray Crystallography Reports Relevant to Chapter 3	
CHAPTER 4	226
Enantioselective Total Synthesis of Epidithiodiketopiperazine	
Natural Product (–)-Acetylapoaranotin	
4.1 INTRODUCTION	226
4.1.1 Biological Origins	228
4.1.2 Previous Synthetic Efforts	229
4.2 SYNTHETIC EFFORTS TOWARD CYCLOHEXADIENOL ETP	233
4.2.1 Retrosynthetic Analysis	233
4.2.2 Preparation of Cyclohexadienol Fragment and Formal Synthesis of (–)- Emethallicin E and (–)-Haematocin	234
4.2.3 Attempts to Prepare (-)-Acetylapoaranotin	236
4.2.4 Total Synthesis of (-)-Acetylapoaranotin	237
4.3 CONCLUDING REMARKS	239
4.4 EXPERIMENTAL SECTION	239
4.4.1 Materials and Methods	239
4.4.2 Preparative Procedures and Spectroscopic Data	241
4.5 NOTES AND REFERENCES	271

APPENDIX 4	272
Spectra Relevant to Chapter 4	

ABOUT THE AUTHOR

333

Х

LIST OF ABBREVIATIONS

$[\alpha]_{D}$	angle of optical rotation of plane-polarized light
Å	angstrom(s)
Ac	acetyl
AIBN	azobisisobutyronitrile
Alloc	allyloxycarbonyl
APCI	atmospheric pressure chemical ionization
app	apparent
aq	aqueous
Ar	aryl group
At	benztriazolyl
atm	atmosphere(s)
B⁻	base
BARF	tetrakis(3,5-trifluoromethyl)phenylborate
Bn	benzyl
Boc	<i>tert</i> -butoxycarbonyl
BOP-Cl	bis(2-oxo-3-oxazolidinyl)phosphonic chloride
bp	boiling point
br	broad
Bu	butyl
Bu	iso-butyl
"Bu	butyl or <i>norm</i> -butyl
′Bu	<i>tert</i> -butyl

Bz	benzoyl
С	concentration of sample for measurement of optical rotation
¹³ C	carbon-13 isotope
¹⁴ C	carbon-14 isotope
/C	supported on activated carbon charcoal
°C	degrees Celcius
calc'd	calculated
CAN	ceric ammonium nitrate
Cbz	benzyloxycarbonyl
CCDC	Cambridge Crystallographic Data Centre
CDI	1,1'-carbonyldiimidazole
cf.	consult or compare to (Latin: confer)
cm^{-1}	wavenumber(s)
cod	1,5-cyclooctadiene
comp	complex
conc.	concentrated
Су	cyclohexyl
d	doublet
d	dextrorotatory
D	deuterium
dba	dibenzylideneacetone
DBU	1,8-diazabicyclo[5.4.0]undec-7-ene
DCC	N,N'-dicyclohexylcarbodiimide

DCE	1,2-dichloroethane
DCM	dichloromethane
DIAD	diisopropyl azodicarboxylate
DIPEA	N,N-diisopropylethylamine
DKP	diketopiperazine
DMAP	4-dimethylaminopyridine
DMBA	1,3-dimethylbarbituric acid
DME	1,2-dimethoxyethane
DMF	N,N-dimethylformamide
DMDO	dimethyldioxirane
DMSO	dimethylsulfoxide
DNA	deoxyribonucleic acid
dppb	1,4-bis(diphenylphosphino)butane
dr	diastereomeric ratio
ee	enantiomeric excess
E ⁺	electrophile
Ε	trans (entgegen) olefin geometry
EC ₅₀	median effective concentration (50%)
e.g.	for example (Latin: exempli gratia)
EI	electron impact
eq	equation
ESI	electrospray ionization
Et	ethyl

et al.	and others (Latin: et alii)
ETP	epidithiodiketopiperazine or epidpolythiodiketopiperazine
FAD	flavin adenine dinucleotide
g	gram(s)
G	guanine
GSH	glutathione
h	hour(s)
ΙΗ	proton
² H	deuterium
³ H	tritium
[H]	reduction
HATU	2-(7-aza-1 <i>H</i> -benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
Нсу	homocysteine
HG-II	Hoveyda-Grubbs catalyst 2nd generation
HMDS	hexamethyldisilamide or hexamethyldisilazide
h v	light
HPLC	high performance liquid chromatography
HRMS	high resolution mass spectrometry
Hz	hertz
IC ₅₀	half maximal inhibitory concentration (50%)
i.e.	that is (Latin: <i>id est</i>)
IR	infrared spectroscopy
J	coupling constant

k	rate constant
kcal	kilocalorie(s)
kg	kilogram(s)
L	liter or neutral ligand
l	levorotatory
LA	Lewis acid
LDA	lithium diisopropylamide
m	multiplet or meter(s)
М	molar or molecular ion
m	meta
μ	micro
<i>m</i> -CPBA	meta-chloroperbenzoic acid
Me	methyl
mg	milligram(s)
MHz	megahertz
MIC	minimum inhibitory concentration
min	minute(s)
mL	milliliter(s)
MM	mixed method
mol	mole(s)
mp	melting point
Ms	methanesulfonyl (mesyl)
MS	molecular seives

m/z	mass-to-charge ratio
Ν	normal or molar
NBS	N-bromosuccinimide
nm	nanometer(s)
NMP	N-methyl-2-pyrrolidone
NMR	nuclear magnetic resonance
NOE	nuclear Overhauser effect
NOESY	nuclear Overhauser enhancement spectroscopy
Nu ⁻	nucleophile
0	ortho
[0]	oxidation
р	para
PCC	pyridinium chlorochromate
PDC	pyridinium dichromate
Ph	phenyl
рН	hydrogen ion concentration in aqueous solution
p <i>K</i> _a	acid dissociation constant
PMB	para-methoxybenzyl
PMP	para-methoxyphenyl
ppm	parts per million
PPTS	pyridinium para-toluenesulfonate
Pr	propyl
ⁱ Pr	isopropyl

"Pr	propyl or <i>norm</i> -propyl
psi	pounds per square inch
PyBroP	bromotripyrrolidinophosphonium hexafluorophosphate
pyr	pyridine
q	quartet
R	alkyl group
R	rectus
RCM	ring-closing metathesis
ref	reference
R_{f}	retention factor
rt	room temperature
S	singlet or seconds
S	sinister
SAM	S-adenosyl methionine
sat.	saturated
Su	succinimide
t	triplet
TBAF	tetra- <i>n</i> -butylammonium fluoride
TBAI	tetra- <i>n</i> -butylammonium iodide
TBS	tert-butyldimethylsilyl
temp	temperature
Teoc	trimethylsilylethoxycarbonyl
TES	triethylsilyl

Tf	trifluoromethanesulfonyl
TFA	trifluoroacetic acid
TFAA	trifluoroacetic anhydride
TFE	2,2,2-trifluoroethanol
THF	tetrahydrofuran
TIPS	triisopropylsilyl
TLC	thin layer chromatography
TMEDA	<i>N</i> , <i>N</i> , <i>N</i> ', <i>N</i> '-tetramethylethylenediamine
TMS	trimethylsilyl
TOF	time-of-flight
tol	tolyl
TPP	tetraphenylporphyrin
Ts	para-toluenesulfonyl (tosyl)
UV	ultraviolet
w/v	weight per volume
v/v	volume per volume
Х	anionic ligand or halide
Ζ	cis (zusammen) olefin geometry

Chapter 1

Asymmetric Dearomatization via Cycloaddition Reaction⁺

1.1 INTRODUCTION

The ability to rapidly generate structural complexity remains one of the foremost challenges in synthetic organic chemistry. As such, cycloaddition reactions are highly valued for their ability to efficiently construct complex architectures in a single step. In a typical reaction, two or more unsaturated substrates are joined to form a cyclic product in which there is a net reduction of the bond multiplicity.¹ The strong enthalpic benefit of exchanging π -bonds or non-bonded electron pairs for σ -bonds is the predominant driving force for these transformations, and it typically compensates for the unfavorable entropic cost of a highly ordered transition state. Catalytic asymmetric, dearomative cycloaddition reactions are an important subclass of these transformations, as they provide rapid access to a variety of cyclic or polycyclic scaffolds in a single step and often in high

[†] Part of this chapter is submitted as a book chapter and co-written with Dr. Madeleine E. Kieffer (a graduate student in the Reisman laboratory).

enantiomeric excess. Due in part to the potential pharmaceutical properties of heterocyclic compounds, much of the research in this field has focused on the reactions of furans, pyrroles, indoles and other heteroaromatic compounds using transition metals, Lewis acids, Brønsted acids and organo-catalysts. This chapter will cover recent advances in catalytic, asymmetric dearomatization reactions that proceed by cycloaddition.

1.2 (2 + 1) CYCLOADDITION

1.2.1 Asymmetric Büchner Reaction

One of the most ubiquitous aromatic motifs in organic chemistry is the benzene ring. Despite its high stability, which renders it challenging to dearomatize via cycloaddition, Büchner and co-workers discovered the cyclopropanation of benzene in $1896.^2$ They reported that at elevated temperatures in benzene, ethyldiazoacetate underwent thermolytic dediazotization and subsequent cyclopropanation of solvent to afford a norcaradiene product. Doering and co-workers later used nuclear magnetic resonance spectroscopy to determine that the products of the Büchner reaction were actually a mixture of cycloheptatrienes, which result from facile 6π -disrotatory ring opening of the norcaradiene followed by a series of [1,5]-hydride shift events.³ Modern efforts to further develop this reaction and render it enantioselective have focused on transition metal-catalyzed intramolecular variants.



Scheme 1.1. Early investigations of the asymmetric Büchner reaction

In 1990, McKervey and co-workers reported the first catalytic, asymmetric Büchner reaction.⁴ Subjection of α -diazoketone **1** to catalytic rhodium (II) carboxylate **4** provided cycloheptatriene **3** in 80% yield and 33% ee, presumably via 6π -disrotatory electrocyclic ring opening of nocaradiene product **2** (Scheme 1.1a). In a similar system, Maguire and co-workers discovered that the complex generated from CuPF₆ and bis(oxazoline) **8** catalyzed the cyclopropanation of α -diazoketone **5** in improved enantioselectivity (up to 95% ee, Scheme 1.1b).⁵ Unfortunately, the selectivity of this transformation depends heavily on the substrate substitution pattern, and does not provide a general solution for arene cyclopropantion. In 2009, follow-up work by the same group found that addition of NaBARF further improves the ee,⁶ which they suggest reveals a beneficial role of the sodium cation⁷ (Scheme 1.1c). However, more detailed studies are required to elucidate the origin of this effect.

Scheme 1.2. Asymmetric Büchner reactions in naphthyl and diaryl systems



Doyle and coworkers found that $Rh_2(4S-IBAZ)_4$ catalyst (14) could promote the intramolecular cyclopropanation of naphthyl substrate 12 in 80% yield and 81% ee (Scheme 1.2a).⁸ Recently, the same group also disclosed the desymmetrization of diaryl α -diazoacetates 15 using catalytic $Rh_2[(S)-TFPTTL]_4$ (17, Scheme 1.2b).⁹ Good to excellent enantioselectivities and high diastereoselectivity for the *trans* products were observed using *ortho*-methyl or *para*-halogenated arenes.

1.2.2 Cyclopropanation of Heterocyclic Compounds

Metal catalyzed carbenoid cyclopropanation has also been explored in heterocyclic arenes. Reiser and co-workers reported Cu/chiral bis(oxazoline)-catalyzed (2 + 1) enantioselective cycloadditions between acceptor-substituted carbenoids (diazoacetate **19** and **23**) and furans **18** or *N*-Boc-pyrrole **22** (Scheme 1.3).¹⁰ While unsubstituted furan **18a** only provided moderate ee (<50% ee, <20% yield), good enantioselectivity (91% ee) and exclusive *exo* selectivities were observed when placing a

Scheme 1.3. Copper-catalyzed asymmetric cyclopropanation of heteroarenes with acceptor-substituted carbenoids



methyl ester at the C2 position (**18b**, Scheme 1.3a). This superior selectivity was proposed to derive from a secondary H-bonding interaction between the methyl ester and the side chain of the chiral ligand. Interestingly, the opposite facial selectivity, in moderate ee, was observed when *N*-Boc-pyrrole **22** was employed (Scheme 1.3b). Boysen and co-workers were able to further extend this cyclopropanation to *N*-acyl indole scaffolds (**26**, Scheme 1.3c).¹¹ Using novel carbohydrate-derived bis(oxazoline) ligand **28**, *N*-Boc-3-methylindole **26** undergoes smooth cyclopropanation to give *exo* indoline **27** in 96% ee, while moderate enantioselectivities were observed in other substrates. This methodology was successfully applied to the total synthesis of (–)-desoxyeseroline.

Cyclopropanation between donor-acceptor-substituted carbenoids and heterocycles has also been reported. Davies and co-workers extensively studied the **Scheme 1.4.** Rhodium-catalyzed asymmetric cyclopropanation of heteroarenes with donor-acceptor-substituted carbenoids



ability and propensity of diazoacetate **30** to cyclopropanate a variety of aromatic heterocycles (Scheme 1.4).¹² In contrast to the Cu-catalyzed reactions of acceptorsubstituted carbenoids discussed previously, double cyclopropanation of the heteroarenes was observed with these carbenoids (Scheme 1.4b). The monocyclopropanation product could be only isolated as the major product when an excess of the heterocyclic starting material was employed (Scheme 1.4a). Rh₂(*S*-DOSP)₄(**32**) was identified as the catalyst of choice to promote enantioselective cyclopropanation of furan, *N*-Boc-pyrrole, and 3methylbenzofuran. Interestingly, double cyclopropanation on the benzenoid ring was observed with substituted indole and 2-methylbenzofuran substrates (**34a–34d**), while unsubstituted *N*-Boc indole was less reactive and resulted in carbene dimerization.

1.3 (3 + 2) CYCLOADDITION

The unique chemistry of indoles, which possess reactivity analogous to enamines but are hydrolytically stable, has resulted in their extensive use in the development of cycloaddition and formal cycloaddition reactions. Although these types of transformations have been known for decades, it was only recently that catalytic, asymmetric variants were developed.





In 2009, Davies and co-workers reported that treatment of indoles with vinyl diazoacetate **38** in the presence of rhodium catalyst **32** results in formal (3 + 2)

cycloaddition to provide fused tricyclic products (Scheme 1.5a).¹³ Interestingly, the substitution pattern of the indole starting material greatly affects the product of this reaction. Whereas 1,3-dimethylindole (**36**) gives rise to indoline **40**, the isomeric 1,2-dimethylindole (**37**) delivers indoline **42**; both reactions occur with good to excellent diastereo- and enantioselectivity. The authors rationalize these divergent reactivities by the steric encumberance of the C2- or C3-methyl substituent, which forces the initial nucleophilic attack to occur at the unsubstituted position of the indole. The same group later disclosed that in the presence of rhodium catalyst **48**, 1-phenylsulfonyl triazoles **44** can be used to generate α -iminocarbenoids *in situ*, which react with 1,3-dimethyl indoles (**43**) to furnish pyrroloindolines (**47**) in good yields and high enantioselectivities (Scheme 1.5b).¹⁴ In the contrast to the zwitterionic mechanism proposed in the previous reaction, the authors suggest that this reaction might proceed through initial cyclopropanation to form **45**, followed by cyclopropane opening and iminium trapping to afford the formal (3 + 2) cycloaddition product **47**.

Hashimoto and co-workers have investigated the Rh-catalyzed (3 + 2) cycloaddition reactions between *N*-methylindoles and 2-diazo-3,6-diketoesters **49** to prepare tetracyclic products (**51**), presumably via Rh-bound carbonyl ylide **50** (Scheme 1.6).¹⁵ Polychlorinated dirhodium complex **52** was found to catalyze the formation of *exo*-tetracycle **51** in good yields and high enantioselectivities. Whereas the reaction tolerates substitution of the indole backbone, use of the analogous 2-diazo-3,5-diketoesters results in significantly lower enantioinduction. This is the only report of an asymmetric dearomatization reaction that proceeds by cycloaddition with a carbonyl ylide.

Scheme 1.6. Rhodium-catalyzed (3 + 2) cycloaddition between indoles and diazodiketoesters



Scheme 1.7. Asymmetric (3 + 2) cycloaddition of indoles and donor-acceptor cyclopropanes



Donor-acceptor cyclopropanes have also been explored as dipoles in asymmetric (3 + 2) cycloaddition reactions (Scheme 1.7). Tang and co-workers found that these substrates participate in highly diastereo- and enantioseletive annulations of indoles when chiral Cu(II)-BOX complexes are used as catalysts.¹⁶ When di-benzyl linked BOX ligand **56** is employed, a variety of substituted indoles (**53**) and aryl-substituted cyclopropanes (**54**) react to produce enantioenriched indoline products (**55**). Whereas cyclopropanes bearing electron-rich arenes react through a mechanism in which both enantiomers converge to a single diastereomer of highly enantioenriched product (e.g. **57**),

cyclopropanes bearing less electron-rich arenes undergo kinetic resolution, with only the (R)-configured cyclopropane proceeding to product (e.g. **58**). This methodology was successfully applied to prepare the core of the natural product borreverine (**59**).

Scheme 1.8. Formal enantioselective (3 + 2) cycloadditions of indoles



Reisman and coworkers developed a formal (3 + 2) cycloaddition between methyl 2-trifluoroacetamidoacrylate (**61**, Scheme 1.8a) and 3-substituted indoles (**60**).^{17,18} Although the reaction requires stoichiometric SnCl₄, the chiral diol (*R*)-3,3'-dichloro-BINOL (**65**) is employed catalytically. A variety of indole substrates undergo cycloaddition with acrylate **61** to provide highly functionalized pyrroloindolines (**62**) in excellent enantioselectivities, favoring the *exo* diastereomer. Mechanistically, the reaction is proposed to proceed through cooperative Lewis acid–Brønsted acid activation. Activation of acrylate **61** by SnCl₄ results in nucleophilic attack of the indole to generate a tin enolate (63). A catalyst-controlled protonation of the enolate by $SnCl_4$ ·65 followed by cyclization affords the enantioenriched pyrroloindoline (62) in good yield with high diastereoselection and excellent ee.

Quinone monoimines (**67**, Scheme 1.8b) have also been found to engage in asymmetric cycloaddition reactions with indoles. Zhang and co-workers reported that chiral phosphoric acid **69** catalyzes the conjugate addition of indoles (**66**) to quinone monoimine **67**.¹⁹ Subsequent rearomatization of enamide intermediate **70** followed by phenol cyclization furnishes benzofuroindoline products (**68**). This method tolerates a wide range of substitution on the indoles and generally proceeds with excellent enantioselectivities.

Scheme 1.9. Formal enantioselective (3 + 2) cycloadditions between 3-nitroindoles and iminoesters



The aforementioned (3 + 2) cycloaddition reactions generally rely on the intrinsic nucleophilicity of the C3 site of indole to initiate reactivity. Alternatively, Arai and coworkers discovered a cascade reaction between 3-nitroindoles and iminoesters that proceeds by initial Cu-catalyzed attack of an iminoenolate at C2 of the indole to generate nitronate **76** (Scheme 1.9).²⁰ Subsequent intramolecular nitro-Mannich addition provides indoline **74** in a highly enantio- and diastereoselective fashion. The authors suggest that the presence of electron-withdrawing substituents at the N1 and C3 positions of indole are required to render these substrates sufficiently electrophilic at C2.

1.4 (3 + 3) CYCLOADDITION

Few examples of asymmetric dearomatization via (3 + 3) cycloaddition reactions have been reported in the literature. In 2013, Tang and co-workers reported a highly enantioselective cycloaddition between isoquinoline-derived dipole **77** and donoracceptor cyclopropanes **78** (Scheme 1.10a).²¹ Lewis acid activation of cyclopropane **78**, presumably through bidentate coordination to chiral Ni(II)-TOX catalyst (generated from **80**), results in nucleophilic attack by azomethine imine **77**. Control experiments reveal that the reaction proceeds by a kinetic resolution of the cyclopropane, in which the (*S*)enantiomer reacts more quickly. In order to obtain high yields of product, two equivalents of cyclopropane **78** are employed under standard conditions.

The Doyle group developed a highly enantioselective formal (3 + 3) cycloaddition between isoquinolinium or pyridinium methylides (**81**) and enol diazoacetate **82** (Scheme 1.10b).²² Chiral dirhodium complex **84**, in conjunction with enol diazoacetate **82**, is proposed to form a chiral metallo-1,3-dipole, which can then undergo (3 + 3)cycloaddition to form a variety of quinolizidines (**82**) with good enantioinduction. Recently, the Guo group demonstrated an enantioselective (3 + 3) cycloaddition reaction between phthalazinium dicyanomethanides (**85**) and iminoesters (**86**), catalyzed by a Cu(I)/[†]Pr-Phosferrox complex (**88**, Scheme 1.10c).²³ The authors propose that iminoester **86** is activated by the chiral Cu(I) complex to generate a metallo-1,3-dipole, which undergoes cycloaddition with phthalazinium dicyanomethanide **85**. This mild method **Scheme 1.10.** Catalytic, asymmetric (3 + 3) dearomatizing cycloaddition reactions



tolerates a wide range of aryl groups on the iminoester, as well as cinnamyl and isobutyl groups, and provides tricyclic compounds (87) in high yields with excellent diastereoand enantioselectivities.

1.5 (4 + 2) CYCLOADDITION

Despite the large number of catalytic asymmetric Diels–Alder reactions developed to date, relatively few examples involve dearomatization. In 2008, Bernardi, Ricci, and co-workers reported the first catalytic, asymmetric Diels–Alder reaction of 3-vinyl indoles (**89**) with assorted dienophiles (e.g. **90**, Scheme 1.11a).²⁴ Utilizing hydrogen-bonding catalyst **92**, a variety of tetrahydrocarbazole products (**91**) could be formed in good yields and excellent enantioselectivities. The authors hypothesize that the reaction proceeds through a cooperative mechanism involving Brønsted base

activation of the 3-vinyl indole and hydrogen bond activation of the dieneophile. When a mixture of (E)- and (Z)-3-(prop-1-en-1-yl)-1*H*-indole is subjected to the reaction conditions, only the *E*-diene proceeds to product; the *Z*-diene, in which the required *S*-*cis* conformation is disfavored, is recovered unchanged. These findings provide empirical support for a concerted mechanism.

Scheme 1.11. Organocatalytic asymmetric Diels–Alder reactions of 3-vinyl indoles



A similar approach was successfully employed by Barbas and co-workers (Scheme 1.11b).²⁵ Bisthiourea **96** was found to catalyze an exceedingly mild Diels–Alder reaction between 3-vinyl indoles (**93**) and 3-methyleneindolinones (**94**) for the direct synthesis of complex carbazolespirooxindoles (**95**). The products were isolated in nearly quantitative yield and with excellent enantio- and diastereoselection.

In 2009, MacMillan and co-workers disclosed a nine-step total synthesis of (+)minfiensine (103, Scheme 1.12).²⁶ Key to their synthesis was the development of an **Scheme 1.12.** Organocatalytic asymmetric Diels–Alder/cyclization cascade reaction



organocatalytic Diels-Alder/cyclization cascade reaction to construct the pyrroloindoline core of the molecule. The reaction is proposed to proceed via condensation of organocatalyst **100** with propynal (**98**) to generate an activated iminium ion, which enables an asymmetric, *endo*-selective Diels–Alder cycloaddition with diene **97** to give **101** and set the stereochemistry of the all-carbon quaternary center. Isomerization to iminium **102** followed by cyclization of the pendant amine and hydrolytic release of the catalyst provides the pyrroloindoline core. A reductive quench reduces the aldehyde to alcohol **99**, which can be further advanced to (+)-minfiensine (**103**) in only five steps. Using a similar cascade sequence, MacMillan and co-workers were also able to synthesize vincorine (**104**) in only nine steps, setting three of the four stereogenic centers in a single cascade reaction.²⁷

This catalytic asymmetric dearomative cascade strategy was further applied to members of the strychnos, aspidosperma, and kopsia alkaloids.²⁸ In the key cascade reaction, the asymmetric (4 + 2) is followed by β -elimination of methyl selenide and

Scheme 1.13. Organocatalytic asymmetric Diels–Alder/elimination/conjugate addition cascade reaction



conjugate addition of the pendant amine to access tetracycle **107** (Scheme 1.13). From this common intermediate, MacMillan and co-workers successfully synthesized six structurally distinct alkaloid natural products. An analogous sequence employing an ynone instead of an ynal was used to produce (–)-minovincine.²⁹

You and co-workers have developed formal (4 + 2) cycloadditions to prepare enantioenriched polycycles, which proceed by a tandem Michael addition/Mannich reaction sequence. In 2011, they reported that cinchona alkaloid **111** catalyzes the intramolecular, dearomative cycloaddition of indolyl enones (**108**) to provide tricycles (**110**) bearing three stereogenic centers (Scheme 1.14a).³⁰ The reaction exhibits a broad substrate scope and delivers products under mild conditions and in excellent enantioselectivities. Using similar conditions, they subsequently developed an intermolecular formal (4 + 2) cycloaddition between 2,3-disubstituted indoles (**112**) and methylvinylketone (**113**, Scheme 1.14b).³¹ The tetrahydrocarbazole products **114** are produced in good yields and excellent selectivities. **Scheme 1.14.** Organocatalytic asymmetric Michael addition/Mannich cyclization cascade reactions



In 2014, Chen and co-workers also utilized alkaloid **111** to catalyze (4 + 2) cycloaddition reactions of heteroaryl enones (**115**, Scheme 1.15).³² The reaction proceeds through the *in situ* generation of a trienamine species, which is proposed to result in a HOMO-activated diene. Subsequent selective (4 + 2) cycloaddition with electron deficient dienophiles delivers the observed product (**117**, **119**). C2- and C3-linked heteroaryl enones (**115** and **118**, respectively) are competent in the transformation; however, the C2-linked substrates exhibit a broader substrate scope. The polycyclic products are isolated in good yields and selectivities.





Organocatalysis has also been utilized to effect dearomative Diels–Alder reactions of anthracenylacetaldehydes (Scheme 1.16, **120** and **124**). In 2012, Jørgenson and co-workers reported the first asymmetric example of this transformation, which like the previously discussed reaction developed by Chen, utilizes a HOMO-raising strategy.³³ Good selectivity is achieved with bifunctional catalyst **123**, which is proposed to operate through a cooperative mechanism involving enamine formation with the aldehyde (**120**) and H-bond activation of the nitroalkene (**121**). A variety of (4 + 2) adducts are isolated in good yields and excellent enantioselectivities. Follow-up studies identified C2-symmetric catalyst **126**, which enabled the use of maleimides as dienophiles (**124**).³⁴ With this symmetric dienophile, the use of a bifunctional catalyst did not provide improved results.

Scheme 1.16. Organocatalytic dearomative Diels-Alder reactions with anthracenylacetaldehydes



As an alternative to organocatalysis, Nishida and co-workers disclosed the use of a novel, chiral holmium(III) complex to catalyze an enantioselective Diels–Alder reaction of 3-enoxy-indoles (**127**, Scheme 1.17).³⁵ Using only 5 mol % of Ho(NTf₂)₃·**130**, carbazole products (**129**) are isolated in excellent yields and with good enantioinduction.


Scheme 1.17. Holmium(III)-catalyzed enantioselective Diels-Alder reactions

Additionally, the silylenol ether functionality was found to preclude deleterious air oxidation and 1,3-hydride shifts that can result in rearomatization of the indole ring and loss of chiral information. The silylenol ether products (**129**) could be further functionalized to afford polycycles with four contiguous stereocenters in only two steps.

Bandini and co-workers employed a chiral gold catalyst to effect the dearomatization of indoles through an intramolecular, step-wise (4 + 2) cycloaddition (Scheme 1.18).³⁶ Subjection of alkynyl indole precursors (131) to chiral dinuclear gold catalyst (AuBF₄)₂·134 resulted in 5-*exo*-dig hydroindolination of the alkyne followed by iminium trapping to afford tetracyclic products (133) in good yields and moderate selectivities. When the corresponding tryptamine-dervied substrates were employed, 7-*endo*-dig selectivity was observed.





Furans have also been found to undergo catalytic asymmetric (4 + 2) cycloaddition reactions. In 2012, Shibatomi and co-workers utilized a Lewis acid-

activated oxazaborolidine catalyst (**138**, Scheme 1.19) to promote an asymmetric Diels– Alder cycloaddition between furans (**136**) and β -trifluoromethylacrylates.³⁷ The fluorinecontaining bicycles **137** were produced in good yield with moderate diastereoselection and excellent enantioselection. Substituents are tolerated at the C2- and C3-position of the furan; β -difluoromethylacrylates are also suitable dienophiles. The cycloaddition products could be further elaborated to fluorinated bioactive compounds.

Scheme 1.19. Asymmetric Diels-Alder cycloaddition reactions of furans and β -trifluoromethylacrylates



Recently, Larinov and co-workers disclosed the first example of a catalytic, enantioselective (4 + 2) annulation with highly reactive nitrosoalkenes (Scheme 1.20).³⁸ These alkenes were generated in-situ from 2-chlorooxime precursors (**140**), which then underwent Cu-catalyzed, asymmetric, inverse demand hetero-Diels–Alder reactions with 1,3-disubstituted indoles (**139**). The use of stoichiometric silver salts enabled catalysis through the sequestration of chloride ion. These (4 + 2) cycloadditions provide structurally unique heterocycles (**141**) in highly enantioenriched form.

Scheme 1.20. Enantioselective (4 + 2) cycloaddition reactions of indoles and nitrosoalkenes



A similar reaction was disclosed by Wang and co-workers in which copper catalyzes the asymmetric hetero-Diels–Alder reaction between indoles and α -halogenated hydrazones (Scheme 1.21).³⁹ In analogy to the generation of nitrosoalkenes from α -halooximes, it is proposed that coordination of hydrazone **143** to the chiral catalyst **145** followed by base-induced elimination of chloride generates the catalyst-bound azoalkene *in situ*, which undergoes (4 + 2) cycloaddition with a variety of indoles to furnish the 2,3-fused indoline products (**144**) in excellent yields and selectivities. The selectivities observed in this transformation are remarkable given the extremely facile un-catalyzed background reaction.

Scheme 1.21. Enantioselective (4 + 2) cycloaddition reactions of indoles and α -halogenated hydrazones



1.6 (4 + 3) CYCLOADDITION

In 1996, Davies and co-workers disclosed their efforts to develop a Rh-catalyzed asymmetric formal (4 + 3) cycloaddition between furan (146) and vinyldiazoester 147.⁴⁰ They hypothesized this reaction could proceed via an initial enantioselective cyclopropanation followed by a Cope rearrangement to give bicyclic product 149 (Scheme 1.22). Using Rh₂(*S*-TBSP)₄ (152) as the catalyst, they were able to isolate the desired product in moderate yields and 80% ee. Although these conditions were limited in scope, they identified a more general solution through the use of chiral esters. Similar

reactivity and selectivity issues were encountered when employing pyrroles, providing tropane products in low enantiomeric excess (Scheme 1.22b).⁴¹

Scheme 1.22. Preliminary studies of asymmetric Rhodium-catalyzed (4 + 3) cycloaddition reactions of heteroarenes and vinyldiazoesters



Ten years later, Davies and co-workers reported that the use of 2-(siloxy)vinyldiazoacetate **154** as a Rh-carbenoid precursor enables highly enantioselective formal (4 + 3) cycloaddition reactions of *N*-Boc-pyrroles (**153**, Scheme 1.23). The best selectivities were obtained using $Rh_2(S-PTAD)_4$ (**48**) as the catalyst.⁴² This catalyst system was compatible with a variety of substituted *N*-Boc-pyrroles, providing functionalized tropanes (**155**) in good yields and excellent enantioselectivities.

Scheme 1.23. Asymmetric Rh-catalyzed (4 + 3) cycloaddition reactions of pyrroles and siloxyvinyldiazoacetates



Inspired by MacMillan's work on secondary amine-catalyzed (4 + 2) cycloadditions, Harmata and co-workers described the first organocatalytic asymmetric (4 + 3) cycloaddition (Scheme 1.24a).⁴³ Imidazolidinone **160** was found to catalyze the cycloaddition between disubstituted furans (e.g. **157**) and siloxydienals (e.g. **156**) to produce oxa-bicycl[3.2.1]octanones (e.g. **158**) in modest to good yields and enantioselectivities. The major side products of this reaction were alkylated furan derivatives, suggesting a step-wise cycloaddition mechanism. This methodology was subsequently employed by Lin and co-workers in their synthesis of core of englerin A (**164**).⁴⁴ Although the regioselectivity of the cycloaddition with differentially-substituted furan **162** was poor, providing a mixture of **163a** and **163b**, the desired product was produced in promising enantioselectivity (Scheme 1.24b).

Scheme 1.24. Organocatalytic (4 + 3) cycloaddition reactions of furans



In 2004, a chiral Lewis acid-catalyzed (4 + 3) cycloaddition between furans and alleneamides was reported by Hsung and co-workers (Scheme 1.25).⁴⁵ The reaction occurs by *in situ* oxidative generation of a nitrogen-stabilized oxyallyl cation from

alleneamide **165**. Following (4 + 3) cycloaddition with furan **166**, the tricyclic products were isolated in moderate to good yields and enantioselectivities. The level of regioselectivity for the *syn* versus *anti* isomer of the product varied, and depended on the substitution pattern. It is proposed that enantioinduction occurs via coordination of the oxyallyl cation to Cu(OTf)₂·**168**, providing facial differentiation for the incoming diene. The scope of this reaction is complementary to that of Harmata (see above), as 2,5*un*substituted furans provide the best yields and selectivities.





1.7 CONCLUDING REMARKS

Over the past three decades, significant progress has been made in the development of new, catalytic asymmetric cyloaddition reactions of arenes. Yet, most of the progress to date has focused on the cycloadditions of heteroarenes, and indoles in particular. These systems benefit from a lower aromatic stabilization energy, relative to benzene, and thus a lower enthalpic cost to dearomatization. In essence, heteroarenes represent the "low hanging fruit." Moving forward, the discovery of novel modalities for enantioselective dearomatization reactions will be an important area of research, particularly as we seek to develop synthetically useful transformations for the dearomatization of non-hetero arenes.

Nevertheless, recently development of catalytic dearomatization transformation has introduced new and powerful synthetic tools to quickly assemble complex natural products. Chapters 2 and 3 will focus on the direct application of enantioselective formal (3 + 2) cycloaddition reaction developed in our lab (Scheme 1.8a) to access pyrroloindoline-containing diketopiperazine natural products.

1.8 REFERENCES

(1) Muller, P. Pure Appl. Chem. **1994**, 66, 1077.

(2) Büchner, E.; Curtius, T. Chem. Ber. 1896, 29, 106.

(3) von E. Doering, W.; Laber, G.; Vonderwahl, R.; Chamberlain, N. F.; Williams, R. B. J. Am. Chem. Soc. 1956, 78, 5448.

(4) Kennedy, M.; McKervey, M. A.; Maguire, A. R.; Roos, G. H. P. J. Chem. Soc., Chem. Commun. 1990, 361.

(5) O'Keeffe, S.; Harrington, F.; Maguire, A. R. Synlett 2007, 15, 2367.

(6) O'Neill, S.; O'Keeffe, S.; Harrington, F.; Maguire, A. R. *Synlett* **2009**, *14*, 2312.

(7) Slattery, C. N.; Clarke, L.-A.; O'Neill, S.; Ring, A.; Ford, A.; Maguire, A. R. *Synlett* **2012**, *23*, 765.

(8) P. Doyle, M.; G. Ene, D.; C. Forbes, D.; H. Pillow, T. Chem. Commun. 1999, 1691.

(9) Liu, Y.; Deng, Y.; Zavalij, P. Y.; Liu, R.; Doyle, M. P. Chem. Commun. **2015**, *51*, 565.

(10) Schinnerl, M.; Böhm, C.; Seitz, M.; Reiser, O. *Tetrahedron: Asymmetry* **2003**, *14*, 765.

(11) Özüduru, G.; Schubach, T.; Boysen, M. M. K. Org. Lett. 2012, 14, 4990.

(12) Hedley, S. J.; Ventura, D. L.; Dominiak, P. M.; Nygren, C. L.; Davies, H. M. L. J. Org. Chem. 2006, 71, 5349.

(13) Lian, Y.; Davies, H. M. L. J. Am. Chem. Soc. 2010, 132, 440.

(14) Spangler, J. E.; Davies, H. M. L. J. Am. Chem. Soc. 2013, 135, 6802.

(15) Shimada, N.; Oohara, T.; Krishnamurthi, J.; Nambu, H.; Hashimoto, S. Org. Lett. 2011, 13, 6284.

(16) Xiong, H.; Xu, H.; Liao, S.; Xie, Z.; Tang, Y. J. Am. Chem. Soc. 2013, 135, 7851.

(17) Repka, L. M.; Ni, J.; Reisman, S. E. J. Am. Chem. Soc. 2010, 132, 14418.

(18) Ni, J.; Wang, H.; Reisman, S. E. *Tetrahedron* **2013**, *69*, 5622.

(19) Liao, L.; Shu, C.; Zhang, M.; Liao, Y.; Hu, X.; Zhang, Y.; Wu, Z.; Yuan, W.; Zhang, X. *Angew. Chem. Int. Ed.* **2014**, *53*, 10471.

(20) Awata, A.; Arai, T. Angew. Chem. Int. Ed. 2014, 53, 10462.

(21) Zhou, Y.-Y.; Li, J.; Ling, L.; Liao, S.-H.; Sun, X.-L.; Li, Y.-X.; Wang, L.-J.; Tang, Y. Angew. Chem. Int. Ed. 2013, 52, 1452.

(22) Xu, X.; Zavalij, P. Y.; Doyle, M. P. J. Am. Chem. Soc. 2013, 135, 12439.

(23) Yuan, C.; Liu, H.; Gao, Z.; Zhou, L.; Feng, Y.; Xiao, Y.; Guo, H. Org. Lett. 2015, 17, 26.

(24) Gioia, C.; Hauville, A.; Bernardi, L.; Fini, F.; Ricci, A. Angew. Chem. Int. Ed. 2008, 47, 9236.

(25) Tan, B.; Hernández-Torres, G.; Barbas, C. F. J. Am. Chem. Soc. 2011, 133, 12354.

(26) Jones, S. B.; Simmons, B.; MacMillan, D. W. C. J. Am. Chem. Soc. 2009, 131, 13606.

(27) Horning, B. D.; MacMillan, D. W. C. J. Am. Chem. Soc. 2013, 135, 6442.

(28) Jones, S. B.; Simmons, B.; Mastracchio, A.; MacMillan, D. W. C. *Nature* **2011**, *475*, 183.

(29) Laforteza, B. N.; Pickworth, M.; MacMillan, D. W. C. Angew. Chem. Int. Ed. 2013, 52, 11269.

(30) Cai, Q.; Zheng, C.; Zhang, J.-W.; You, S.-L. Angew. Chem. Int. Ed. 2011, 50, 8665.

(31) Cai, Q.; You, S.-L. Org. Lett. 2012, 14, 3040.

(32) Xiao, Y.-C.; Yue, C.-Z.; Chen, P.-Q.; Chen, Y.-C. Org. Lett. 2014, 16, 3208.

(33) Jiang, H.; Rodríguez-Escrich, C.; Johansen, T. K.; Davis, R. L.; Jørgensen, K. A. Angew. Chem. Int. Ed. 2012, 51, 10271.

(34) Rodríguez-Escrich, C.; Davis, R. L.; Jiang, H.; Stiller, J.; Johansen, T. K.; Jørgensen, K. A. *Chem. Eur. J.* **2013**, *19*, 2932.

(35) Harada, S.; Morikawa, T.; Nishida, A. Org. Lett. 2013, 15, 5314.

(36) Cera, G.; Chiarucci, M.; Mazzanti, A.; Mancinelli, M.; Bandini, M. Org. Lett. 2012, 14, 1350.

(37) Shibatomi, K.; Kobayashi, F.; Narayama, A.; Fujisawa, I.; Iwasa, S. Chem. Commun. 2012, 48, 413.

(38) Zhang, Y.; Stephens, D.; Hernandez, G.; Mendoza, R.; Larionov, O. V. *Chem. Eur. J.* **2012**, *18*, 16612.

(39) Tong, M.-C.; Chen, X.; Li, J.; Huang, R.; Tao, H.; Wang, C.-J. Angew. Chem. Int. Ed. 2014, 53, 4680.

(40) Davies, H. M. L.; Ahmed, G.; Churchill, M. R. J. Am. Chem. Soc. 1996, 118, 10774.

(41) Davies, H. M. L.; Matasi, J. J.; Hodges, L. M.; Huby, N. J. S.; Thornley, C.; Kong, N.; Houser, J. H. *J. Org. Chem.* **1997**, *62*, 1095.

(42) Reddy, R. P.; Davies, H. M. L. J. Am. Chem. Soc. 2007, 129, 10312.

(43) Harmata, M.; Ghosh, S. K.; Hong, X.; Wacharasindhu, S.; Kirchhoefer, P. *J. Am. Chem. Soc.* **2003**, *125*, 2058.

(44) Sun, B.-F.; Wang, C.-L.; Ding, R.; Xu, J.-Y.; Lin, G.-Q. *Tetrahedron Lett.* **2011**, *52*, 2155.

(45) Huang, J.; Hsung, R. P. J. Am. Chem. Soc. 2005, 127, 50.

Chapter 2

Direct Application of Enantioselective (3 + 2) Formal Cycloaddition: Concise Enantioselective Total Synthesis of (–)-Lansai B⁺

2.1 INTRODUCTION

Pyrroloindoline structure (highlighted in red, Figure 2.1) is found in a large number of natural products,¹ which possess broad spectra of pharmaceutical properties including anti-cancer², anti-bacterial activities³. Biosynthetically, pyrroloindolines are derived from tryptophan amino acid – one of the 23 proteinogenic ("protein-building") amino acids, which explains the prevalence of pyrroloindoline motif in nature.

More specifically, tryptophan derivative **176** was first engaged in a nucleophilic reaction with the electrophile (E, Scheme 2.1), where the resulting iminium ion could be quenched by the subsequent cyclization of the appendant *N*-atom to provide pyrroloindolines. In this process, the C11 stereocenter could affect the facial selectivity of the nucleophilic attack and give rise to two diastereomers: *exo*-**178** and *endo*-**178**.

[†] Part of this chapter was published as the following communications: Wang, H.; Reisman, S. E. *Angew. Chem. Int. Ed.* **2014**, *53*, 6206.



Figure 2.1. Representative pyrroloindoline-containing natural products

Scheme 2.1. Biosynthetic pathway of pyrroloindoline synthesis



In comparison, *endo* diastereomer **178**, where the C2' substituent (CO_2R^2) stands on the opposite face of the pyrrolidine ring with respect to the C3 substituent (E), is *thermodynamically more stable* due to the lesser torsional strain between C2' substituent and N' substituent $R^{3.4}$

Careful examination of the pyrroloindoline alkaloid family members reveals that most of them share the same C2' absolute configuration, originated from the natural abundant L-tryptophan; however, the C3 substituents can reside as either *endo* or *exo* relative stereochemistry. For example, lansai B (169) contains two *exo* pyrroloindolines, while pestalazine A (172) possesses an *endo* pyrroloindoline. This indicates the flexibility of facial selectivity of electrophiles E approaching indoles. Intriguingly, nocardioazine A (171) comprises the *rare* D-tryptophans (the original isolation paper proposed the opposite absolute configuration,⁵ which was corrected by this work) and the C3 stereocenters on two pyrroloindoline fragments have the opposite configurations within one molecule, which make them attractive synthetic targets.

Besides above-mentioned pyrroloindolines, there is another important subfamily of pyrroloindoline natural products lacking C2' substituent (for example, psychotrimine **174**, Figure 2.1), which have inspired numerous enantioselective methodologies to access those alkaloids⁶ and will not be discussed here.

2.1.1 Cyclization of Tryptophans Accessing C3-Substituted Pyrroloindoline Alkaloids via Transient Functional Groups

Within pyrroloindoline natural products, those possessing C3 *all-carbon quaternary* centers are most prevalent and present a unique challenge for organic synthesis. Inspired by the biosynthetic pathway, many groups have been investigating substrate-controlled *diastereoselective* strategies to access related pyrroloindoline natural products. Several indirect C3-alkylation methodologies have been developed by introducing a temporary functional handle (e.g. halide atom or selenium group) for the subsequent carbon substituent installation.

In 1994, Danishefsky reported the stereospecific formation of a phenyl selenium pyrroloindoline (Scheme 2.2).⁷ Starting from tryptophan derivative **179**, treatment with

N-phenylselenophthalimide in methylene chloride in the presence of catalytic *p*toluenesulfonic acid afforded **180** in 78% yield as a 9 : 1 mixture of diastereomers favoring the kinetic *exo* product. The C3 phenylselenium functional group in **180** was then activated by MeOTf to form a transient cation, which was quenched by the following nucleophilic attack of prenyl stannane **181** to form angular reverse prenyl product **182**. Pyrroloindoline **182** was then advanced via selective deprotection and peptide coupling to provide dipeptide **183**, where the Boc group was removed and the resulting secondary amine cyclized *in situ* to form natural product (–)-amauoramine (**170**).





De Lera and coworkers rationalized the *exo*-selectivity observed by Danishefsky by going through an azetidine intermediate (not shown) where *exo*-selective process has a significantly lower activation energy barrier.⁸ They were also able to extend this reactivity to C3-bromination using *N*-bromosuccinimide (NBS) as the electrophile. This methodology was applied in the total synthesis of (–)-nocardioazine B (*ent*-**187**) by the Ye group (Scheme 2.3).⁹ The brominated *exo*-pyrroloindoline **184** was successfully prepared by treating tryptophan *ent*-**179** with NBS and pyridinium *p*-toluenesulfonate

(PPTS). Subjection of C3-Br pyrroloindoline **184** to KO'Bu provided a highly strained cyclopropylazetoindoline **185**, which could undergo ring-opening by a variety of nucleophiles at the C3 position (as disclosed by Rainier and coworkers).¹⁰ In the case of *ent*-**187** synthesis, **185** was opened by trimethylaluminum to generate C3-Me *endo*-pyrroloindoline **186**, which was advanced to *ent*-**187** in a short sequence (detailed synthetic route will be discussed in Chapter 3).

Scheme 2.3. Total synthesis of (–)-nocardioazine B by Ye



Scheme 2.4. Total synthesis of (+)-naseseazine A by Movassaghi



In comparison to NBS-mediated *exo*-selective bromination of tryptophans, Movassaghi and coworkers developed a method to access brominated *endo*pyrroloindoline **189** by treating tryptophan-diketopiperazine **188** with pyridinium tribromide (Scheme 2.4).¹¹ Subsequent halide abstraction of **189** using silver hexafluoroantimonate (AgSbF₆), followed by the attack of various nucleophiles, furnished C3-substituted pyrroloindolines, where the addition of trifluoroborate **190** provided highly functionalized C3-arylated pyrroloindoline **191**. The removal of Cbz protecting groups accomplished the total synthesis of (+)-naseseazine A (**192**).

Scheme 2.5. Total synthesis of (+)-WIN 64821 by Movassaghi



Alternatively, instead of forming a cation at the C3 position via halide abstraction, Movassaghi and coworkers were able to generate a C3 radical by treating bromopyrroloindoline **193** with reducing reagent tris(triphenylphosphine)cobalt chloride (Scheme 2.5).¹² The resulting radical intermediate readily dimerized to form bis(pyrroloindoline) **194**, which was converted to (+)-WIN 64821 (**175**) upon deprotection.

2.1.2 Direct Alkylation/Cyclization Strategies of Tryptophans

Even though the preinstalling of a functional handle allows the further derivatization of the C3 position of pyrroloindolines, the two-step sequence is less ideal compared to a direct incorporation of the requisite functional group at the C3 position. Qin and coworkers were able to promote a diastereoselective cyclopropanation of tryptophan derivative **195** with diazoester **19** and catalytic amount of $Cu(OTf)_2$ (Scheme 2.6).^{13,14} The subsequent cyclopropane ring-opening and cyclization provided C3-substituted *exo*-pyrroloindoline **197**. However, this cyclopropanation strategy permits a narrow range of functional groups to be incorporated at C3 position, where it requires a 6-step sequence to convert **197** into the desired reverse prenylated **198** in order to prepare natural product (–)-ardeemin (**199**).

Scheme 2.6. Total synthesis of (-)-ardeemin by Qin



In 2013, Reisman and coworkers developed a novel diastereoselective C3arylation methodology utilizing Cu(I)/diimine ligand **204** to catalyze aryl-group transfer from iodonium salt (e.g. **201** Scheme 2.7) onto indoles (e.g. **200**), providing a variety of

C3-arylated pyrroloindolines.¹⁵ This methodology was applied to prepared highly functionalized pyrroloindoline **202**, which was subjected to deprotection of *N*-TFA group and the subsequent Larock indole synthesis to accomplish a concise five-step total synthesis of (+)-naseseazine B (**203**).

Scheme 2.7. Total synthesis of (+)-naseseazine B by Reisman



2.1.3 Enantioselective Synthesis of Pyrroloindolines

Apart from utilizing the intrinsic chiral information from tryptophan C11 stereocenter to gain access to both *exo* and *endo* products, a more challenging strategy of accessing pyrroloindoline lies in asymmetric catalysis, which could greatly broaden the substitution patterns of pyrroloindoline products suitable for total synthesis.

One indirect but practical approach involves conversion of the corresponding enantioenriched oxindole to the desired pyrroloindoline through cyclization events (Scheme 2.8).¹⁶ Oxindoles can be functionalized at the C3 position by enantioselective





alkylations⁶, which has been reported by several groups including Trost¹⁷, Barbas¹⁸, Stoltz¹⁹, and Luo²⁰. Most approaches utilize the intrinsic nucleophilicity of oxindoles originated from its enolate form. Luo and coworkers applied thiourea catalyst **208** to affect an asymmetric conjugate addition of 2-chloroacrylonitrile to afford product **209** in good enantioselectivities.²⁰ Alternatively, it is also possible to realize an umpolung strategy where the oxindoles become the electrophile. Stoltz and coworkers discovered

that oxindoles **211** could be converted to to an imine intermediate by eliminating HCl, which could be intercepted by chiral copper **213**–coordinated malonate nucleophile to generate the C3-all carbon quaternary center enantioselectively.¹⁹

Other ways of installing the C3 stereocenter are also investigated. In the total synthesis of (+)-gliocladin C (**173**), Overman and coworkers utilized the planar-chiral ferrocenyl pyridine **217** (initially disclosed by the Fu group)²¹ to catalyze an intramolecular acyl O-to-C migration of indolyl carbonate **216** to form chiral oxindole **218**.²² Recently, Macmillan and coworkers reported Cu/chiral Box catalyzed enantioselective direct C3-arylation of indole **219** with aryliodonium **220** to provide pyrroloindoline **222** with good selectivities.²³

Most of the aforementioned strategies require further functional group manipulations to close the third ring in order to access the pyrroloindoline structures. In the MacMillan's strategy, extra steps are required to install necessary functional groups at the C2' position for the diketopiperazine (DKP) motif construction, which are present in various pyrroloindoline-containing DKP natural products (e.g. **171**, **172**, Figure 2.1).

Scheme 2.9. Enantioselective pyrroloindoline synthesis by Reisman



As mentioned in Chapter 1, our group developed a new method to access *exo*-pyrroloindolines directly from C3-substituted indoles and 2-amidoacrylates using $SnCl_4$ and catalytic (*R*)-3,3'-dichloro-BINOL (**65**, Scheme 2.9).^{24,25} The reactions typically

proceed in good yields and high diastereo- and enantioselectivities. We anticipated that this formal (3 + 2) cycloaddition reaction could be utilized to rapidly and enantioselectively prepare natural product (–)-lansai B (**169**, Figure 2.1), which is composed of two *exo*-pyrroloindolines.

2.2 FIRST TOTAL SYNTHESIS OF (-)-LANSAI B

(–)-Lansai B (**169**) was isolated in 2008 from the endophytic microorganism *Streptomyces* sp. SUC1.³ It has been found to exhibit anti-inflammatory activity. Retrosynthetically, it is envisioned that the diketopiperazine core could be formed from two orthogonally protected amino acids **223** and **224** via initial peptide bond formation, deprotection, then cyclization by formation of the second peptide (Scheme 2.10). These *Scheme 2.10. Retrosynthetic analysis of (–)-lansai B*



two orthogonal molecules could be accessed from selective deprotection of corresponding pyrroloindoles. The required pyrroloindolines *exo*-**225** and *exo*-**226** could in turn be synthesized by formal (3 + 2) cycloaddition reactions of the corresponding indoles **227**/**228** and acrylate **61a**.

Our efforts commenced with bromoindole **229** (Scheme 2.11), which was prepared in one step from commercially available 5-bromo-3-methyl-1*H*-indole.²⁴ Suzuki–Miyaura coupling of indole **229** with prenylboronate **230** furnished reverse-prenylated indole **228** in good yield using modified conditions reported by Buchwald and coworkers.²⁶ Subjection of indole **228** and methyl 2-trifluoroacetamidoacrylate (**61a**) to our formal (3 + 2) cycloaddition conditions on 0.2 mmol scale provided pyrroloindoline *exo*-**226** in 84% yield and 92% ee. However, lower yields of **226** were obtained when the **Scheme 2.11.** Attempted orthogonal peptide coupling to access (–)-lansai B



reaction was conducted on preparatively useful scales (>1.0 mmol). It was hypothesized that trace water could help to turn over the chiral catalyst on small scale; thus, a survey of several protic additives revealed that addition of 0.4 equiv 2,6-dibromophenol to the reaction mixture improves the scalability of the reaction, providing **226** in 85% yield, 14:1 dr, and 92 % ee (major diastereomer). Cleavage of the TFA group with anhydrous HCl provided amine **224**.²⁷ Likewise, pyrroloindoline **225** could be prepared from 1,3-dimethyl indole **227** and acrylate **61a** in 79% yield, 12:1 dr, and 93% ee (major diastereomer). Treatment with LiOH chemoselectively hydrolyzed the methyl ester to give carboxylic acid **223**.

With orthogonally protected pyrroloindolines **223** and **224** in hand, completion of the synthesis required DKP formation. Unfortunately, amide **232** was not formed under a wide variety of peptide coupling conditions (Scheme 2.11);²⁸ instead, decomposition of acid **223** was observed. It is important to note that Danishefsky and coworkers successfully couple two orthogonally-protected *exo*-pyrroloindolines in their synthesis of amauromine (Scheme 2.12); however, in contrast to *N*-methyl pyrroloindoline **223** in our route, the carboxylic acid partner **233**, which contained *N-t*-butylcarbamate protecting group, was able to be successfully coupled to amine **234** in the Danishefsky system.²⁹







Scheme 2.13. Endgame of (–)-lansai B total synthesis via amino acid dimerization

Taken together, these findings reveal that the *N*-substitution of the *exo*pyrroloindoline significantly influences the stability of the activated ester under peptide coupling conditions. After considerable experimentation, it was determined that pyrroloindolines **225** and **226** could be converted to the corresponding amino acids **235** and **236** by TFA deprotection and saponification (Scheme 2.13). Treatment of an equimolar mixture of amino acids **235** and **236** with bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl) delivered (–)-lansai B (**169**) in 38% yield, matching all the spectra data of the isolation paper.³ Each of the two homodimers was also isolated in 20% yield. Despite the modest yield on the final coupling step, the natural product is accessible in only six steps (longest linear sequence) and 20% overall yield from commercially available materials.

2.3 LANSAI B-ETP DERIVATIVES PREPARATION

The diketopiperazine (DKP) motif is the parental structure that epipolythiodiketopiperazine (ETP) molecules are built up upon,³⁰ which requires the incooperation of polysulfide linkage between the two carbon centers (Figure 2.2). Due to

Figure 2.2. Representative ETP natural products



the redox activities of the sulfur-sulfur bond, ETP natural products, such as chaetocin A (**237**), present diverse therapeutic functions including virulence factors, and immunoimpressive and anti-cancer activities.³¹ Synthetically, ETP natural products are often prepared from the corresponding DKP compounds.³² Thus, access to the pyrroloindoline-containing DKP family of molecules could allow the preparation of unnatural ETP derivatives, which might possess biological importance. Having DKPs in hand including lansai B (**169**), we decided to investigate epidisulfide bridge formation to prepare related ETP compounds.

Our first attempt at thiolation utilized the conditions in Movassaghi's total synthesis of (+)-11,11'-dideoxyverticillin A (244, Scheme 2.14).³³ They were able to promote DKP C-H oxidations of bis(diketopiperazine) 241 using oxidant bispyridinium silver permanganate to provide tetraol 242. Subsequent deprotection and displacement of hydroxyl groups with hydrogen sulfide afforded free thiol 243, which could be converted to episulfide 244 upon oxidation with KI₃. Based on this methodology, DKP 245 was treated with Py_2AgMnO_4 (Scheme 2.15); however, no DKP C-H oxidation was observed (247), while *N*-methyl oxidation product 246 was isolated instead. The same conditions were then applied to pyrroloindoline 225. After optimization, *N*1-oxidation was effected in 61% yield, again with no C-H oxidation observed. Subsequent formamide cleavage

Scheme 2.14. C-H oxidation strategy for episulfide installation by Movassaghi



Scheme 2.15. Attempted C-H oxidation and resulting N-demethylation sequence



under mildly acidic conditions yielded *N*1-H product **249**, without affecting the TFA group. Similar transformation has been reported using PCC or PDC.^{13,34} However, this is the first report that Py_2AgMnO_4 can promote a similar oxidation reaction and this fruitful discovery allows a mild *N*-demethylation protocol for pyrroloindolines.

Encouraged by Nicolaou's protocol for DKP sulfenylation, we returned our efforts to disulfide bridge formation.³⁵ In accordance with Nicolaou's procedure, a solution of DKP (**169**, **245**, **250**, Scheme 2.16) in THF was treated with sodium

Scheme 2.16. Synthesis of lansai B-ETP derivatives



hexamethyldisilazide (NaHMDS), and the resulting solution was added to a mixture of NaHMDS and S_8 , after which additional NaHMDS was added. However, this gave low yield and messy mixture of products. After optimizing the reaction parameters, the yield was boosted up to 55% by performing at 0 °C and 0.01 M concentration. Thus, all three ETP derivatives of the lansai B analogues (**251a-c**) were synthesized.

In collaboration with City of Hope, biological evaluation of these compounds was conducted. Of the ETP derivatives screened, only homodimer ETP **251a** showed moderate activity against A2058 melanoma (3.8 μ M) and DU145 prostate (4.8 μ M) cell lines. Further biological examination is under way.

2.4 CONCLUDING REMARKS

In conclusion, the first asymmetric total synthesis of (–)-lansai B (169) has been accomplished in only six steps (longest linear sequence), featuring an enantioselective formal (3 + 2) cycloaddition to install all the requisite stereocenters. An unexpected challenge was encountered when applying the orthogonal peptide coupling strategy to access the DKP core of (–)-169, where the carboxylic acid coupling partner decomposes under different peptide coupling conditions. The recognition of the importance of *N*substituent on the acid coupling partner led to the development of an amino acid dimerization strategy to access diketopiperazines with good yields, even though it generates a statistical mixture of DKPs. This dimerization strategy might be applied to synthesis of related compounds.

During the attempts to prepare the ETP derivatives of lansai B (169), an unusual N-methyl oxidation rather than the desired C-H oxidation was observed when treating DKP with oxidant Py₂AgMnO₄. Even though it does not provide the targeted diol, this provides a mild method to demethylate N-Me pyrroloindolines, which is not trivial. Using Nicolaou's protocol, the successful preparation of ETP derivatives allowed the collaboration with City of Hope. Among these ETP compounds, homodimeric 251a showed promising anti-cancer properties.

The great efficiency of the formal (3 + 2) cycloaddition methodology in achieving a concise (–)-lansai B (169) synthesis encouraged us to study total synthesis of structurally more complex natural products: (+)-nocardioazines A (171) and B (187), which will be discussed in Chapter 3.

2.5 EXPERIMENTAL SECTION

2.5.1 Materials and Methods

Unless otherwise stated, reactions were performed under a nitrogen atmosphere using freshly dried solvents. Tetrahydrofuran (THF), methylene chloride (CH_2Cl_2), acetonitrile (MeCN), dimethylformamide (DMF), and toluene (PhMe) were dried by passing through activated alumina columns. Unless otherwise stated, chemicals and reagents were used as received. Triethylamine (Et₃N) was distilled over calcium hydride prior to use. All reactions were monitored by thin-layer chromatography using

EMD/Merck silica gel 60 F254 pre-coated plates (0.25 mm) and were visualized by UV, *p*-anisaldehyde, or KMnO₄ staining. Flash column chromatography was performed either as described by Still et al.³⁶ using silica gel (particle size 0.032-0.063) purchased from Silicycle or using pre-packaged RediSep[®]Rf columns on a CombiFlash Rf system (Teledyne ISCO Inc.). Optical rotations were measured on a Jasco P-2000 polarimeter using a 100 mm path-length cell at 589 nm. ¹H and ¹³C NMR spectra were recorded on a Varian 400 MR (at 400 MHz and 101 MHz, respectively), a Bruker 400 equipped with a cryoprobe (at 400 MHz and 101 MHz, respectively), a Varian Inova 500 (at 500 MHz and 126 MHz, respectively), or a Varian Inova 600 (at 600 MHz and 150 MHz, respectively), and are reported relative to internal CHCl₃ (¹H, δ = 7.26), CHDCl₂ (¹H, δ = 5.32), CD₂HOD (¹H, δ = 3.31), MeCN-d2 (¹H, δ = 1.94), or DMSO-d5 (¹H, δ = 2.50), and CDCl₃ (¹³C, δ = 77.0), CD₂Cl₂ (¹³C, δ = 54.0), CD₃OD (¹³C, δ = 49.0), MeCN-d3 $({}^{13}C, \delta = 118.3)$, or DMSO-d6 $({}^{13}C, \delta = 40.0)$. Data for ¹H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicity and qualifier abbreviations are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, app = apparent. IR spectra were recorded on a Perkin Elmer Paragon 1000 spectrometer and are reported in frequency of absorption (cm⁻¹). HRMS were acquired using an Agilent 6200 Series TOF with an Agilent G1978A Multimode source in electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), or mixed (MM) ionization mode. Analytical chiral HPLC was performed with an Agilent 1100 Series HPLC utilizing Chiralpak AD or Chiralcel OD-H columns (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd with visualization at 254 nm. Preparative HPLC was performed with an Agilent 1100 Series

HPLC utilizing an Agilent Eclipse XDB-C18 5 μ m column (9.4 x 250 mm) or an Agilent Zorbax RX-SIL 5 μ m column (9.4 x 250 mm). Melting points were determined using a Büchi B-545 capillary melting point apparatus and the values reported are uncorrected.

2.5.2 Preparative Procedures and Spectroscopic Data

Preparation of reverse prenylated indole 228²⁶



To a flame-dried 50 mL Schlenk tube was added [(allyl)PdCl]₂ (9 mg, 0.025 mmol, 1 mol %) and phosphine ligand **231** (42 mg, 0.098 mmol, 4 mol %). Then the tube was evacuated and charged with argon three times. Allyl boronic acid pinacol ester **230** (0.65 ml, 2.95 mmol, 1.2 equiv) and dimethyl-bromoindole²⁴ **229** (560 mg, 2.50 mmol, 1.0 equiv) were added using a microsyringe. THF (5 mL) and 2.5 M K₃PO₄ (5 mL) were then added to the reaction flask. The Schlenk tube was sealed and the reaction was heated to 40 °C for 24 hours. It was then cooled to room temperature and diluted with EtOAc (25 mL). The mixed layers were then washed with distilled water (25 mL). The aqueous layer was then extracted with EtOAc (3 x 25 mL). Combined organic layers were washed with brine (40 mL). It was dried over MgSO₄, filtered and concentrated down to give a yellow oil. The crude material was then dissolved in EtOAc (30 mL) and washed with saturated KHF₂ solution (3 x 20 mL) to get rid of the remaining boronic acid pinacol ester. It was then dried over NaSO₄, filtered and concentrated to give a yellow oil. Flash chromatography (5% to 9% ether in hexanes) afforded reverse prenylated indole **228** as a

light yellow oil (442 mg, 2.07 mmol, 83% yield). ¹H NMR (500 MHz, CDCl₃) 7.51 (t, J = 0.9 Hz, 1H), 7.24 (dd, J = 8.7, 1.83 Hz, 1H), 7.21 (d, J = 8.5 Hz, 1H), 6.80 (d, J = 1.0 Hz, 1H), 6.13 (dd, J = 17.5, 10.6 Hz, 1H), 5.09 (dd, J = 17.6, 1.5 Hz, 1H), 5.04 (dd, J = 10.5, 1.5 Hz, 1H), 3.71 (s, 3H), 2.32 (d, J = 1.0 Hz, 3H), 1.49 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) 149.1, 138.8, 135.4, 128.3, 126.7, 120.6, 115.5, 110.1, 109.9, 108.5, 41.1, 32.5, 28.8, 9.5; IR (NaCl/thin film): 3080, 2964, 2920, 1634, 1489, 1455, 1425, 1387, 1376, 1365, 1292, 1256, 1201, 1152, 1053, 1004, 909, 874, 788; HRMS (MM) calc'd for C₁₅H₂₀N [M+H]⁺ 214.1590, found 214.1592.





To a flame-dried flask was added reverse prenylated indole **228** (350 mg, 1.64 mmol, 1.0 equiv), acrylate³⁷ **61a** (390 mg, 1.97 mmol, 1.2 equiv), (*R*)-3,3'-Cl₂-BINOL (117 mg, 0.33 mmol, 0.2 equiv), 2,6-dibromo-phenol (165 mg, 0.66 mmol. 0.4 equiv) and DCM (12 mL). SnCl₄ (1M solution in DCM, 1.97 mL, 1.97 mmol, 1.2 equiv) was added at last. The orange mixture was allowed to stir at room temperature for 24 hours. The solution was diluted with acetonitrile (10 mL) and quenched with 1M HCl (10 mL), followed by addition of distilled water (50 mL). The mixture was separated and the aqueous layer was extracted with ether (3 x 50 mL). Combined organic layers were washed with 3 M NaOH solution (3 x 75 mL). It was dried over MgSO₄, filtered and concentrated down to give yellow mixture of oil and solid. Flash chromatography (1% to

8% EtOAc in hexanes) afforded reverse prenylated pyrroloindoline 226 (14 : 1 mixture of *exo:endo* diastereomers by ¹H NMR), as a thick orange oil (568 mg, 1.34 mmol, 85%) yield). The mixture of diastereomers was further purified by flash chromatography (0% to 10% EtOAc in hexanes) to give major diastereomer 226 for characterization purposes. The enantiomeric excess of exo-226 was determined to be 92% by chiral SFC analysis (OD, 2.5 mL/min, 3% IPA in CO₂, $\lambda = 254$ nm): $t_{\rm R}$ (major) = 6.1 min, $t_{\rm R}$ (minor) = 5.3 min. The major diastereomer was separated by flash chromatography $(0 \rightarrow 10\% \text{ ethyl})$ acetate/hexanes). $[\alpha]_{D}^{25} = -115^{\circ}$ (c = 0.45, CHCl₃); ¹H NMR (500 MHz, CDCl₃; compound exists as a 2.1:1 mixture of rotamers, the major rotamer is denoted by *, minor rotamer denoted by §) δ 7.16 (d, J = 8.1 Hz, 1H*, 1H§), 7.02 (s, 1H§), 6.99 (s, 1H*), 6.52 $(d, J = 7.7 \text{ Hz}, 1\text{H}^{\$}), 6.45 (d, J = 8.2 \text{ Hz}, 1\text{H}^{\ast}), 6.00 (dd, J = 17.3, 10.5 \text{ Hz}, 1\text{H}^{\ast}, 1\text{H}^{\$}),$ 5.60 (s, 1H*), 5.31 (s, 1H[§]), 5.07 – 4.96 (m, 2H*, 2H[§]), 4.73 (d, J = 9.3 Hz, 1H*), 4.47 – 4.41 (m, 1H[§]), 3.82 (s, 1H^{*}), 3.77 (s, 1H[§]), 3.06 (s, 1H^{*}), 2.86 (s, 1H[§]), 2.60 (dd, J = 13.1, 9.9 Hz, 1H*), 2.52 (t, J = 10.7 Hz, 1H[§]), 2.38 (d, J = 12.5 Hz, 1H*), 2.14 – 1.98 (m, 1H[§]), 1.57 - 1.31 (m, 9H*, 9H[§]); ¹³C NMR (126 MHz, CDCl₃) 172.6*, 170.6[§], 159.1* (q, J = 37.0 Hz), $157.5^{\$}$ (q, J = 39.6 Hz), 148.4^{\ast} , $148.2^{\$}$, 147.5^{\ast} , $147.3^{\$}$, $140.6^{\$}$, 139.3^{\ast} , 134.1^{\ast} , $134.0^{\$}, 126.5^{\$}, 126.3^{\ast}, 119.3^{\ast\$}, 116.1^{\ast}$ (q, J = 288.5 Hz), $115.9^{\$}$ (app d, J = 287.2 Hz), $110.4^{\$}, 110.2^{\$}, 109.2^{\$}, 107.6^{\ast}, 93.7^{\ast}, 92.1^{\$}, 61.2^{\$}, 60.3^{\ast}, 53.3^{\$}, 53.0^{\ast}, 52.5^{\$}, 49.3^{\ast},$ 44.0*, 40.7[§], 40.7*, 40.4[§], 37.1*, 34.9[§], 28.4*[§], 23.5*, 22.9[§]; FTIR (NaCl, thin film): 3081, 2965, 2874, 2822, 1753, 1698, 1618, 1496, 1434, 1359, 1283, 1257, 1204, 1156, 1117, 1054, 995, 912, 844, 813 cm⁻¹; HRMS (ESI) calc'd for C₂₁H₂₆F₃N₂O₃ [M+H]⁺ 411.1890, found 411.1901.

Preparation of reverse prenylated pyrroloindoline amine 224



Acetyl chloride (0.40 mL, 5.69 mmol, 5.0 equiv) was added slowly to dry methanol (5 mL). The mixture was added to reverse prenylated pyrroloindoline 226 (467 mg, 1.14 mmol, 1.0 equiv, 14 : 1 mixture of *exo:endo* diastereomers by ¹H NMR) dissolved in dry methanol (7 mL). After being heated to 60 °C for three days, the reaction was quenched with saturated sodium bicarbonate (5 mL), and concentrated down to get rid of methanol. The residue was diluted with DCM (10 mL) and washed with water (10 mL). Aqueous layer was back extracted with DCM (3 x 5 mL). Combined organic layer was dried over Na₂SO₄, filtered and concentrated down to give a chartreuse oil. Flash chromatography (20% to 80% EtOAc in hexanes) afforded reverse prenylated secondary amine **224**, as a yellow oil (326 mg, 1.04 mmol, 80% yield). $[\alpha]_{D}^{25} = -58^{\circ}$ (c = 1.15, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.08 (dd, J = 8.1, 2.0 Hz, 1H), 7.00 (d, J = 2.0 Hz, 1H), 6.30 (d, J = 8.1 Hz, 1H), 6.02 (dd, J = 17.5, 10.6 Hz, 1H), 5.02 (ddd, J = 19.0, 14.0, 1.4 Hz, 2H), 4.61 (s, 1H), 3.76 (dd, *J* = 9.5, 6.8 Hz, 1H), 3.73 (s, 3H), 2.82 (s, 3H), 2.67 (br s, 1H), 2.40 (dd, J = 12.2, 6.8 Hz, 1H), 1.93 (dd, J = 12.3, 9.4 Hz, 1H), 1.43 (s, 3H), 1.38 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 174.5, 148.7, 148.6, 137.4, 134.6, 125.5, 120.3, 109.8, 105.0, 92.2, 59.7, 52.5, 52.0, 46.0, 40.5, 31.8, 28.4, 25.6; FTIR (NaCl, thin film): 3350, 3080, 2962, 2925, 2868, 1738, 1634, 1615, 1498, 1450, 1377, 1358, 1326, 1282, 1233, 1202, 1133, 1055, 996, 911, 862, 808 cm⁻¹; HRMS (APCI) calc'd for C₁₉H₂₇N₂O₂ [M+H]⁺ 315.2067, found 315.2067.

Preparation of dimethyl pyrroloindoline exo-225



To a flame-dried flask was added reverse prenylated indole 227 (300 mg, 2.07 mmol, 1.0 equiv), acrylate 61a (489 mg, 2.48 mmol, 1.2 equiv), (R)-3,3'-Cl₂-BINOL (147 mg, 0.41 mmol, 0.2 equiv), 2,6-dibromo-phenol (208 mg, 0.83 mmol, 0.4 equiv) and DCM (15 mL). SnCl₄ (1M solution in DCM, 2.48 mL, 2.48 mmol, 1.2 equiv) was added at last. The orange mixture was allowed to stir at room temperature for 24 hours. The solution was diluted with acetonitrile (10 mL) and guenched with 1M HCl (10 mL), followed by addition of distilled water (50 mL). The mixture was separated and the aqueous layer was extracted with ether (3 x 50 mL). Combined organic layers were washed with 3 M NaOH solution (3 x 75 mL). It was dried over MgSO₄, filtered and concentrated down to give yellow mixture of oil and solid. Flash chromatography (1% to 8% EtOAc in hexanes) afforded dimethyl pyrroloindoline 225 (12 : 1 mixture of exo:endo diastereomers by ¹H NMR), as a thick orange oil (553 mg, 1.62 mmol, 79%) yield). The enantiomeric excess of exo-225 was determined to be 93% by chiral SFC analysis (AD, 2.5 mL/min, 7% IPA in CO₂, $\lambda = 254$ nm): $t_{\rm R}$ (major) = 2.9 min, $t_{\rm R}$ (minor) = 2.4 min. Spectral data matches that reported in the literature.²

Preparation of pyrroloindoline acid 223



A solution of lithium hydroxide (14 mg, 0.58 mmol, 2.0 equiv) in distilled water (2.5 mL) was added dropwise to a solution of pyrroloindoline 225 (100 mg, 12 : 1 mixture of diastereomers, 0.29 mmol, 1.0 equiv) in THF (2.5 mL). After stirring at room temperature for 30 minutes, reaction was quenched with pH = 2.5 acidic buffer (10 mL, prepared by acidifying a 10% NaH₂PO₄ aqueous solution by KHSO₄ until pH reaches 2.5). It was extracted with DCM (5 x 10 mL). Combined layers were washed with brine (30 mL). The aqueous layer was back extracted with DCM (10 mL). The resulting organic layer was dried over Na₂SO₄, filtered, and concentrated down a yellow thick oil. Flash chromatography (1% to 10% MeOH is DCM) afforded pyrroloindoline acid 223, as a yellow solid (86 mg, 0.26 mmol, 90% yield). The minor diastereomer does not react under reaction conditions and can be isolated using flash chromatography. $\left[\alpha\right]_{D}^{25} = -86^{\circ}$ $(c = 1.15, CHCl_2)$; ¹H NMR (500 MHz, CDCl₃; compound exists as a 1.7:1 mixture of rotamers; the major rotamer is denoted by *, minor rotamer denoted by δ 7.18 (t, J = 7.6 Hz, 1H*, 1H[§]), 7.09 (s, 1H[§]), 7.04 (d, J = 7.3 Hz, 1H*), 6.86 (s, 1H[§]), 6.78 (t, J = 7.4Hz, 1H*), 6.60 (s, 1H[§]), 6.52 (d, J = 7.9 Hz, 1H*), 5.59 (s, 1H*), 5.31 (s, 1H[§]), 4.66 (s, 1H*), 4.34 (s, 1H[§]), 3.08 (s, 3H*), 2.91 (s, 3H[§]), 2.57 (s, 1H*, 1H[§]), 2.41 (d, J = 13.3 Hz, 1H*), 2.15 (s, 1H[§]), 1.48 (s, 3H[§]), 1.40 (s, 3H*); ¹³C NMR (126 MHz, CDCl₃) δ 177.5*, $175.8^{\$}, 159.4^{*}$ (q, J = 37.8 Hz), $157.8^{\$}$ (q, J = 35.6 Hz), $149.4^{\$}, 149.3^{*}, 134.5^{*\$}, 128.9^{\$}$, 128.6° , 121.7° , 121.5° , 120.4° , 118.8° , 116.2° (q, J = 288.5 Hz), 116.0° (q, J = 286.1Hz), 110.2[§], 108.0^{*}, 93.2^{*}, 91.9[§], 62.0[§], 60.9^{*}, 53.5[§], 49.2^{*}, 43.8^{*}, 39.8[§], 36.8^{*}, 35.6[§], 23.6*, 23.3[§]; FTIR (NaCl, thin film): 3215, 3053, 3027, 2966, 2933, 2876, 2824, 2519, 1689, 1609, 1489, 1450, 1432, 1344, 1300, 1256, 1202, 1157, 1107, 1094, 1063, 1021,

992, 949, 925, 855, 792, 754 cm⁻¹; HRMS (MM) calc'd for C₁₅H₁₆F₃N₂O₃ [M+H]⁺ 329.1108, found 329.1118.

Preparation of pyrroloindoline amine A-1



Acetyl chloride (0.35 mL, 4.88 mmol, 5.0 equiv) was added slowly to dry methanol (4 mL). The mixture was added to pyrroloindoline **225** (334 mg, 0.98 mmol, 1.0 equiv) dissolved in dry methanol (6 mL). After being heated to 60 °C for 52 hours, the reaction was quenched with saturated sodium bicarbonate (5 mL), and concentrated down to get rid of methanol. The residue was diluted with DCM (10 mL) and washed with water (10 mL). Aqueous layer was back extracted with DCM (3 x 5 mL). Combined organic layer was dried over Na₂SO₄, filtered, and concentrated down to give greenish yellow oil. Flash chromatography (20% to 80% EtOAc in hexanes) afforded secondary amine A-1, as a yellow oil (222 mg, 0.90 mmol, 93% yield). $[\alpha]_D^{25} = -34^\circ$ (c = 1.02, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.09 (td, J = 7.7, 1.2 Hz, 1H), 7.02 (dd, J = 6.6,1.0 Hz, 1H), 6.65 (td, J = 7.5, 1.0 Hz, 1H), 6.35 (d, J = 7.8 Hz), 4.62 (s, 1H), 3.69 – 3.74 (m, 4H), 2.83 (s, 3H), 2.69 (br s, 1H), 2.40 (dd, J = 12.5, 6.6 Hz, 1H), 1.92 (dd, J = 12.2, 1H)9.5 Hz, 1H), 1.43 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 174.5, 150.6, 134.7, 128.1, 122.3, 117.0, 105.5, 91.6, 59.8, 52.5, 52.0, 46.1, 31.5, 25.5; FTIR (NaCl, thin film): 3345, 3049, 2953, 2922, 2866, 1738, 1607, 1491, 1448, 1381, 1353, 1327, 1300, 1282, 1258, 1234, 1203, 1144, 1117, 1081, 1063, 1044, 1020, 990, 963, 909, 820, 741 cm⁻¹; HRMS (APCI) calc'd for $C_{14}H_{19}N_2O_2$ [M+H]⁺247.1441, found 247.1441.





A solution of lithium hydroxide (29 mg, 1.22 mmol, 3.0 equiv) in distilled water (1.5 mL) was added dropwise to a solution of amine A-1 (100 mg, 0.406 mmol, 1.0 equiv) in THF (1.5 mL). After stirring at room temperature for 30 minutes, reaction was quenched with 1M HCl until pH reached 6. The resulting solution was concentrated down to get rid of all solvent. The white residue was redissolved in DCM and filtered through a plug of celite to remove inorganic salt, which yielded a light yellow foam upon concentrating down. The crude product amino acid 235 was carried to the next reaction without further purification. (87.0 mg, 0.375 mmol, 93% yield). $[\alpha]_{D}^{25} = -91^{\circ} (c = 0.94,$ CH_2Cl_2 ; ¹H NMR (500 MHz, CD_3OD) δ 7.15 – 7.10 (m, 2H), 6.76 (t, J = 7.5 Hz, 1H), 6.55 (d, J = 8.1 Hz, 1H), 5.05 (s, 1H), 3.60 (dd, J = 11.3, 6.5 Hz, 1H), 3.01 (s, 3H), 2.66 $(dd, J = 13.3, 6.4 Hz, 1H), 2.22 (dd, J = 13.1, 11.4 Hz, 1H), 1.40 (s, 3H); {}^{13}C NMR (126)$ MHz, CD₃OD) δ 173.3, 150.3, 134.6, 130.1, 123.6, 120.7, 108.3, 92.0, 62.0, 54.6, 49.0, 43.9, 33.6, 25.4; FTIR (NaCl, thin film): 3390, 3051, 3024, 2961, 2926, 2668, 2621, 2485, 1609, 1494, 1420, 1339, 1307, 1283, 1265, 1223, 1208, 1156, 1115, 1078, 1036, 1020, 1007, 989, 944, 923, 868, 794, 742 cm⁻¹; HRMS (MM) calc'd for $C_{13}H_{17}N_2O_2$ [M+H]⁺ 233.1285, found 233.1291.

Preparation of reverse prenylated pyrroloindoline amino acid 236



Amino acid **236** was prepared following the same procedure as preparation of amino acid **235**. The crude product was carried to the next reaction without further purification, (64.8 mg, 0.216 mmol, 95% yield). $[\alpha]_D^{25} = -102^\circ$ (c = 1.33, CH₂Cl₂); ¹H NMR (500 MHz, CD₂Cl₂) δ 7.11 (dd, J = 8.2, 1.9 Hz, 1H), 7.04 (d, J = 1.9 Hz, 1H), 6.37 (d, J = 8.3 Hz, 1H), 6.00 (dd, J = 17.4, 10.6 Hz, 1H), 5.17 (s, 1H), 5.04 (d, J = 17.4 Hz, 1H), 5.00 (d, J = 10.6 Hz, 1H), 3.70 (dd, J = 12.4, 6.1 Hz, 1H), 2.99 (s, 3H), 2.56 (dd, J = 12.8, 6.0 Hz, 1H), 2.30 (t, J = 12.6 Hz, 1H), 1.47 (s, 3H), 1.36 (s, 6H); ¹³C NMR (126 MHz, CD₂Cl₂) δ 173.9, 149.1, 148.3, 140.0, 133.9, 127.0, 120.8, 110.5, 106.6, 90.9, 61.4, 53.7, 43.7, 41.2, 34.1, 28.8, 25.7; FTIR (NaCl, thin film): 3400, 2963, 2928, 2873, 2804, 1602, 1502, 1439, 1387, 1377, 1358, 1333, 1289, 1253, 1226, 1211, 1175, 1127, 1098, 1066, 1036, 1007, 904, 810, 768, 753 cm⁻¹; HRMS (MM) calc'd for C₁₈H₂₅N₂O₂ [M+H]⁺ 301.1911, found 301.1906.




Dissolved amino acid **235** (19.4 mg, 0.084 mmol, 1.0 equiv) and reverse prenylated amino acid **236** (25.1 mg, 0.084 mmol, 1.0 equiv) in dry DCM (4.1 ml). After addition of dry *N*,*N*-diisopropylethylamine (DIPEA, 67 μ L, 50 mg, 0.384 mmol, 4.6 equiv), the solution was then cooled to 0 °C. Bis(2-oxo-3-oxazolidinyl) phosphonic chloride (BOP-Cl, 85 mg, 0.334 mmol, 4.0 equiv) was added in one portion. The

chloride (BOP-Cl, 85 mg, 0.334 mmol, 4.0 equiv) was added in one portion. The resulting mixture was allowed to warm to room temperature and stirred for 13 hours. It was quenched with saturated sodium bicarbonate (5 mL), followed by brine (5 mL). Aqueous layer was extracted with EtOAc (3 x 5 mL). Combined organic layer was dried over Na₂SO₄, filtered, and concentrated down to give yellow mixture of oil and solid. Flash chromatography (0% to 20% EtOAc in hexanes) afforded three compounds: diketopiperazine **A-2** as white solid (7.2 mg, 0.017 mmol, 21% yield), (–)-lansai B (**169**) as white solid (15.4 mg, 0.031 mmol, 38% yield), diketopiperazine **A-3** as white solid (9.4 mg, 0.017 mmol, 20% yield).

(-)-*Lansai B* (**169**): $[\alpha]_D^{25} = -505^\circ$ (*c* = 0.12, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.13 – 7.05 (m, 1H), 7.07 (dd, *J* = 8.1, 1.8 Hz, 1H), 7.04 (dd, *J* = 7.3, 1.2 Hz, 1H), 7.01 (d, *J* = 1.9 Hz, 1H), 6.70 (td, *J* = 7.4, 0.9 Hz, 1H), 6.34 (d, *J* = 7.8 Hz, 1H), 6.28 (d, *J* = 8.1 Hz, 1H), 5.97 (dd, *J* = 17.4, 10.6 Hz, 1H), 5.44 (s, 1H), 5.42 (s, 1H), 5.01 (dd, *J* = 14.0, 1.4 Hz, 1H), 4.99 (dd, *J* = 7.2, 1.4 Hz, 1H), 4.15 (app dddd, *J* = 13.5, 11.1, 6.1, 2.1 Hz, 2H), 2.97 (s, 3H), 2.95 (s, 3H), 2.71 (dd, *J* = 12.7, 3.0 Hz, 1H), 2.69 (dd, *J* = 12.7, 3.0 Hz, 1H), 2.18 (dd, *J* = 12.6, 6.3 Hz, 1H), 2.15 (dd, *J* = 12.7, 6.4 Hz, 1H), 1.47 (s, 3H), 1.46 (s, 3H), 1.34 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 165.7, 165.5, 150.1, 148.6, 148.2, 138.7, 132.9, 132.8, 128.7, 126.3, 122.3, 120.2, 118.1, 110.1, 105.8, 105.4, 86.9, 86.5, 60.1, 60.1, 50.5, 50.3, 42.7, 42.7, 40.7, 33.1, 32.9, 28.5, 28.5, 25.5, 25.4; FTIR

(NaCl, thin film): 2960, 2926, 2866, 1668, 1608, 1495, 1418, 1340, 1300, 1206, 1163, 1082, 1004, 910, 810, 740 cm⁻¹; HRMS (MM) calc'd for C₃₁H₃₇N₄O₂ [M+H]⁺ 497.2911, found 497.2911.

Diketopiperazine **245**: $[\alpha]_D^{25} = -561^\circ$ (*c* = 1.12, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.09 (td, *J* = 7.6, 1.1 Hz, 1H), 7.04 (dd, *J* = 7.3, 0.7 Hz, 1H), 6.70 (td, *J* = 7.4, 0.9 Hz, 1H), 6.34 (d, *J* = 7.8 Hz, 1H), 5.44 (s, 1H), 4.15 (dd, *J* = 10.6, 5.7 Hz, 1H), 2.97 (s, 3H), 2.70 (dd, *J* = 12.7, 5.9 Hz, 1H), 2.17 (dd, *J* = 12.5, 11.5 Hz, 1H), 1.47 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 165.6, 150.1, 132.9, 128.7, 122.3, 118.1, 105.8, 86.5, 60.1, 50.3, 42.7, 32.9, 25.4; FTIR (NaCl, thin film): 3318, 3052, 3007, 2958, 2926, 2866, 2829, 1665, 1608, 1493, 1421, 1341, 1300, 1259, 1206, 1163, 1122, 1081, 1020, 1004, 936, 895, 818, 799, 751 cm⁻¹; HRMS (APCI) calc'd for C₂₆H₂₉N₄O₂ [M+H]⁺ 429.2285, found 429.2287.

Diketopiperazine **250**: $[\alpha]_{D}^{25} = -501^{\circ}$ (*c* = 0.65, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.07 (dd, *J* = 8.2, 1.6 Hz, 1H), 7.01 (d, *J* = 1.7 Hz, 1H), 6.28 (d, *J* = 8.1 Hz, 1H), 5.97 (dd, *J* = 17.3, 10.5 Hz, 1H), 5.42 (s, 1H), 5.01 (d, *J* = 17.4 Hz, 1H), 4.99 (d, *J* = 10.4 Hz, 1H), 4.15 (dd, *J* = 10.5, 5.9 Hz, 1H), 2.96 (s, 3H), 2.70 (dd, *J* = 12.7, 5.9 Hz, 1H), 2.16 (t, *J* = 12.0 Hz, 1H), 1.46 (s, 3H), 1.34 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 165.7, 148.6, 148.2, 138.6, 132.7, 126.3, 120.2, 110.1, 105.3, 86.9, 60.1, 50.4, 42.7, 40.6, 33.1, 28.50, 28.49, 25.5; FTIR (NaCl, thin film): 3080, 2962, 2923, 2867, 2824, 1666, 1612, 1500, 1414, 1341, 1317, 1289, 1208, 1161, 1081, 1004, 910, 810, 754 cm⁻¹; HRMS (MM) calc'd for C₃₆H₄₅N₄O₂ [M+H]⁺ 565.3537, found 565.3549.

Tuntiwachwuttikul et al. Report ³	This Work	
Notural () Jangaj B	Supplied to the second	
Induital (-)-failsaí D	Synthetic (–)-lansal B	
$\frac{1}{10000000000000000000000000000000000$	$\frac{\text{H NMR}, 500 \text{ MHZ}, \text{CDCI}_3}{5.7.12 \times 7.05}$	
δ 7.11 (dt, J = 7.8, 1.5 Hz, 1H)	δ 7.13 – 7.05 (m, 1H)	
$7.08 (\mathrm{dd}, J = 8.1, 1.5 \mathrm{Hz}, 1\mathrm{H})$	7.07 (dd, <i>J</i> = 8.1, 1.8 Hz, 1H)	
$7.06 (\mathrm{dd}, J = 7.8, 1.5 \mathrm{Hz}, 1\mathrm{H})$	7.04 (dd, J = 7.3, 1.2 Hz, 1H)	
7.02 (d, J = 1.5 Hz, 1H)	7.01 (d, $J = 1.9$ Hz, 1H)	
6.71 (dt, <i>J</i> = 7.8, 1.5 Hz, 1H)	6.70 (td, J = 7.4, 0.9 Hz, 1H)	
6.36 (dd, <i>J</i> = 7.8, 1.5 Hz, 1H)	6.34 (d, <i>J</i> = 7.8 Hz, 1H)	
6.29 (d, J = 8.1 Hz, 1H)	6.28 (d, J = 8.1 Hz, 1H)	
5.99 (dd, <i>J</i> = 17.5, 10.6 Hz, 1H)	5.97 (dd, <i>J</i> = 17.4, 10.6 Hz, 1H)	
5.46 (s, 1H)	5.44 (s, 1H)	
5.44 (s, 1H)	5.42 (s, 1H)	
5.03 (d, J = 10.6 Hz, 1H)	5.01 (dd, <i>J</i> = 14.0, 1.4 Hz, 1H)	
5.01 (d, J = 17.5 Hz, 1H)	4.99 (dd, <i>J</i> = 7.2, 1.4 Hz, 1H)	
4.16 (m, 1H)	4.15 (app dddd, $J = 13.5, 11.1, 6.1, 2.1$ Hz, 2H)	
4.16 (m, 1H)	_	
2.99 (s, 3H)	2.97 (s, 3H)	
2.97 (s, 3H)	2.95 (s, 3H)	
2.72 (dd, J = 12.3, 5.9 Hz, 1H)	2.71 (dd, <i>J</i> = 12.7, 3.0 Hz, 1H)	
2.72 (dd, J = 12.3, 5.9 Hz, 1H)	2.69 (dd, <i>J</i> = 12.7, 3.0 Hz, 1H)	
2.18 (dd, <i>J</i> = 12.3, 11.3 Hz, 1H)	2.18 (dd, <i>J</i> = 12.6, 6.3 Hz, 1H)	
2.17 (dd, <i>J</i> = 12.3, 11.3 Hz, 1H)	2.15 (dd, <i>J</i> = 12.7, 6.4 Hz, 1H)	
1.49 (s, 3H)	1.47 (s, 3H)	
1.48 (s, 3H)	1.46 (s, 3H)	
1.36 (s, 6H)	1.34 (s, 6H)	

 Table 2.1. Comparison of ¹H NMR data for natural vs. synthetic (-)-lansai B (169)

 Table 2.2. Comparison of ¹³C NMR data for natural vs. synthetic (–)-lansai B

Tuntiwachwuttikul et al. Report, ³	This Work,	Chemical Shift
Natural (–)-lansai B	Synthetic (–)-lansai B	Difference, $\Delta\delta$
¹³ C NMR, 75 MHz, CDCl ₃	¹³ C NMR, 126 MHz, CDCl ₃	
δ 165.8	δ 165.7	0.1
165.6	165.5	0.1
150.1	150.1	0.0
148.6	148.6	0.0
148.3	148.2	0.1
138.7	138.7	0.0
132.9	132.9	0.0
132.8	132.8	0.0
128.8	128.7	0.1

126.3	126.3	0.0
122.3	122.3	0.0
120.2	120.2	0.0
118.1	118.1	0.0
110.2	110.1	0.1
105.8	105.8	0.0
105.4	105.4	0.0
86.9	86.9	0.0
86.6	86.5	0.1
60.1	60.1	0.0
60.1	60.1	0.0
50.5	50.5	0.0
50.3	50.3	0.0
42.7	42.7	0.0
42.7	42.7	0.0
40.7	40.7	0.0
33.1	33.1	0.0
32.9	32.9	0.0
28.5	28.5	0.0
28.5	28.5	0.0
25.5	25.5	0.0
25.4	25.4	0.0

Preparation of N-formyl DKP 246



To a vial containing DKP **245** (5.5 mg, 0.013 mmol, 1.0 equiv) and $Py_2AgMnO_4^{38}$ (21 mg, 0.05 mmol, 4.0 equiv) was added dry DCM (0.2 mL). The resulting mixture was stirred at room temperature for 22 hours. Then a second portion of Py_2AgMnO_4 (10 mg, 0.025 mmol, 2.0 equiv) was added and the reaction was further stirred for another 18 hours. The mixture was then diluted with EtOAc (5 mL), which was sequentially washed with saturated sodium bisulfite (2 mL), saturated copper sulfate (2 mL), and saturated

ammonium chloride (2 mL). Combined organic layer was dried over Na₂SO₄, filtered, and concentrated down. Flash chromatography (20% to 100% EtOAc in hexanes) afforded *N*-formyl DKP **246** as a white solid (1.9 mg, 0.004 mmol, 33% yield). $[\alpha]_{D}^{25} = -$ 378° (*c* = 0.105, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 8.99 (s, 1H), H NMR (400 MHz, CDCl₃) δ 9.01 (s, 1H), 7.95 (d, *J* = 8.0 Hz, 1H), 7.25 (td, *J* = 7.7, 1.4 Hz, 1H), 7.22 – 7.19 (m, 1H), 7.13 (td, *J* = 7.5, 1.1 Hz, 1H), 5.80 (s, 1H), 4.13 (dd, *J* = 10.5, 5.8 Hz, 1H), 2.81 (dd, *J* = 13.0, 5.9 Hz, 1H), 2.30 (dd, *J* = 13.0, 11.4 Hz, 1H), 1.53 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 165.2, 161.8, 139.8, 134.9, 129.2, 125.7, 122.6, 117.1, 80.0, 60.2, 51.0, 40.8, 24.9; FTIR (NaCl/thin film): 2963, 2924, 2868, 1678, 1599, 1552, 1485, 1464, 1446, 1413, 1378, 1344, 1292, 1232, 1206, 1157, 1102, 793, 761 cm⁻¹; HRMS (MM) calc'd for C₂₆H₂₅N₄O₄ [M+H]⁺ 457.1870, found 457.1882.

Preparation of N-formyl pyrroloindoline 248



To a vial containing pyrroloindoline **225** (54 mg, 0.16 mmol, 1.0 equiv) and Py_2AgMnO_4 (304 mg, 0.79 mmol, 5.0 equiv) was added dry DCM (1.6 mL). The resulting mixture was heated to 50 °C for 21 hours after being sealed. The mixture was then cooled to room temperature and diluted with EtOAc (10 mL), and sequentially washed with saturated sodium bisulfite (5 mL), saturated copper sulfate (5 mL), and saturated ammonium chloride (5 mL). Combined organic layer was dried over Na₂SO₄, filtered, and concentrated down. Flash chromatography (0% to 40% EtOAc in hexanes) afforded *N*-formyl pyrroloindoline **248** as a thick oil (37.1 mg, 0.104 mmol, 66% yield).

 $[\alpha]_{D}^{25} = -159^{\circ} (c = 1.815, CHCl_3); {}^{1}H NMR (500 MHz, CDCl_3) \delta 8.99 (s, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.32 (td, J = 7.8, 1.4 Hz, 1H), 7.23 (d, J = 7.1 Hz, 1H), 7.18 (t, J = 7.4 Hz, 1H), 5.93 (s, 1H), 4.48 (t, J = 8.0 Hz, 1H), 3.80 (s, 3H), 2.94 (dd, J = 13.3, 8.1 Hz, 1H), 2.31 (dd, J = 13.4, 8.3 Hz, 1H), 1.45 (s, 3H); {}^{13}C NMR (126 MHz, CDCl_3) \delta 206.3, 171.5, 162.1, 158.8 (q, J_{C-F} = 38.2 Hz), 138.8, 135.8, 129.2, 125.7, 122.1, 118.0, 115.4 (q, J_{C-F} = 287.9 Hz), 83.9, 59.9, 53.2, 50.3, 48.4, 43.9, 41.8, 24.3; FTIR (NaCl/thin film): 3014, 2961, 2931, 2874, 1752, 1691, 1603, 1484, 1467, 1452, 1437, 1409, 1389, 1381, 1357, 1331, 1312, 1288, 1277, 1253, 1212, 1166, 1106, 1067, 1021, 1007, 979, 945, 914, 878, 805, 759, 729 cm⁻¹; HRMS (MM) calc'd for C₁₆H₁₆F₃N₂O₄ [M+H]⁺ 357.1057, found 357.1071.$

Preparation of N-proto-pyrroloindoline 249



To a solution of *N*-formyl-pyrroloindoline **248** (12.6 mg, 0.035 mmol, 1.0 equiv) in MeOH (0.35 mL) was added freshly prepared 1M HCl methanol solution (39 μ L, 0.039 mmol, 1.1 equiv). The resulting solution was allowed to stir at room temperature for 7 hours. It was carefully quenched with saturated sodium bicarbonate (5 mL), followed by brine (5 mL). The aqueous layer was extracted with EtOAc (3 x 5 mL). Combined organic layer was dried over Na₂SO₄, filtered, and concentrated down. Flash chromatography (0% to 20% EtOAc in hexanes) afforded secondary amine **249**, as a colorless oil (10.6 mg, 0.032 mmol, 92% yield). Spectral data matches that reported in the literature.³⁹

Preparation of lansai ETP derivatives 251a-c³⁵



Typical procedure of preparation of ETP **251c**: To a suspension of sulfur (4.2 mg, 0.13 mmol) in THF (2 mL) at 0 °C under argon was added NaHMDS (0.6 M in PhMe, 330 μ L, 0.20 mmol) dropwise over 2 min. This solution was stirred for an additional 1 min, and lansai B (**169**) (8.2 mg, 0.017 mmol) dissolved in THF (8.5 mL) was added dropwise at 0 °C over 2 min. The mixture was stirred for an additional 1 min, then more NaHMDS (0.6 M in PhMe, 180 μ L, 0.11 mmol) was added and the resulting mixture was stirred 0.5 hours at 0 °C. The reaction mixture was quenched with saturated aq. NH₄Cl solution (5 mL). The mixture was extracted with DCM (3 × 5 mL), and the combined organic layers were dried over MgSO₄, filtered, and concentrated. The resulting brownish residue was used for the next step without further purification.

To the above crude product dissolved in a mixture of degassed THF/EtOH (1:1, 1.0 mL) at 0 °C was added NaBH₄ (15.6 mg, 0.41 mmol) in small portions over 1 min. The resulting mixture was stirred for 45 min while it was allowed to warmed up to 25 °C. After this time, the solution was cooled to 0 °C, and quenched by careful addition of saturated aq. NH₄Cl solution (3 mL). The resulting mixture was extracted with EtOAc (3 × 3 mL) and to the combined organic extracts was added an aq. solution of KI₃ (3 mL, 1.4 M). This mixture was stirred for 10 min and then quenched by the addition of sat. aq. Na₂S₂O₃ solution (3 mL). The resulting mixture was extracted with EtOAc (3 × 5 mL),

dried over MgSO₄, filtered, and concentrated *in vacuo*. The obtained residue was purified by flash column chromatography (0% to 20% EtOAc in hexanes) to afford epidithiodiketopiperazine **251c** (5.0 mg, 0.009 mmol, 54% yield).

Epidithiodiketopiperazine **251***a*: $[\alpha]_D^{25} = -576^\circ$ (*c* = 0.390, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.16 (td, *J* = 7.7, 1.2 Hz, 1H), 7.07 (dd, *J* = 7.3, 0.7 Hz, 1H), 6.76 (td, *J* = 7.5, 0.7 Hz, 1H), 6.45 (d, *J* = 7.8 Hz, 1H), 5.34 (s, 1H), 3.27 (d, *J* = 14.7 Hz, 1H), 3.07 (s, 3H), 2.59 (d, *J* = 14.7Hz, 1H), 1.50 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 164.4, 149.2, 133.9, 128.9, 121.7, 118.4, 107.0, 90.7, 52.1, 44.3, 34.9, 25.1; FTIR (NaCl/thin film): 3052, 3020, 2959, 2925, 2867, 1693, 1608, 1493, 1445, 1384, 1357, 1324, 1302, 1274, 1185, 1124, 1104, 1093, 1060, 1020, 997, 941, 797, 742 cm⁻¹; HRMS (APCI) calc'd for C₂₆H₂₇N₄O₂ [M+H–S₂]⁺ 491.1570, found 491.1576.

Epidithiodiketopiperazine **251b**: $[\alpha]_{D}^{25} = -613^{\circ}$ (c = 0.355, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.20 – 7.12 (m, 2H), 7.08 (dd, J = 7.5, 0.9 Hz, 1H), 7.04 (d, J = 2.0 Hz, 1H), 6.76 (td, J = 7.4, 0.9 Hz, 1H), 6.46 (d, J = 7.8 Hz, 1H), 5.99 (dd, J = 17.3, 10.5 Hz, 1H), 5.35 (s, 1H), 5.32 (s, 1H), 5.02 (dd, J = 11.0, 1.5 Hz, 1H), 4.99 (dd, J = 7.2, 1.4 Hz, 1H), 3.28 (d, J = 2.2 Hz, 1H), 3.25 (d, J = 2.2 Hz, 1H), 3.09 (s, 3H), 3.04 (s, 3H), 2.59 (dd, J = 14.5, 8.7 Hz, 2H), 1.51 (s, 3H), 1.50 (s, 3H), 1.37 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 164.5, 164.4, 149.2, 148.6, 147.4, 138.9, 133.9, 133.7, 128.9, 126.3, 121.7, 112.0, 118.4, 110.3, 107.0, 106.6, 91.2, 90.7, 76.0, 75.9, 52.3, 52.1, 44.4, 44.4, 40.7, 35.0, 34.9, 28.5, 28.5, 25.1, 24.7; FTIR (NaCl/thin film): 2961, 2925, 2868, 1693, 1608, 1494, 1358, 1317, 1302, 1186, 1120, 1053, 997, 911, 812, 753 cm⁻¹; HRMS (APCI) calc'd for C₃₁H₃₅N₄O₂ [M+H–S₂]⁺ 559.2196, found 559.2183.

Epidithiodiketopiperazine **251***c*: $[\alpha]_{D}^{25} = -577^{\circ}$ (*c* = 0.210, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.15 (dd, *J* = 8.1, 2.0 Hz, 1H), 7.04 (d, *J* = 2.0 Hz, 1H), 6.40 (d, *J* = 8.3 Hz, 1H), 5.99 (dd, *J* = 17.5, 10.6 Hz, 1H), 5.32 (s, 1H), 5.02 (dd, *J* = 11.1, 1.2 Hz, 1H), 4.99 (dd, *J* = 4.4, 1.2 Hz, 1H), 3.26 (d, *J* = 14.4 Hz, 1H), 3.05 (s, 3H), 2.59 (dd, *J* = 14.7 Hz, 1H), 1.50 (s, 3H), 1.37 (s, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 164.5, 148.6, 147.4, 138.9, 133.8, 126.3, 119.7, 110.3, 106.5, 91.2, 52.3, 44.4, 40.7, 35.0, 28.55, 28.50, 24.7; FTIR (NaCl/thin film): 3079, 2962, 2926, 2869, 2824, 1695, 1619, 1498, 1446, 1431, 1411, 1358, 1315, 1287, 1185, 1136, 1117, 1099, 1053, 996, 910, 809, 754 cm⁻¹; HRMS (APCI) calc'd for C₃₆H₄₃N₄O₂ [M+H–S₂]⁺ 627.2822, found 627.2819.

2.6 NOTES AND REFERENCES

(1) Anthoni, U.; Christophersen, C.; Nielsen, P. H. In *Alkaloids: Chemical and Biological Perspectives*; Pelletier, S. W., Ed.; Pergamon: 1999; Vol. Volume 13, p 163.

(2) Yanagihara, M.; Sasaki-Takahashi, N.; Sugahara, T.; Yamamoto, S.; Shinomi, M.; Yamashita, I.; Hayashida, M.; Yamanoha, B.; Numata, A.; Yamori, T.; Andoh, T. *Cancer Sci.* **2005**, *96*, 816.

(3) Tuntiwachwuttikul, P.; Taechowisan, T.; Wanbanjob, A.; Thadaniti, S.; Taylor, W. C. *Tetrahedron* **2008**, *64*, 7583.

(4) Crich, D.; Chan, C.-O.; Davies, J. W.; Natarajan, S.; Vinter, J. G. J. Chem. Soc., Perkin Trans. 2 1992, 2233.

(5) Raju, R.; Piggott, A. M.; Huang, X.-C.; Capon, R. J. Org. Lett. 2011, 13, 2770.

(6) Repka, L. M.; Reisman, S. E. J. Org. Chem. 2013, 78, 12314.

(7) Marsden, S. P.; Depew, K. M.; Danishefsky, S. J. J. Am. Chem. Soc. 1994, 116, 11143.

(8) López, C. S.; Pérez-Balado, C.; Rodríguez-Graña, P.; de Lera, Á. R. Org. Lett. 2008, 10, 77.

(9) Wang, M.; Feng, X.; Cai, L.; Xu, Z.; Ye, T. Chem. Commun. 2012, 48, 4344.

(10) Espejo, V. R.; Li, X.-B.; Rainier, J. D. J. Am. Chem. Soc. 2010, 132, 8282.

(11) Kim, J.; Movassaghi, M. J. Am. Chem. Soc. 2011, 133, 14940.

(12) Movassaghi, M.; Schmidt, M. A.; Ashenhurst, J. A. Angew. Chem. Int. Ed. **2008**, 47, 1485.

- (13) He, B.; Song, H.; Du, Y.; Qin, Y. J. Org. Chem. 2008, 74, 298.
- (14) Zhang, D.; Song, H.; Qin, Y. Acc. Chem. Res. 2011, 44, 447.

(15) Kieffer, M. E.; Chuang, K. V.; Reisman, S. E. J. Am. Chem. Soc. 2013, 135, 5557.

(16) Ashimori, A.; Matsuura, T.; Overman, L. E.; Poon, D. J. J. Org. Chem. **1993**, 58, 6949.

(17) Trost, B. M.; Zhang, Y. J. Am. Chem. Soc. 2006, 128, 4590.

(18) Bui, T.; Syed, S.; Barbas, C. F. J. Am. Chem. Soc. 2009, 131, 8758.

(19) Ma, S.; Han, X.; Krishnan, S.; Virgil, S. C.; Stoltz, B. M. Angew. Chem. Int. Ed. 2009, 48, 8037.

(20) Li, X.; Luo, S.; Cheng, J.-P. Chem. Eur. J. 2010, 16, 14290.

- (21) Hills, I. D.; Fu, G. C. Angew. Chem. Int. Ed. 2003, 42, 3921.
- (22) DeLorbe, J. E.; Jabri, S. Y.; Mennen, S. M.; Overman, L. E.; Zhang, F.-L.

J. Am. Chem. Soc. 2011, 133, 6549.

- (23) Zhu, S.; MacMillan, D. W. C. J. Am. Chem. Soc. 2012, 134, 10815.
- (24) Repka, L. M.; Ni, J.; Reisman, S. E. J. Am. Chem. Soc. 2010, 132, 14418.
- (25) Ni, J.; Wang, H.; Reisman, S. E. *Tetrahedron* **2013**, *69*, 5622.
- (26) Yang, Y.; Buchwald, S. L. J. Am. Chem. Soc. 2013, 135, 10642.
- (27) King, S. B.; Ganem, B. J. Am. Chem. Soc. 1994, 116, 562.
- (28) Valeur, E.; Bradley, M. Chem. Soc. Rev. 2009, 38, 606.

(29) Depew, K. M.; Marsden, S. P.; Zatorska, D.; Zatorski, A.; Bornmann, W. G.; Danishefsky, S. J. J. Am. Chem. Soc. **1999**, *121*, 11953.

(30) Boyer, N.; Morrison, K. C.; Kim, J.; Hergenrother, P. J.; Movassaghi, M. Chem. Sci. 2013, 4, 1646.

(31) Gardiner, D. M.; Waring, P.; Howlett, B. J. *Microbiology* **2005**, *151*, 1021.

(32) Welch, T. R.; Williams, R. M. Nat. Prod. Rep. 2014, 31, 1376.

- (33) Kim, J.; Ashenhurst, J. A.; Movassaghi, M. Science 2009, 324, 238.
- (34) Takano, S.; Moriya, M.; Iwabuchi, Y.; Ogasawara, K. Chem. Lett. 1990, 109.

(35) Nicolaou, K. C.; Giguère, D.; Totokotsopoulos, S.; Sun, Y.-P. Angew. Chem. Int. Ed. 2012, 51, 728.

(36) Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.

(37) Navarre, L.; Martinez, R.; Genet, J.-P.; Darses, S. J. Am. Chem. Soc. 2008, 130, 6159.

(38) Firouzabadi, H.; Vessal, B.; Naderi, M. Tetrahedron Lett. 1982, 23, 1847.

(39) Ni, J. Thesis Development of Asymmetric Protonation Reactions for the Synthesis of Indoline Alkaloids. Ph.D. Dissertation, California Institute of Technology, 2015.

Appendix 1

Spectra Relevant to Chapter 2: Direct Application of Enantioselective (3 + 2) Formal Cycloaddition: Concise Enantioselective Total Synthesis of (–)-Lansai B



Appendix 1 – Spectra Relevant to Chapter 2















udd














































Chapter 3

Enantioselective Total Synthesis of (+)-Nocardioazines A and B^{\dagger}

3.1 INTRODUCTION

Having accomplished the first total synthesis of (–)-lansai B (**169**), which illustrated the utility of our enantioselective formal (3 + 2) cycloaddition strategy in accessing related pyrroloindolines,^{1,2} we turned our attention to structurally related diketopiperazine-containing bis(pyrroloindoline) natural products (+)-nocardioazines A (**171**) and B (**187**). Both of these natural products were isolated in 2011 by Capon and coworkers as a new class of prenylated diketopiperazines from the Australian marine sediment-derived isolate, *Nocardiopsis* sp. (CMB-M0232).³ Nocardioazine A (**171**) has been found to be a potential multidrug resistance reversal candidate due to its P-glycoprotein binding property.³

Although these natural products appear quite similar structurally, close analysis reveals subtle differences in the relative stereochemistry of the pyrroloindoline units.

[†] Part of this chapter was published as the following communications: Wang, H.; Reisman, S. E. *Angew. Chem. Int. Ed.* **2014**, *53*, 6206.

Whereas lansai B (169) is composed of two *exo*-pyrroloindolines, 171 and 187 each possess one *endo*- and one *exo*-pyrroloindoline. Moreover, the *endo*- and *exo*-pyrroloindolines are in the opposite enantiomeric series, which is necessary to geometrically accommodate the macrocycle of 171.

Figure 3.1. Structures of (+)-nocardioazines A and B



3.1.1 Proposed Biosynthesis of Nocardioazines A and B

Biosynthetically, it is proposed that both nocardioazines A and B are synthesized in bacteria from L-tryptophan cyclic dimer **252** (Scheme 3.1), which is alkylated at both C3 positions with either a methyl or a prenyl group to provide imine intermediate **253**.³ The diketopiperazine (DKP) nitrogen atoms would then cyclize to form the pyrroloindoline core, providing nocardioazine B (*ent*-**187**). *ent*-**187** is proposed to undergo two subsequent oxidation reactions to produce hydroxyl-epoxide **254**. The elimination of water facilitated by the indoline nitrogen then forms nocardioazine A (*ent*-**171**).

It is important to note that the naturally abundant L-tryptophan series dictates the absolute stereochemistry at the DKP core to be of the (*S*)-configuration, as proposed in the isolation paper.³ Our total synthesis work, as will be described in this chapter, and related studies by Ye and coworkers⁴ have corrected the absolute stereochemistry to be of

the (*R*)-configurations, indicating that the nocardioazine family are derived from the rare D-tryptophan series. In alignment with this claim, Capon and coworkers co-isolated cyclo-(L-Trp-L-Trp) and cyclo-(L-Trp-D-Trp) along with the nocardioazines.³ It is suggested that cyclo-(L-Trp-D-Trp) could be the biosynthetic precursor of nocardioazines A and B; however, such a hypothesis requires that the L-Trp fragment undergoes epimerization at some point during the biological pathway.

Scheme 3.1. Proposed biosynthetic origins of nocardioazines A and B



3.1.2 The Total Synthesis of (–)-Nocardioazine B by Ye

At the outset of our endeavor toward nocardioazines A (**171**) and B (**187**) in 2011, there were no reported total syntheses of these diketopiperazine-containing pyrroloindoline natural products. Only a year afterwards, Ye and coworkers accomplished the first total synthesis of (–)-nocardioazine B (*ent*-**187**).⁴



Scheme 3.2. Preparation of nocardioazine B fragments from tryptophans by Ye

Starting from D-tryptophan (255), a well-established three-step procedure provided *exo*-Br-pyrroloindoline 184 in good yield (Scheme 3.2). Utilizing methodology developed by Rainier and coworkers,⁵ the bromide of pyrroloindoline *exo*-184 was converted to a methyl group via a highly strained cyclopropane intermediate (See Chapter 2, Scheme 2.3 for detailed discussion), which provided the *endo*-pyrroloindoline fragment *endo*-186. In order to assemble the eastern fragment of the natural product, L-tryptophan was converted to *ent*-184 following the same procedure, and was subjected to a Keck radical alkylation, as utilized by the Danishefsky group.⁶ The allyl group in 256 was subjected to a Johnson-Lemieux oxidation to form the corresponding aldehyde, which underwent a Wittig olefination reaction to provide the prenyl group of the pyrroloindoline fragment *exo*-257.

After preparation of both fragments, a step-wise peptide coupling strategy was pursued to form the DKP core (Scheme 3.3): *endo*-**186** was hydrolyzed to give acid **258**, and the Boc groups in *exo*-**257** were then removed to provide amine **259**. Carboxylic acid **258** and amine **259** were treated with peptide coupling reagent HATU to form dipeptide **260**, which was subsequently methylated at the aniline nitrogen under reductive

amination conditions. Upon removal of the two Boc protecting groups, the resulting secondary amine intermediate cyclized *in situ* to provide the central DKP and completed the total synthesis of (–)-nocardioazine B (*ent*-**187**). Through *de novo* exercise, Ye and coworkers were able to correct the originally proposed absolute stereochemistry of the natural product by comparison of the optical rotation signs, confirming that (+)-nocardioazine B (**187**, Figure 3.1) is the naturally occurring form. The question left unanswered was the absolute configuration of nocardioazine A (**171**), although it was presumed that it carried the same absolute configuration as **187**.





3.1.3 Retrosynthetic Analysis

The total synthesis reported by the Ye group, albeit a short synthesis, relied entirely on the chiral information obtained from D/L-tryptophan building blocks to control

the construction of subsequent stereocenters. However, we believed that a more efficient synthesis of **171** and **187** could be born by harnessing the power of asymmetric catalysis and starting from achiral starting materials.

We took particular note of the fact that the *endo-* and *exo-*pyrroloindolines are of the opposite enantiomeric series, a structural element that is necessary to geometrically accommodate the macrocycle of **171**. This interesting stereochemical relationship makes **171** and **187** appealing synthetic targets for asymmetric catalysis, where selection of the appropriate enantiomer of catalyst dictates the absolute stereochemistry of the pyrroloindoline building blocks.





Thus, it was envisioned that both **171** and **187** could be accessed from DKP **262** (Scheme 3.4). A simple cross metathesis with isobutene would provide nocardioazine B

(187). On the other hand, cross metathesis with methacrolein and subsequent reduction would generate allylic alcohol 261, which provides a suitable handle for cyclization and sets the stage for a final epoxidation event to complete the total synthesis of nocardioazine A (171). The divergent intermediate 262 is proposed to be accessed by coupling pyrroloindolines *endo*-264 and *exo*-265. In previous studies we have demonstrated that the *exo*-diastereomer can be epimerized to the corresponding *endo*-diastereomer, thus the preparation of both *endo*-264 and *exo*-265 would provide a path forward.¹

3.2 TOTAL SYNTHESIS OF (+)-NOCARDIOAZINE B

In the forward sense, treatment of a solution of *N*-methyl-3-allyl indole (**266**) and acrylate **61a** with (*S*)-BINOL (20 mol %) and $SnCl_4$ (1.2 equiv) delivered *exo*-pyrroloindoline **265** in 52% yield and 90% ee (Scheme 3.5). These conditions were highly diastereoselective for *exo*-**265** (19:1); however, the yield is modest due to allyl migration from C3 to C2 of the indole under the reaction conditions.⁷ Neither addition of 2,6-dibromophenol nor use of other catalysts improved the yield of **265**. Cleavage of the TFA group using TfOH in anhydrous methanol provided, upon basic workup, *exo*-amine **267**.





On the other hand, treatment of *N*-allylindole 268 and benzyl trifluoroacetamidoacrylate (61b) with (R)-3,3'-dichloro-BINOL (20 mol %), $SnCl_4$ (1.6 equiv), and 2,6-dibromophenol (0.4 equiv) furnished exo-pyrroloindoline 269 in 57% yield and 98% ee (Scheme 3.6). It is noteworthy that additive 2,6-dibromophenol significantly improves the ee of this reaction, compared to the observed 92% ee without it.² The modest yield of *exo*-**269** results from the moderate diastereoselectivity (5.8:1) of the transformation. In this case, benzyl acrylate **61b** was employed instead of methyl acrylate 61a because the dr was improved and the exo- and endo- diastereomers were more readily separated. In order to prepare the corresponding carboxylic acid 271, benzyl ester was first converted to methyl ester 270 using K₂CO₃ in methanol. Treatment of exo-270 with LiHMDS at low temperatures followed by acetic acid quench provided the thermodynamically favored *endo* diastereomer **264**, which was deprived of the methyl ester with BBr₃ to deliver *endo*-pyrroloindoline acid **271**.

Scheme 3.6. Preparation of endo-pyrroloindoline 271 fragment



With access to *endo*-acid **271** and *exo*-amine **267**, we were poised to prepare key DKP **263** (Scheme 3.4). In contrast to our unsuccessful efforts to couple *exo*-

pyrroloindolines in the lansai B (169) synthesis (Chapter 2), mixing of *endo*-acid 271 and *exo*-amine 267 in the presence of BOP-Cl furnished the desired dipeptide 272, albeit in low yield due to side reactions including epimerization and decomposition of 271 (entry 1, Table 3.1). After considerable optimization, we discovered that the nature of the base in the peptide coupling plays a key role in determining the reactivity. When DMAP or pyridine was used, the major product was the anhydride derived from dimerization of acid 271. Fortunately, 2,4,6-collidine was found to be effective in favoring product formation over anhydride production to provide 45% yield of product (entry 4). The yield was further improved to 81% by slow addition of acid 271 to 2.0 equiv amine 267 (entry 6). Importantly, the unreacted amine 267 could be recovered by silica gel chromatography. When compared to the challenges encountered in the coupling of *exo*-pyrroloindolines, the ability to couple *exo*-267 and *endo*-271 reveals that, in addition to the identity of the *N*-substituents, the relative stereochemistry of the pyrroloindoline coupling partners is a key determinate in the ease of peptide formation.





[a] ratio determined by LCMS.[b] slow addition of endo-271 into reaction.

Saponification of **272** with LiOH generated amino acid **273**, which could be detected by LC-MS (Scheme 3.7). Interestingly, acidification of the reaction mixture with 1M HCl delivered DKP **263**, which represents an unusually facile DKP cyclization. Subsequent palladium-catalyzed deallylation of **263** in the presence of 1,3-dimethylbarbituric acid as the allyl scavenger gave free amine **262**.⁸ Cross metathesis of **262** with 2-methyl-2-butene (**274**) provided (+)-nocardioazine B (**187**).⁹ Thus, the enantioselective total synthesis of (+)-**187** was completed in nine linear steps and 21% overall yield from 3-methylindole.





3.3 TOTAL SYNTHESIS OF (+)-NOCARDIOAZINE A

3.3.1 A Late-stage Epoxidation Strategy

At this stage, our focus shifted to advancing amine 262 to (+)-nocardioazine A (171). Exposure of 262 to excess methacrolein (274) and *ortho*-isopropyl Hoveyda-Grubbs II catalyst (10 mol %) delivered enal 275 in 76% yield as a 10 : 1 E/Z mixture

(Scheme 3.8).¹⁰ Luche reduction followed by Finkelstein chlorination provided allyl chloride **276**. Gratifyingly, treatment of **276** with tetrabutylammonium iodide (TBAI) and base in acetonitrile at 80 °C promoted intramolecular *N*-alkylation, furnishing macrocycle **277**. Interestingly, the base was found to be important in this S_N^2 process: use of a less bulky base like triethylamine provided lower yields due to competing displacement of chloride to form an ammonium salt. Interestingly, the ¹H NMR spectra of alkene **277** revealed two interconverting conformations, adding difficulties to the elucidation of its structure. Eventually, the structure of this unusual macrocycle **277** was confirmed by X-ray crystallography, setting the stage for the final epoxidation step.

Scheme 3.8. Preparation of macrocyclic alkene 277



Unfortunately, exposure of 277 to a wide variety of epoxidation conditions, including dimethyldioxirane, *m*-chloroperoxybenzoic acid, and Jacobsen epoxidation

catalysts, failed to produce the natural product; instead, the major product was unstable *N*-oxide **278** (Scheme 3.9), which was characterized by a significant downfield shift of the *N*-methyl group in the ¹H NMR. Use of excess oxidant or efforts to isolate **278** and resubject it to epoxidation conditions were also unsuccessful, revealing that the trisubstituted alkenes of **277** and **278** are remarkably inert toward epoxidation. The origin of this effect is unclear; however, inspection of the crystal structure of alkene **277** suggests that it is not simply steric shielding of the double bond.

Scheme 3.9. Attempts to install the epoxide



Alternatively, it was possible to diastereoselectively dihydroxylate alkene **279** using potassium osmate.¹¹ Selective mesylation of the secondary alcohol and exposure of the resulting mesylate to potassium carbonate in methanol closed the epoxide to form *epi*-(C2")-nocardioazine A (**280**). Unfortunately, attempts to correct the stereochemistry by double inversion strategies or oxidation/reduction sequences were unsuccessful.

Fully aware of the challenges associated with epoxidizing the macrocyclic alkene **277**, a strategy involving switching the order of epoxidation and cyclization was pursued. Epoxidation of allylic alcohol **261** proceeded smoothly under Sharpless asymmetric epoxidation conditions (Scheme 3.10).¹² However, intramolecular Mitsunobu reaction did

not occur, presumably due to the lower acidity of the aniline *N*-H in **281**. Alternatively, the primary alcohol could be converted to the mesylate (**282**). Unfortunately, either epimerization or no reaction was observed when treating **282** with a wide array of base. Other leaving groups including iodide and triflate were also explored, but no cyclization product was detected in either case. The lower reactivity toward cyclization of epoxide **282** versus alkene **277** is not entirely surprising due to the loss of reactivity gained from the allylic halide in **277**.



Scheme 3.10. Attempts to promote the last-stage cyclization

3.3.2 An Early-stage Epoxide Installation Approach

Given the challenges encountered in attempting to epoxidize late-stage intermediate 277, a revised strategy utilizing an early-stage epoxidation and diketopiperazine-forming macrocyclization was pursued (Scheme 3.11). Thus, 3a-allyl pyrroloindoline *exo-265* was transformed into aldehyde 283 via cross metathesis with 274. Luche reduction and Sharpless asymmetric epoxidation using (+)-diethyltartrate delivered epoxy alcohol 285 in 10:1 dr,¹² which was converted to mesylate 286 by Scheme 3.11. Early incorporation of epoxide



treatment with mesyl chloride. The corresponding epoxy iodide **287** could also be prepared by subjecting mesylate **286** to NaI in acetone. Concomitantly, amine **288** was prepared from *endo*-pyrroloindoline **264** by Pd-catalyzed deallylation (Scheme 3.12). Both epoxide nucleophiles **286** and **287** were exposed to amine **288** and Hünig's base in acetonitrile at high temperatures. Interestingly, mesylate **286** showed no reactivity, while iodide **287** afforded desired coupled product **289** in 30% yield. However, epoxide **289** was accompanied with the formation of side product **290** in 42% yield, which was proposed to arise from iodide-triggered epoxide opening followed by pyrroloindoline ring-opening and intramolecular trapping with the secondary alcohol.

In order to harness the reactivity of epoxide iodide and minimize the undesired rearrangement side pathway, it was proposed that the addition of a catalytic amount of an iodide source to mesylate **286** could generate epoxide iodide **287** *in situ*, thus the lower concentration of iodide would suppress the undesired side reaction pathway. Indeed, after

Scheme 3.12. Intermolecular alkylation attempts



Scheme 3.13. Endgame of (+)-nocardioazine A synthesis



considerable optimization, it was observed that treatment of amine **288** and mesylate **286** with 0.2 equivalent of TBAI and Hünig's base in acetonitrile at 90 °C delivers bis(pyrroloindoline) **289** in 74% yield (Scheme 3.13). Exposure of **289** to excess LiOH

resulted in saponification of the methyl esters and hydrolysis of the TFA groups to give bis(amino acid) **293**. We were pleased to find that subjection of **293** to bromotripyrrolidinophosphonium hexafluorophosphate (PyBroP, a peptide coupling reagent) in DMF promoted intramolecular DKP formation to afford (+)-nocardioazine A (**171**). The synthesis of (+)-**171** requires only nine steps and proceeds in 11% overall yield from 3-allylindole. Moreover, these findings establish the viability of macrocyclization by intramolecular DKP formation.

Through this process, we also established that the naturally isolated nocardioazine A (**171**) possesses the same absolute stereo configurations as nocardioazine B (**187**), suggesting that both natural products might be produced from the same biological source, namely cyclo-(L-Trp-D-Trp).

3.4 CONCLUDING REMARKS

In summary, the enantioselective total syntheses of the diketopiperazin-containing pyrroloindoline natural products (+)-nocardioazine A (**171**) and B (**187**) were accomplished. These studies demonstrate the utility of enantioselective formal (3 + 2) cycloaddition reactions to prepare highly functionalized pyrroloindolines for applications in total synthesis. In addition, subtle changes in the relative stereochemistry and nitrogen substitution patterns of pyrroloindolines were shown to significantly influence the ability to prepare bis(pyrroloindolines) by DKP formation. Further investigations of **171** as an inhibitor of P-glycoprotein are ongoing with collaboration with the Chang laboratory in UC San Diego.

3.5 EXPERIMENTAL SECTION

3.5.1 Materials and Methods

Unless otherwise stated, reactions were performed under a nitrogen atmosphere using freshly dried solvents. Tetrahydrofuran (THF), methylene chloride (CH₂Cl₂), acetonitrile (MeCN), dimethylformamide (DMF), and toluene (PhMe) were dried by passing through activated alumina columns. Unless otherwise stated, chemicals and reagents were used as received. N,N-Diisopropylethamine (DIPEA) was distilled over calcium hydride prior to use. All reactions were monitored by thin-layer chromatography using EMD/Merck silica gel 60 F254 pre-coated plates (0.25 mm) and were visualized by UV, p-anisaldehyde, or KMnO₄ staining. Flash column chromatography was performed either as described by Still et al.¹³ using silica gel (particle size 0.032-0.063) purchased from Silicycle or using pre-packaged RediSep[®]Rf columns on a CombiFlash Rf system (Teledyne ISCO Inc.). Optical rotations were measured on a Jasco P-2000 polarimeter using a 100 mm path-length cell at 589 nm. ¹H and ¹³C NMR spectra were recorded on a Varian 400 MR (at 400 MHz and 101 MHz, respectively), a Bruker 400 equipped with a cryoprobe (at 400 MHz and 101 MHz, respectively), a Varian Inova 500 (at 500 MHz and 126 MHz, respectively), or a Varian Inova 600 (at 600 MHz and 150 MHz, respectively), and are reported relative to internal CHCl₃ (¹H, δ = 7.26), CHDCl₂ (¹H, δ = 5.32), CD₂HOD (¹H, δ = 3.31), MeCN-d2 (¹H, δ = 1.94), or DMSO-d5 (¹H, δ = 2.50), and CDCl₃ (¹³C, δ = 77.0), CD₂Cl₂ (¹³C, δ = 54.0), CD₃OD (¹³C, δ = 49.0), MeCN-d3 $({}^{13}C, \delta = 118.3)$, or DMSO-d6 $({}^{13}C, \delta = 40.0)$. Data for ¹H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicity and qualifier abbreviations are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, app = apparent. IR spectra were recorded on a Perkin Elmer Paragon 1000 spectrometer and are reported in frequency of absorption (cm⁻¹). HRMS were acquired using an Agilent 6200 Series TOF with an Agilent G1978A Multimode source in electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), or mixed (MM) ionization mode. Analytical chiral HPLC was performed with an Agilent 1100 Series HPLC utilizing Chiralpak AD or Chiralcel OD-H columns (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd with visualization at 254 nm. Preparative HPLC was performed with an Agilent 1100 Series HPLC utilizing an Agilent Eclipse XDB-C18 5µm column (9.4 x 250 mm) or an Agilent Zorbax RX-SIL 5µm column (9.4 x 250 mm). Melting points were determined using a Büchi B-545 capillary melting point apparatus and the values reported are uncorrected.

3.5.2 Preparative Procedures and Spectroscopic Data

Preparation of N-methyl-3-allylindole 266



To a 500 mL flame-dried flask was added NaH (60%, 4.94 g, 123.6 mmol, 1.5 equiv) and DMF (120 mL). Commercially aviallable 3-allylindole **A-2** (12.95 g, 82.4 mmol, 1.0 equiv) was transferred to the reaction flask via DMF (40 mL). After 90 minutes, methyl iodide (7.7 mL, 123.6 mmol, 1.5 equiv) was added slowly, while the reaction flask was cooled using an ice-bath. After 1 hour, the reaction was diluted with EtOAc (100 mL) and carefully quenched with distilled water (300 mL). The mixture was separated and the aqueous layer was then extracted with EtOAc (2 x 200 mL). Combined

organic layers were washed with brine (3 x 300 mL) to get rid of DMF. It was dried over Na_2SO_4 , filtered and concentrated down to a yellow oil. Flash chromatography (0% to 10% EtOAc in hexanes) afforded *N*-methyl-3-allylindole **266**, as a yellow oil (13.77 g, 80.4 mmol, 98% yield). Spectral data matches that reported in the literature.¹⁴

Preparation of N-methyl-3-allyl pyrroloindoline 265



To a flame-dried flask was added N-methyl-3-allylindole 266 (1.0 g, 5.80 mmol, 1.0 equiv), methyl acrylate **61a** (1.15 g, 5.80 mmol, 1.0 equiv), (S)-BINOL (334 mg, 1.20 mmol, 0.2 equiv), and DCM (30 mL). The reaction flask was covered with aluminum foil. SnCl₄ (1M solution in DCM, 9.34 mL, 9.34 mmol, 1.6 equiv) was added at last. The reaction mixture was allowed to stir at room temperature for 24 hours. The solution was diluted with acetonitrile (12 mL) and quenched with 1M HCl (12 mL), followed by addition of distilled water (60 mL). The mixture was separated and the aqueous layer was extracted with EtOAc (3 x 60 mL). Combined organic layers were washed with saturated NaHCO₃ solution (75 mL) and then brine (75 mL). It was dried over Na₂SO₄, filtered and concentrated down to give an orange oil. Flash chromatography (0% to 20% EtOAc in hexanes) afforded 3-allyl-pyrroloindoline 265 (19:1 mixture of exo:endo diastereomers by ¹H NMR), as a thick orange oil (1.10 g, 2.99 mmol, 52% yield); A-3 was isolated as the major side product, resulting from C3 to C2 rearrangement. The mixture of diastereomers was further purified by flash chromatography (0% to 10% EtOAc in hexanes) to give major diastereomer **265** for characterization purposes. The enantiomeric

excess of exo-265 was determined to be 90% by chiral SFC analysis (AD, 2.5 mL/min, 3% IPA in CO₂, $\lambda = 254$ nm): $t_{\rm R}$ (major) = 3.2 min, $t_{\rm R}$ (minor) = 6.5 min. $[\alpha]_{\rm D}^{25} = +112^{\circ}$ (c = 0.96, CHCl₃); ¹H NMR (500 MHz, CDCl₃; compound exists as a 2.0:1 mixture of rotamers the major rotamer is denoted by *, minor rotamer denoted by δ 7.17 (t, J = 7.7) Hz, 1H*, 1H[§]), 7.05 (d, J = 7.3 Hz, 1H*, 1H[§]), 6.84 (t, J = 8.1 Hz, 1H[§]), 6.77 (t, J = 7.5Hz, 1H*), 6.58 (d, J = 7.2 Hz, 1H[§]), 6.52 (d, J = 7.9 Hz, 1H*), 5.62 (s, 1H*), 5.60 – 5.45 $(m, 1H^*, 1H^{\$}), 5.44 (s, 1H^{\$}), 5.15 - 5.04 (m, 2H^*, 2H^{\$}), 4.64 (d, J = 5.5 Hz, 1H^*), 4.38 -$ 4.31 (m, 1H[§]), 3.81 (s, 3H^{*}), 3.76 (s, 3H[§]), 3.10 (s, 3H^{*}), 2.89 (s, 3H[§]), 2.64 (dd, J = 13.6, 9.3 Hz, 1H*), 2.62 – 2.57 (m, 1H[§]), 2.54 (dd, J = 14.0, 6.7 Hz, 1H*, 1H[§]), 2.52 – 2.47 (m, $1H^{\$}$, 2.46 – 2.40 (m, 1H*), 2.32 (dd, J = 13.9, 8.4 Hz, 1H*), 2.19 – 2.11 (m, 1H[§]); ¹³C NMR (126 MHz, CDCl₃) δ 172.5*, 170.5[§], 158.8* (q, J = 37.1 Hz), 157.5[§] (q, J = 38.0 Hz), 150.2*[§], 133.2*, 132.2[§], 129.0[§], 128.8*, 122.1*, 120.0[§], 119.1*, 118.7[§], 116.0* (q, J = 288.4 Hz), 115.8[§] (app d, J = 285.2 Hz), 109.9[§], 108.2^{*}, 90.4^{*}, 89.0[§], 60.6[§], 59.5^{*}, $57.3^{\$}, 53.4^{\ast}, 52.9^{\ast}, 52.4^{\$}, 42.1^{\ast}, 41.6^{\ast}, 41.0^{\$}, 39.0^{\$}, 36.8^{\ast}, 35.4^{\$}$ (both ¹H and ¹³C spectra were taken using the enantiomer of 23); FTIR (NaCl, thin film): 3076, 3053, 3008, 2955, 2918, 2848, 2829, 1751, 1693, 1641, 1608, 1490, 1435, 1357, 1302, 1203, 1158, 1061, $1023, 994, 952, 925, 875, 854, 810, 795, 746 \text{ cm}^{-1}$; HRMS (MM) calc'd for $C_{18}H_{20}F_3N_2O_3$ [M+H]⁺ 369.1421, found 369.1432.

Preparation of exo-pyrroloindoline amine 267



To a 200 mL flame-dried flask was added *exo*-3-allyl-pyrroloindoline **265** (6.57 g, 17.8 mmol, 1.0 equiv) and dissolved with MeOH (90 mL). Triflic acid (15.7 mL, 178.4 mmol, 10.0 equiv) was added slowly into reaction flask. The dark purple mixture was allowed to stir at room temperature for 50 hours. The solution was cautiously quenched with saturated NaHCO₃ solution (150 mL). The mixture was separated and the aqueous layer was extracted with DCM (3 x 150 mL). Combined organic layers were dried over Na_2SO_4 , filtered and concentrated down to give an orange oil. Flash chromatography (0%) to 60% EtOAc in hexanes) afforded 3-allyl-pyrroloindoline amine exo-267 as a thick orange oil (3.60 g, 13.2 mmol, 75% yield). $[\alpha]_{D}^{25} = +43^{\circ}$ (c = 0.95, CHCl₃); ¹H NMR $(500 \text{ MHz}, \text{CDCl}_3) \delta 7.05 \text{ (td}, J = 7.6, 1.3 \text{ Hz}, 1\text{H}), 6.98 \text{ (dd}, J = 7.4, 1.2 \text{ Hz}, 1\text{H}), 6.61$ (td, J = 7.4, 1.0 Hz, 1H), 6.31 (d, J = 7.8 Hz, 1H), 5.67 (dddd, J = 16.7, 10.1, 7.9, 6.4 Hz)1H), 5.08 - 4.99 (m, 2H), 4.68 (s, 1H), 3.64 (s, 3H), 3.62 (dd, J = 10.4, 6.1 Hz, 1H), 2.78(s, 3H), 2.67 (s, 1H), 2.51 (ddt, J = 13.9, 6.5, 1.4 Hz, 1H), 2.41 (ddt, J = 13.7, 8.0, 1.1 Hz)1H), 2.34 (dd, J = 12.1, 6.1 Hz, 1H), 1.95 (dd, J = 12.2, 10.4 Hz, 1H); ¹³C NMR (126) MHz, CDCl₃) δ 173.8, 150.8, 134.0, 132.2, 127.9, 122.6, 117.6, 116.4, 104.9, 88.0, 58.9, 56.0, 51.5, 44.1, 42.5, 30.9; FTIR (NaCl, thin film): 3344, 3073, 3050, 3024, 3003, 2950, 2916, 1738, 1639, 1606, 1493, 1449, 1437, 1383, 1354, 1328, 1300, 1267, 1236, 1206, 1166, 1140, 1121, 1105, 1073, 1019, 998, 973, 948, 918, 889, 817, 790, 741 cm⁻¹; HRMS (MM) calc'd for $C_{16}H_{21}N_2O_2$ [M+H]⁺ 273.1598, found 273.1067.

Preparation of *N***-allyl pyrroloindoline 269**



To a flame-dried flask was added N-allylindole 268¹⁵ (815 mg, 4.76 mmol, 1.0 equiv), benzyl acrylate **61b**¹⁶ (1.56 g, 5.71 mmol, 1.2 equiv), (R)-3,3'-Cl₂-BINOL (338 mg, 0.95 mmol, 0.2 equiv), 2,6-dibromo-phenol (480 mg, 1.90 mmol, 0.4 equiv) and DCM (35 mL). SnCl₄ (1M solution in DCM, 7.62 mL, 7.62 mmol, 1.2 equiv) was added at last. The orange mixture was allowed to stir at room temperature for 42 hours. The solution was diluted with acetonitrile (12 mL) and guenched with 1M HCl (12 mL), followed by addition of distilled water (60 mL). The mixture was separated and the aqueous layer was extracted with ether (3 x 60 mL). Combined organic layers were washed with 3M NaOH solution (3 x 75 mL). It was dried over MgSO₄, filtered and concentrated down to give yellow mixture of oil and solid. Flash chromatography (1% to 8% EtOAc in hexanes) afforded major diastereomer exo-pyrroloindoline 269 as a thick orange oil (1.19 g, 2.68 mmol, 57% yield); minor diastereomer endo-pyrroloindoline A-4 was also isolated as a thick orange oil (204 mg, 0.46 mmol, 10% yield). The enantiomeric excess of 269 was determined to be 98% by chiral SFC analysis (OJ, 2.5 mL/min, 6% IPA in CO₂, $\lambda = 254$ nm): $t_{\rm R}$ (major) = 5.7 min, $t_{\rm R}$ (minor) = 4.4 min. The enantiomeric excess of A-4 was determined to be 93% by chiral SFC analysis (OJ, 2.5 mL/min, 2% IPA in CO₂, $\lambda = 254$ nm): $t_{\rm R}$ (major) = 5.7 min, $t_{\rm R}$ (minor) = 4.4 min. Spectral data of both diastereomers matches that reported in the literature.²



N-Allyl pyrroloindoline benzyl ester **269** (1.11 g, 2.51 mmol, 1.0 equiv) was dissolved in dry methanol (25 mL); then K_2CO_3 (70 mg, 0.50 mmol, 0.2 equiv) was added as one portion. After running at room temperature for 6 hours, the reaction was quenched with 1M HCl (50 mL), and extracted with EtOAc (3 x 40 mL). Combined organic layer was washed with sodium bicarbonate saturated solution (50 mL) and then dried over Na₂SO₄, filtered and concentrated down to give yellow oil. Flash chromatography (0% to 15% EtOAc in hexanes) afforded corresponding methyl ester **270**, as a white solid (818 mg, 2.22 mmol, 89% yield). Spectral data matches that reported in the literature.³

Preparation of endo-N-allyl pyrroloindoline 264



N-Allyl pyrroloindoline methyl ester **270** (700 mg, 1.90 mmol) was dissolved in dry THF (16 mL) and brought to -78 °C. LiHMDS solution (1M in THF, 2.85 mL, 2.85 mmol, 1.5 equiv) was added slowly to substrate in THF. After 1 hour, the reaction was quenched with acetic acid (1 mL) and warmed to room temperature. Then the reaction was quenched carefully with sodium bicarbonate saturated solution (40 mL). The aqueous layer was then extracted with EtOAc (3 x 50 mL). Combined organic layer was washed with brine (50 mL). It was then dried over Na₂SO₄, filtered, and concentrated

Preparation of N-allyl pyrroloindoline methyl ester 270

down to give a yellow oil. Flash chromatography (0% to 10% EtOAc in hexanes) afforded corresponding epimerized *endo* pyrroloindoline methyl ester **264**, as a yellow oil (700 mg, 1.90 mmol, quantitative yield). $[\alpha]_D^{25} = -200^\circ$ (c = 1.62, CHCl₃); spectral data matches that the corresponding enantiomer reported in the literature.³

Preparation of endo-N-allyl pyrroloindoline carboxylic acid 271



endo-N-Allyl pyrroloindoline methyl ester 264 (1.50 g, 4.07 mmol, 1.0 equiv) was added to a flame-dried 100 mL flask and dissolved in DCM (36 mL). The flask was then cooled to -78 °C and freshly prepared BBr₃ in DCM solution (BBr₃: 1.15 mL, 12.22 mmol, 3.0 equiv; DCM: 12 mL) was added slowly into reaction flask. After 5 minutes, the reaction was allowed to warm to room temperature and stirred for 90 minutes. It was then quenched carefully with addition of distilled water (10 mL), then followed by addition of pH = 2.5 acidic buffer (40 mL, prepared by acidifying a 10% NaH₂PO₄ aqueous solution by KHSO₄ until pH reaches 2.5). The aqueous layer was extracted with EtOAc (4 x 40 mL). Combined organic layer was washed with brine (80 mL). It was then dried over Na₂SO₄, filtered, and concentrated down to give a yellow oil. Flash chromatography (0% to 20% EtOAc in hexanes, with 1% acetic acid) afforded corresponding pyrroloindoline carboxylic acid *endo*-271, as a brown foam (1.26 g, 3.56 mmol, 88% yield). $[\alpha]_{D}^{25} = -179^{\circ}$ (c = 1.39, CHCl₃); ¹H NMR (500 MHz, CDCl₃; compound exists as a 8.0 : 1 mixture of rotamers the major rotamer is denoted by *, minor rotamer denoted by §) δ 10.90 (s, 1H*, 1H§), 7.11 (td, J = 7.7, 1.3 Hz, 1H§), 7.07

 $(dd, J = 7.4, 1.2 Hz, 1H^{\$}), 6.99 (td, J = 7.7, 1.3 Hz, 1H^{\ast}), 6.95 (dd, J = 7.5, 1.2 Hz, 1H^{\ast}),$ 6.75 (td, J = 7.4, 1.0 Hz, 1H[§]), 6.57 (td, J = 7.4, 0.9 Hz, 1H^{*}), 6.50 (d, J = 7.9 Hz, 1H[§]), 6.39 (d, J = 7.9 Hz, 1H*), 5.85 (ddt, J = 17.3, 10.6, 5.4 Hz, 1H*), 5.81 – 5.72 (m, 1H[§]), 5.59 (s, 1H*), 5.55 (d, J = 1.9 Hz, 1H[§]), 5.29 (dq, J = 17.2, 1.7 Hz, 1H*), 5.22 – 5.20 (m, $1H^{\$}$), 5.20 – 5.17 (m, $1H^{\$}$), 5.15 (dq, J = 10.2, 1.5 Hz, $1H^{*}$), 5.06 (dd, J = 9.9, 5.4 Hz, $1H^{\$}$, 4.73 (dt, J = 8.7, 1.5 Hz, $1H^{*}$), 4.13 (qdt, J = 16.7, 5.1, 1.7 Hz, $2H^{*}$), 3.91 - 3.69 $(m, 2H^{\$}), 2.76 (dd, J = 13.2, 1.4 Hz, 1H^{*}), 2.42 (dd, J = 13.1, 8.8 Hz, 1H^{*}), 2.39 - 2.34$ (m, 1H[§]), 2.29 (dd, J = 13.4, 9.9 Hz, 1H[§]), 1.45 (s, 3H[§]), 1.43 (s, 3H^{*}); ¹³C NMR (126) MHz, CDCl₃) δ 175.3[§], 175.2^{*}, 156.8 (q, J_{C-F} = 37.0 Hz), 156.6 (q, J_{C-F} = 37.5 Hz), 149.1*, 147.3[§], 133.8*, 133.1[§], 132.4[§], 131.8*, 128.9*, 128.5[§], 122.2*, 121.4[§], 118.7[§], $118.0^{*}, 117.1^{\$}, 116.3^{*}, 116.0^{*}$ (q, $J_{C-F} = 288.5$ Hz), $108.1^{\$}, 107.1^{*}, 88.9^{\$}, 88.3^{*}, 59.8^{\$},$ 59.6* (q, $J_{C-F} = 3.1$ Hz), 52.2[§], 50.4*, 48.8*, 46.2[§], 42.3*, 41.1[§], 25.2*, 22.0[§]; FTIR (NaCl, thin film): 3079, 3057, 3026, 2963, 2928, 2870, 2647, 2560, 1729, 1696, 1608, 1491, 1448, 1352, 1314, 1253, 1210, 1184, 1145, 1106, 1093, 1083, 1027, 992, 942, 921, 888, 854, 742 cm⁻¹; HRMS (APCI) calc'd for $C_{17}H_{18}F_3N_2O_3$ [M+H]⁺ 355.1264, found 355.1275.

Preparation of dipeptide 272



To a 250 mL flame-dried flask was added 3-allyl-amine *exo-***267** (1.94 g, 7.11 mmol, 2.0 equiv), BOP-Cl (1.81 g, 7.11 mmol, 2.0 equiv) and dissolved with DCM (93

Carboxylic acid endo-271 (1.26 g, 3.56 mmol, 1.0 equiv) was dissolved in DCM (47 mL) and the resulting solution was added slowly into the reaction flask using a syringe pump over 12 hours. The resulting reaction solution was allowed to stir at room temperature for another 10 hours. The reaction was quenched with saturated NaHCO₃ solution (200 mL). The mixture was separated and the aqueous layer was extracted with EtOAc (3 x 150 mL). Combined organic layers were washed with brine (300 mL), dried over Na₂SO₄, filtered and concentrated down to give an orange oil. The crude material was left in the flask for 36 hours to allow the hydrolysis of anhydride formed under reaction conditions. Flash chromatography (0% to 60% EtOAc in hexanes) afforded dipeptide 272 as a pink foam (1.81 g, 2.97 mmol, 84% yield). $[\alpha]_{D}^{25} = +18^{\circ}$ (c = 1.22, CHCl₃); ¹H NMR (500 MHz, DMSO- d_6 compound exists as a 1.4 : 1 : 1 mixture of rotamers) complicated spectrum, please see the attached ¹H NMR spectrum; ¹³C NMR (126 MHz, DMSO- d_6 , compound exists as a mixture of rotamers) δ 173.0, 171.6, 171.5, 170.8, 170.2, 168.7, 157.7 (q, $J_{C-F} = 36.5 \text{ Hz}$), 157.0 (q, $J_{C-F} = 36.3 \text{ Hz}$), 156.6 (q, $J_{C-F} = 36.4 \text{ Hz}$), 151.0, 150.6, 149.6, 149.2, 148.3, 147.2, 135.1, 134.9, 134.6, 134.5, 134.4, 134.3, 134.0, 133.9, 133.0, 132.5, 129.1, 128.7, 128.6, 128.4, 128.4, 123.1, 122.6, 122.4, 122.0, 121.3, 120.5, 119.0, 118.7, 118.6, 118.1, 118.0, 117.9, 117.9, 117.1, 117.0, 116.5, 116.3 (q, $J_{CF} = 288.6 \text{ Hz}$), 116.3 (q, $J_{C-F} = 288.6$ Hz), 116.3 (app d, $J_{C-F} = 287.3$ Hz), 111.5, 108.0, 107.9, 107.5, 107.5, 106.9, 91.1, 89.5, 89.3, 89.1, 87.9, 87.7, 62.2, 61.1, 60.1, 60.0, 58.8, 58.1, 55.7, 53.2, 53.1, 52.6, 52.0, 50.2, 49.9, 49.5, 49.2, 46.0, 43.4, 42.8, 42.1, 41.6, 41.5, 40.8, 38.5, 37.7, 37.6, 36.1, 32.8, 26.5, 23.4, 19.4; FTIR (NaCl, thin film): 3075, 3052, 3016, 2954, 2869, 1744, 1696, 1681, 1638, 1607, 1491, 1448, 1437, 1406, 1357, 1298, 1282, 1210, 1184, 1145, 1106, 1022, 992, 922, 847, 742 cm⁻¹; HRMS (APCI) calc'd for C₃₃H₃₆F₃N₄O₄ [M+H]⁺ 609.2683, found 609.2683.

Preparation of bis(allyl)-diketopiperazine 263



To a 200 mL flask was added dipeptide 272 (1.81 g, 2.97 mmol, 1.0 equiv) and it was dissolved with THF (50 mL). LiOH (428 mg, 17.84 mmol, 6.0 equiv) was dissolved in distilled water (50 mL) and the resulting aqueous solution was added into the reaction flask. The reaction was allowed to stir at room temperature for 12 hours. 1M HCl (20 mL) was then added into the reaction, and the reaction was stirred for another 40 minutes. The mixture was extracted with EtOAc (3 x 50 mL). Combined organic layers were washed with saturated NaHCO₃ (150 mL) and brine (150 mL). It was dried over Na₂SO₄, filtered and concentrated down to give a yellow oil. Flash chromatography (0% to 50% EtOAc in hexanes) afforded diketopiperazine 263 as a white solid (1.05 g, 2.18 mmol, 74% yield). $[\alpha]_{D}^{25} = +90^{\circ} (c = 1.13, CHCl_{3}); {}^{1}H NMR (500 MHz, CDCl_{3}) \delta 7.14 (app tdd,$ J = 7.8, 6.6, 1.3 Hz, 2H), 7.07 (app ddd, J = 7.0, 5.6, 1.2 Hz, 2H), 6.75 (td, J = 7.5, 1.0Hz, 1H), 6.73 (td, J = 7.5, 0.9 Hz, 1H), 6.48 (d, J = 7.9 Hz, 1H), 6.40 (d, J = 7.7 Hz, 1H), 5.86 (dddd, J = 16.5, 10.4, 6.1, 4.3 Hz, 1H), 5.61 (dddd, J = 16.7, 10.1, 7.9, 6.4 Hz, 1H), 5.42 (s, 1H), 5.41 (s, 1H), 5.27 (dq, J = 17.1, 1.9 Hz, 1H), 5.13 (dq, J = 10.3, 1.6 Hz, 1H), 5.11 - 5.08 (m, 1H), 5.07 (q, J = 1.7 Hz, 1H), 4.40 (ddd, J = 9.9, 8.3, 1.5 Hz, 1H), 4.29(ddt, J = 16.8, 4.2, 1.9 Hz, 1H), 4.16 (ddd, J = 10.5, 6.7, 1.4 Hz, 1H), 4.09 - 3.98 (m, 100) 1H), 3.03 (s, 3H), 2.69 (dd, J = 12.9, 6.7 Hz, 1H), 2.52 (ddt, J = 13.8, 6.5, 1.4 Hz, 1H), 2.40 (ddt, J = 13.7, 8.0, 1.0 Hz, 1H), 2.36 – 2.29 (m, 3H), 1.45 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 168.9, 166.3, 150.6, 148.4, 133.9, 133.8, 133.1, 131.3, 128.9, 128.5, 122.8, 121.3, 118.9, 118.3, 117.9, 116.4, 107.8, 106.1, 87.9, 84.6, 60.8, 59.7, 54.2, 51.0, 50.8, 42.7, 40.5, 40.4, 33.6, 22.1; FTIR (NaCl, thin film): 3336, 3075, 3053, 3008, 2978, 2956, 2927, 2891, 2873, 2836, 1676, 1608, 1489, 1465, 1447, 1407, 1335, 1304, 1278, 1219, 1193, 1160, 1123, 1093, 1050, 1026, 999, 978, 922, 846, 800, 746, 707 cm⁻¹; HRMS (MM) calc'd for C₃₀H₃₃N₄O₂ [M+H]⁺ 481.2598, found 481.2612.

Preparation of diketopiperazine 262



To a 25 mL flame-dried screw-cap Schlenk flask was added bis(allyl)diketopiperazine **263** (650 mg, 1.35 mmol, 1.0 equiv) and dimethylbibarturic acid (DMBA, 634 mg, 4.06 mmol, 3.0 equiv). The Schlenk flask was then evacuated and backfilled with argon three times. The solids were then dissolved in dry DCE (3.7 mL). In the meantime, in a 1-dram vial, mixed $Pd_2(dba)_3$ (62 mg, 0.068 mmol, 5 mol %) and 1,4-bis(diphenylphosphino)butane (dppb, 58 mg, 0.135 mmol, 10 mol %) in DCE (1.7 mL) and it was allowed to stir at room temperature for one hour; then the resulting solution was added into Schlenk flask. The reaction was heated to 80 °C. After 42 hours, the reaction was cooled to room temperature and quenched with saturated Na₂CO₃ aqueous solution (40 mL). The mixture was extracted with EtOAc (3 x 40 mL). Combined organic layers were washed with brine (100 mL). It was dried over Na₂SO₄, filtered and concentrated down to give a brown oil. Flash chromatography (0% to 40% EtOAc in hexanes) afforded diketopiperazine 262, which was contaminated with phosphine oxide formed from the dppb ligand. The mixture was then subjected to preparative reverse phase HPLC (40% to 90% CH₃CN in H₂O in 10 minutes, $t_{\rm R}$ =7.4-7.8 min), to give pure product **262** as a yellow foam (596 mg, 1.35 mmol, quantitative yield). $[\alpha]_{D}^{25} = +71^{\circ} (c = 0.49, \text{CHCl}_{3}); ^{1}\text{H NMR} (500 \text{ MHz}, \text{CDCl}_{3}) \delta 7.14 (td, J = 7.7, 1.3 \text{ Hz},$ 1H), 7.12 - 7.04 (m, 3H), 6.78 (td, J = 7.4, 1.0 Hz, 1H), 6.72 (td, J = 7.4, 1.0 Hz, 1H), 6.59 (dt, J = 7.7, 0.8 Hz, 1H), 6.39 (d, J = 7.8 Hz, 1H), 5.56 (dddd, J = 16.8, 10.1, 8.0, 6.5)Hz, 1H), 5.38 (s, 1H), 5.34 (s, 1H), 5.27 (br s, 1H), 5.08 - 5.04 (m, 1H), 5.03 (dtd, J =2.8, 1.8, 1.1 Hz, 1H), 4.44 (ddd, J = 10.1, 7.4, 1.8 Hz, 1H), 4.15 (ddd, J = 10.7, 6.5, 1.8Hz, 1H), 3.01 (s, 3H), 2.65 (dd, J = 12.9, 6.5 Hz, 1H), 2.50 (ddt, J = 13.8, 6.6, 1.3 Hz, 1H), 2.46 – 2.34 (m, 3H), 2.28 (dd, J = 12.9, 10.7 Hz, 1H), 1.47 (s, 3H); ¹³C NMR (126) MHz, CDCl₃) δ 167.1, 165.8, 150.7, 147.0, 133.3, 133.1, 131.2, 128.8, 128.4, 122.9, 122.4, 119.2, 118.9, 117.9, 109.3, 106.1, 84.7, 83.7, 60.2, 59.2, 54.1, 51.3, 42.8, 40.7, 40.2, 33.5, 23.4; FTIR (NaCl, thin film): 3346, 3074, 3052, 3007, 2976, 2955, 2925, 2896, 2871, 2834, 1666, 1608, 1487, 1468, 1414, 1341, 1300, 1252, 1198, 1161, 1122, 1091, 1059, 1048, 1018, 1000, 978, 921, 887, 824, 746 cm⁻¹; HRMS (MM) calc'd for $C_{27}H_{29}N_4O_2$ [M+H]⁺ 441.2285, found 441.2294.

Preparation of (+)-nocardioazine B (187)



To a 25 mL flame-dried flask was added diketopiperazine 262 (8.4 mg, 0.019 mmol, 1.0 equiv), which was then co-evaporated with benzene $(2 \times 1 \text{ mL})$, and dried under high vacuum. Hoveyda-Grubbs II catalyst (1.2 mg, 0.002 mmol, 10 mol %) was added, followed by 2-methyl-2-butene (4.5 mL). The flask was equipped with a condenser and heated to 38 °C for 10 hours. The reaction was then quenched with ethyl vinyl ether (0.1 mL) and filtered through a silica gel plug, eluting with 50% EtOAc in hexanes. The filtrate was concentrated down to give a light brown oil. Flash chromatography (5% to 50% EtOAc in hexanes) afforded (+)-nocardioazine B (187) as a light grey solid (7.4 mg, 0.016 mmol, 83% yield). $[\alpha]_{D}^{25} = +65^{\circ}$ (c = 0.36, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.16 – 7.09 (m, 2H), 7.09 (td, J = 7.7, 1.2 Hz, 1H), 7.04 (dd, J = 7.3, 1.2 Hz, 1H), 6.78 (td, J = 7.4, 1.0 Hz, 1H), 6.71 (td, J = 7.4, 1.0 Hz, 1H), 6.59 (d, J= 7.7 Hz, 1H), 6.39 (d, J = 7.8 Hz, 1H), 5.35 (s, 1H), 5.31 (s, 1H), 5.21 (br s, 1H), 5.00 (tq, J = 4.9, 1.6 Hz, 1H), 4.44 (ddd, J = 9.8, 7.7, 1.8 Hz, 1H), 4.15 (ddd, J = 10.7, 6.5, 1.8 Hz, 1H)Hz, 1H), 3.01 (s, 3H), 2.64 (dd, J = 12.8, 6.5 Hz, 1H), 2.47 – 2.32 (m, 4H), 2.28 (dd, J =12.8, 10.7 Hz, 1H), 1.65 (s, 3H), 1.50 (s, 3H), 1.47 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 167.3, 165.9, 150.6, 147.1, 135.5, 133.4, 131.9, 128.7, 128.5, 122.8, 122.4, 119.3, 118.6, 118.0, 109.3, 106.2, 84.9, 83.7, 60.4, 59.3, 54.7, 51.3, 40.9, 39.6, 36.5, 33.6, 25.9, 23.4, 18.0; FTIR (NaCl, thin film): 3348, 3051, 2956, 2925, 2870, 2855, 1667, 1608, 1487, 1468, 1445, 1415, 1381, 1342, 1301, 1261, 1232, 1200, 1156, 1099, 1085, 1065, 1042, 1019, 1000, 976, 942, 890, 850, 822, 802, 781, 744 cm⁻¹; HRMS (MM) calc'd for $C_{29}H_{33}N_4O_2$ [M+H]⁺ 469.2598, found 469.2604.

Raju et al. Report, ³	This Work,	
Natural	Synthetic	
(+)-nocardioazine B	(+)-nocardioazine B	
¹ H NMR, 600 MHz, CDCl ₃	Iz, CDCl ₃ ¹ H NMR, 500 MHz, CDCl ₃	
δ 7.11 (ddd, J = 7.7, 7.4, 1.1 Hz, 1H)	δ 7.16 – 7.09 (m, 2H)	
7.08 (ddd, J = 7.7, 7.4, 1.0 Hz, 1H)	-	
7.06 (dd, $J = 7.4$, 1.0 Hz, 1H)	7.09 (td, J = 7.7, 1.2 Hz, 1H)	
7.02 (dd, $J = 7.4$, 1.1 Hz, 1H)	$7.04 (\mathrm{dd}, J = 7.3, 1.2 \mathrm{Hz}, 1\mathrm{H})$	
6.75 (ddd, <i>J</i> = 7.4, 7.4, 0.9 Hz, 1H)	6.78 (td, <i>J</i> = 7.4, 1.0 Hz, 1H)	
6.69 (ddd, <i>J</i> = 7.4, 7.4, 0.9 Hz, 1H)	6.71 (td, <i>J</i> = 7.4, 1.0 Hz, 1H)	
6.57 (dd, <i>J</i> = 7.7, 0.9 Hz, 1H)	6.59 (d, J = 7.7 Hz, 1H)	
6.38 (dd, <i>J</i> = 7.7, 0.9 Hz, 1H)	6.39 (d, J = 7.8 Hz, 1H)	
5.33 (s, 1H)	5.35 (s, 1H)	
5.29 (s, 1H)	5.31 (s, 1H)	
5.18 (s, 1H)	5.21 (br s, 1H)	
4.98 (m, 1H)	5.00 (tq, J = 4.9, 1.6 Hz, 1H)	
4.42 (ddd, <i>J</i> = 9.8, 7.6, 1.8 Hz, 1H)	4.44 (ddd, <i>J</i> = 9.8, 7.7, 1.8 Hz, 1H)	
4.13 (ddd, <i>J</i> = 10.7, 6.5, 1.7 Hz, 1H)	4.15 (ddd, <i>J</i> = 10.7, 6.5, 1.8 Hz, 1H)	
2.99 (s, 3H)	3.01 (s, 3H)	
2.62 (dd, <i>J</i> = 12.9, 6.5 Hz, 1H)	2.64 (dd, <i>J</i> = 12.8, 6.5 Hz, 1H)	
2.37 (m, 2H)	2.47 – 2.32 (m, 4H)	
2.35 (m, 2H)	_	
2.25 (dd, J = 12.9, 10.7 Hz, 1H)	2.28 (dd, J = 12.8, 10.7 Hz, 1H)	
1.63 (s, 3H)	1.65 (s, 3H)	
1.48 (s, 3H)	1.50 (s, 3H)	
1.45 (s, 3H)	1.47 (s, 3H)	

Table 3.2. Comparison of ¹H NMR data for natural vs. synthetic (+)-nocardioazine B (**187**)

Table 3.3. Comparison of ¹³C NMR data for natural vs. synthetic (+)-nocardioazine *B* (**187**)

Raju et al. Report, ³	This Work,	Chemical Shift Difference, $\Delta\delta$
Natural	Synthetic	
(+)-nocardioazine B	(+)-nocardioazine B	
¹³ C NMR, 150 MHz, CDCl ₃	¹³ C NMR, 126 MHz, CDCl ₃	
δ 167.1	δ 167.3	0.2
NR	165.9	—
150.6	150.6	0.0
146.9	147.1	0.2
135.5	135.5	0.0
133.3	133.4	0.1
132.0	131.9	0.1
128.8	128.7	0.1
128.5	128.5	0.0
122.8	122.8	0.0
122.4	122.4	0.0
-------	-------	-----
119.2	119.3	0.1
118.6	118.6	0.0
117.9	118.0	0.1
109.4	109.3	0.1
106.2	106.2	0.0
85.0	84.9	0.1
83.7	83.7	0.0
60.4	60.4	0.0
59.3	59.3	0.0
54.6	54.7	0.1
51.2	51.3	0.1
41.0	40.9	0.1
39.8	39.6	0.2
36.7	36.5	0.2
33.7	33.6	0.1
26.0	25.9	0.1
23.4	23.4	0.0
17.9	18.0	0.1

Preparation of enal 275



To a 50 mL flame-dried flask was added diketopiperazine **262** (431 mg, 0.98 mmol, 1.0 equiv) and DCM (9 mL), followed by methacrolein **274** (95%, 0.85 mL, 9.78 mmol, 10 equiv). *ortho-ⁱ*Pr-Hoveyda-Grubbs II catalyst (61.3 mg, 0.10 mmol, 10 mol %) was added as a DCM solution (0.1 mL) at last. The flask was equipped with a condenser and heated to 40 °C for 18 hours. The reaction was then quenched with ethyl vinyl ether (0.5 mL) and filtered through a silica gel plug, eluting with EtOAc. The filtrate was concentrated down to give a brown oil. Flash chromatography (10% to 80% EtOAc in hexanes) afforded enal **275** as a light grey foam (*E* : *Z* = 10 : 1 mixture, 356 mg, 0.74

mmol, 76% yield). The mixture of isomers was further purified by flash chromatography (10% to 80% EtOAc in hexanes) to give (*E*)-**275** for characterization purposes. $[\alpha]_{D}^{25}$ = +77° (*c* = 0.96, CHCl₃); ¹H NMR (300 MHz, CDCl₃) δ 9.30 (s, 1H), 7.17 (td, *J* = 7.5, 1.2 Hz, 1H), 7.13 – 7.02 (m, 3H), 6.82 – 6.71 (m, 2H), 6.60 (d, *J* = 7.5 Hz, 1H), 6.42 (d, *J* = 7.9 Hz, 1H), 6.25 (ddd, *J* = 8.7, 6.7, 1.5 Hz, 1H), 5.38 (s, 1H), 5.35 (s, 1H), 5.20 (br s, 1H), 4.47 (ddd, *J* = 9.7, 8.0, 1.8 Hz, 1H), 4.19 (ddd, *J* = 10.7, 6.5, 1.9 Hz, 1H), 3.01 (s, 3H), 2.83 – 2.71 (m, 3H), 2.41 (d, *J* = 2.4 Hz, 1H), 2.38 (s, 1H), 2.32 (dd, *J* = 12.8, 10.6 Hz, 1H), 1.66 – 1.65 (m, 3H), 1.47 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 194.6, 166.7, 165.8, 150.4, 147.6, 146.9, 141.6, 133.2, 130.0, 129.3, 128.4, 122.5, 122.3, 119.2, 118.2, 109.3, 106.3, 84.7, 83.6, 60.2, 59.1, 53.7, 51.2, 40.7, 40.3, 37.3, 33.1, 23.2, 9.4; FTIR (NaCl, thin film): 3351, 3051, 3013, 2953, 2929, 2872, 2716, 1670, 1607, 1486, 1468, 1446, 1412, 1339, 1302, 1262, 1235, 1200, 1157, 1126, 1099, 1083, 1040, 1019, 1000, 978, 932, 883, 809, 747 cm⁻¹; HRMS (MM) calc'd for C₂₉H₃₁N₄O₃ [M+H]⁺ 483.2391, found 483.2410.

Preparation of allylic alcohol 261



To a 50 mL flask was added aldehyde **275** (E : Z = 10 : 1 mixture, 159 mg, 0.33 mmol, 1.0 equiv) and methanol (12 mL). Sonicator was used to facilitate **275** to dissolve in solution. Then, cerium chloride heptahydrate (307 mg, 0.82 mmol, 2.5 equiv) was dissolved in methanol (2 mL), while NaBH₄ (25 mg, 0.66 mmol, 2.0 equiv) was dissolved

in methanol (2 mL). The reaction was cooled to 0 °C. The previously prepared methanol solution of cerium chloride was added into the reaction flask, quickly followed by the addition of NaBH₄ methanol solution. After reacting at 0 °C for 40 minutes, the reaction was quenched with saturated ammonium chloride solution (30 mL), followed by EtOAc (30 mL). The mixture was separated and aqueous layer was extracted with EtOAc (3 x 30 mL). Combined organic layers were washed with brine (50 mL), dried over Na₂SO₄, filtered, and concentrated down to give a grey oil. Flash chromatography (20% to 90% EtOAc in hexanes) afforded allylic alcohol 261 as a white foam (133 mg, 0.27 mmol, 84% yield). $[\alpha]_{D}^{25} = +68^{\circ} (c = 0.51, CHCl_{3}); ^{1}H NMR (500 MHz, CDCl_{3}) \delta 7.13 (td, J =$ 7.7, 1.3 Hz, 1H), 7.11 - 7.06 (m, 2H), 7.05 (dd, J = 7.4, 1.2 Hz, 1H), 6.78 (td, J = 7.4, 1.0Hz, 1H), 6.71 (td, J = 7.4, 1.0 Hz, 1H), 6.59 (dt, J = 7.6, 0.8 Hz, 1H), 6.40 (d, J = 7.8 Hz, 1H), 5.36 (s, 1H), 5.35 (br s, 2H), 5.29 (ddt, J = 9.5, 6.7, 1.5 Hz, 1H), 4.44 (ddd, J = 9.9, 18.4, 1.8 Hz, 1H), 4.16 (ddd, J = 10.1, 7.0, 1.8 Hz, 1H), 3.90 (s, 2H), 3.00 (s, 3H), 2.61 (dd, J = 13.0, 7.0 Hz, 1H), 2.51 - 2.39 (m, 2H), 2.39 - 2.30 (m, 3H), 2.15 (s, 1H), 1.56 (s, 1H),3H), 1.46 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 167.2, 165.8, 150.4, 147.0, 138.8, 133.3, 131.8, 128.8, 128.4, 122.6, 122.3, 119.3, 119.2, 118.0, 109.5, 106.2, 85.2, 83.6, 68.2, 60.3, 59.3, 54.2, 51.3, 40.8, 39.4, 35.9, 33.5, 23.2, 13.9; FTIR (NaCl, thin film): 3367, 3051, 3004, 2929, 2872, 1664, 1607, 1486, 1468, 1420, 1341, 1301, 1251, 1199, 1155, 1099, 1085, 1065, 1039, 1018, 1002, 978, 943, 892, 824, 746 cm⁻¹; HRMS (MM) calc'd for $C_{29}H_{33}N_4O_3$ [M+H]⁺ 485.2547, found 485.2554.

Preparation of allylic chloride 276



To a 10 mL flame-dried flask was added allylic alcohol 261 (60 mg, 0.12 mmol, 1.0 equiv) and THF (1.2 mL). The reaction was cooled to 0 °C. Mesyl chloride (MsCl, 11 μ L, 0.14 mmol, 1.1 equiv) was added into the reaction solution, followed by Et₃N (35 μ L, 0.25 mmol, 2.0 equiv). After 1.5 hours, the reaction was filtered through a plug of Kimwipes and washed with THF. The filtrate was concentrated down and co-evaporated with benzene. The crude material was re-dissolved in THF (1 mL), and LiOH (52.5 mg, 1.24 mmol, 10 equiv) in THF (0.2 mL) was transferred into the reaction flask. The resulting white slurry was allowed to stir at room temperature for 1.5 hours before it was quenched with saturated NaHCO₃ (10 mL). The mixture was extracted with EtOAc (3 x 10 mL). Combined organic layers were washed with brine (30 mL), dried over Na₂SO₄, filtered, and concentrated down to give a yellow liquid. Flash chromatography (10% to 50% EtOAc in hexanes) afforded allylic chloride **276** as a light yellow foam (55 mg, 0.11 mmol, 89% yield). $[\alpha]_{D}^{25} = +68^{\circ} (c = 1.30, CHCl_{3}); {}^{1}H NMR (500 MHz, CDCl_{3}) \delta 7.14$ (td, J = 7.6, 1.3 Hz, 1H), 7.12 - 7.06 (m, 2H), 7.05 (dd, J = 7.4, 1.2 Hz, 1H), 6.78 (td, J = 7.4, 1.2 Hz, 1H), 7.8 (td, J = 7.4, 1H), 7.8 (td, J = 7.4,7.4, 1.0 Hz, 1H), 6.72 (td, J = 7.4, 1.0 Hz, 1H), 6.60 (dt, J = 7.7, 0.8 Hz, 1H), 6.40 (d, J =7.8 Hz, 1H), 5.36 (t, J = 6.8 Hz, 1H), 5.35 (s, 1H), 5.31 (s, 1H), 5.23 (br s, 1H), 4.45 (ddd, J = 9.7, 8.1, 1.8 Hz, 1H), 4.16 (ddd, J = 10.6, 6.5, 1.8 Hz, 1H), 3.98 - 3.87 (m, 2H),3.01 (s, 3H), 2.69 (dd, J = 12.8, 6.5 Hz, 1H), 2.45 (d, J = 7.5 Hz, 2H), 2.42 – 2.35 (m, 2H), 2.27 (dd, J = 12.8, 10.6 Hz, 1H), 1.63 (s, 3H), 1.47 (s, 3H); ¹³C NMR (126 MHz,

Chapter 3 – Enantioselective Total Synthesis of (+)-Nocardioazines A and B $CDCl_3$ δ 167.1, 165.9, 150.5, 147.0, 135.3, 133.3, 130.9, 129.0, 128.5, 124.7, 122.9, 122.4, 119.3, 118.1, 109.4, 106.2, 85.0, 83.7, 60.3, 59.2, 54.2, 51.8, 51.3, 40.9, 40.0, 36.6, 33.5, 23.4, 14.5; FTIR (NaCl, thin film): 3345, 3051, 3006, 2954, 2928, 2871, 1667, 1607, 1486, 1468, 1414, 1341, 1302, 1262, 1199, 1157, 1110, 1100, 1083, 1062, 1019, 1001, 977, 932, 746 cm⁻¹; HRMS (MM) calc'd for $C_{29}H_{32}ClN_4O_2$ [M+H]⁺ 503.2208, found 503.2221.

Preparation of macrocyclic alkene 277



To a 25 mL flame-dried Schlenk flask with a screw cap was added allylic chloride **276** (20 mg, 0.04 mmol, 1.0 equiv), tetra-*n*-butylammonium iodide (TBAI, 294 mg, 0.80 mmol, 20.0 equiv), and acetonitrile (4 mL). DIPEA (8.3 μ L, 0.048 mmol, 1.2 equiv) was added at last from freshly prepared DIPEA stock solution. The Schlenk flask was sealed and heated to 80 °C for 24 hours. It was then cooled to room temperature and quenched with saturated NaHCO₃ aqueous solution (20 mL). The mixture was extracted with EtOAc (3 x 15 mL). Combined organic layers were washed with brine (30 mL), dried over Na₂SO₄, filtered and concentrated down to give a yellow liquid. Flash chromatography (5% to 50% EtOAc in hexanes) afforded macrocyclic alkene 277 as a white solid (13.5 mg, 0.029 mmol, 73% yield). $[\alpha]_{D}^{25} = +45^{\circ} (c = 0.47, CHCl_{3}); {}^{1}H NMR$ $(500 \text{ MHz}, \text{CD}_3\text{CN}) \delta 7.16 - 7.09 \text{ (m, 3H)}, 7.07 \text{ (td, } J = 7.7, 1.4 \text{ Hz}, 1\text{H}), 6.72 \text{ (td, } J = 7.7, 1.4 \text{ Hz}, 1\text{H})$ 7.5, 1.0 Hz, 1H), 6.65 (t, J = 7.4 Hz, 1H), 6.52 (d, J = 7.7 Hz, 1H), 6.46 (d, J = 7.9 Hz, 1H), 5.51 (s, 1H), 5.48 (s, 1H), 5.28 (br s, 1H), 4.57 (t, J = 8.8 Hz, 1H), 4.37 (d, J = 10.7

Hz, 1H), 4.02 (d, J = 16.1 Hz, 1H), 3.47 (d, J = 16.1 Hz, 1H), 2.89 (br s, 1H), 2.83 (s, 3H), 2.42 – 2.22 (m, 3H), 1.55 (s, 3H), 1.47 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) 149.3, 128.6, 128.6, 121.7, 121.4, 118.5, 110.0, 107.7, 91.9, 61.9, 59.2, 53.0, 34.0 (Presumably, at room temperature, the alkene in macrocyclic olefin **277** quickly underwent rotation, resulting in ¹H NMR signals broadening and not all carbon signals showing up); ¹H NMR (500 MHz, CD₃CN, 70 °C) δ 7.17 – 7.10 (m, 3H), 7.09 (td, J = 7.8, 1.4 Hz, 1H), 6.73 (td,

(coo minit, CD jett, 15° C) o minit mino (iii, CH), 165 (iii, 5° (iii), 167 (iii), 117 (iii), 067 (iii), J = 7.4, 1.0 Hz, 111), 6.52 (iii), J = 7.7 Hz, 111), 6.46 (iii), J = 7.9 Hz, 111), 5.51 (s, 111), 5.49 (s, 111), 5.30 (t, J = 8.4 Hz, 111), 4.58 (t, J = 8.7 Hz, 111), 4.38 (iii), J = 11.2, 2.3 Hz, 111), 4.03 (iii), J = 16.3 Hz, 111), 3.52 (iii), J = 16.3 Hz, 111), 2.92 (iii), J = 13.9 Hz, 111), 2.90 - 2.82 (iii), 111), 2.86 (s, 311), 2.41 (iii), J = 13.4, 8.8 Hz, 111), 2.34 (iii), J = 8.8 Hz, 111), 2.30 (iii), J = 11.0, 7.0 Hz, 111), 2.19 (iii), J = 13.7, 11.3 Hz, 111), 1.60 (s, 311), 1.50 (s, 311); ¹³C NMR (126 MHz, CD₃CN, 70 °C) δ 171.8, 170.5, 151.0, 149.5, 138.3, 136.1, 135.5, 129.7, 123.0, 122.9, 122.8, 122.7, 119.5, 118.7, 108.6, 108.6, 106.6, 106.5, 92.9, 92.9, 90.3, 63.2, 60.3, 60.3, 56.4, 54.3, 52.3, 41.9, 39.5, 34.7, 34.5, 34.4, 21.7, 15.2; FTIR (NaCl, thin film): 3051, 3008, 2954, 2923, 2870, 2856, 1670, 1609, 1485, 1465, 1450, 1429, 1391, 1348, 1304, 1259, 1216, 1186, 1156, 1142, 1122, 1096, 1065, 1023, 1001, 978, 921, 881, 789, 742 cm⁻¹; HRMS (MM) calc'd for C₂₀H₄₁N₄O₂ [M+H][±] 467.2442, found 467.2450.

Preparation of N-oxide 278



To a 0.5-dram vial was transferred macrocyclic olefin 277 (2.2 mg, 0.0047 mmol, 1.0 equiv), which was dissolved in acetone (0.35 mL). The reaction was cooled to 0 $^{\circ}$ C. Freshly prepared DMDO acetone solution (0.050 M, 104 μ L, 0.0052 mmol, 1.1 equiv) was added. The reaction was allowed to stir for 15 minutes before being concentrated down to give a light yellow solid. Preparative thin layer chromatography (10% MeOH in DCM) afforded N-oxide 278 as a white solid (1.2 mg, 0.0025 mmol, 53% yield); starting material 277 was also isolated (0.8 mg). $[\alpha]_{D}^{25} = +78^{\circ}$ (c = 0.12, CH₂Cl₂); ¹H NMR (500 MHz, CD₂Cl₂) δ 7.54 – 7.49 (m, 1H), 7.49 – 7.42 (m, 2H), 7.42 – 7.34 (m, 1H), 7.09 (app ddd, J = 7.3, 4.4, 3.0 Hz, 2H), 6.69 (t, J = 7.4 Hz, 1H), 6.40 (d, J = 8.1 Hz, 1H), 5.75 (s, 1H), 5.56 (s, 1H), 4.99 - 4.82 (m, 1H), 4.68 (t, J = 8.8 Hz, 1H), 4.00 (d, J = 16.5 Hz, 1H), 3.62 (s, 3H), 3.58 (d, J = 16.5 Hz, 1H), 2.89 (br s, 1H), 2.72 (t, J = 11.9 Hz, 1H), 2.59 - 1002.49 (m, 1H), 2.37 (t, J = 11.4 Hz, 1H), 2.28 (br s, 1H), 1.86 (br s, 4H), 1.52 (s, 3H); ¹³C NMR (126 MHz, CD₂Cl₂) & 70.2, 138.0, 130.5, 130.0, 129.0, 124.4, 122.1, 117.6, 99.1, 66.5, 59.6, 56.4, 52.5, 51.6, 41.1 (Presumably, at room temperature, the alkene in macrocyclic olefin 278 quickly underwent rotation, resulting in ¹H NMR signals broadening and not all carbon signals showing up); FTIR (NaCl, thin film): 3047, 2955, 2907, 1681, 1607, 1482, 1449, 1432, 1388, 1305, 1270, 1225, 1201, 1156, 1142, 1119, 1094, 1064, 1050, 1022, 1004, 962, 932, 917, 884, 832, 816, 805, 780, 741 cm⁻¹; HRMS (MM) calc'd for $C_{29}H_{31}N_4O_3$ [M+H]⁺ 483.2391, found 483.2388.

Preparation of diol 279



K₂CO₃ (4.5 mg, 0.033 mmol, 3.1 equiv) and K₂OsO₄•2H₂O (1.2 mg, 0.003 mmol, 30 mol %), followed by addition of distilled water (240 μ L) and methanesulfonamide (3.0 mg, 0.032mmol, 3.0 equiv). 1,4-Diazabicyclooctane (DABCO, 0.6 mg, 0.005 mmol, 0.5 equiv) was added as a t-butanol solution (10 μ L). At last, macrocyclic alkene 277 (4.8 mg, 0.010 mmol, 1.0 equiv) was added as *tert*-butanol solution (240 μ L; additional heat was required to increase the solubility of 277 in *tert*-butanol; there is a small time window where 277 is completely soluble in tert-butanol after it cools down to room temperature, which marks the time to add it to the reaction flask). The reaction turned into a brown homogeneous solution, which was stirred for 12 hours. It was then quenched with solid Na₂SO₃, followed by addition of 2N KOH (0.5 mL). It was stirred for another two hours before it was diluted with EtOAc (2 mL). The mixture was separated and the aqueous layer was extracted with EtOAc (3 x 2 mL). Combined organic layers were washed with brine (3 mL), dried over Na_2SO_4 , filtered, and concentrated down to give a white solid. Flash chromatography (5% to 50% EtOAc in hexanes) afforded diol 279 as a white solid (3.9 mg, 0.008 mmol, 76% yield). $[\alpha]_D^{25} = +36^\circ$ (c = 0.33, CHCl₃); ¹H NMR $(500 \text{ MHz}, \text{CDCl}_3) \delta 7.14 (\text{tt}, J = 7.7, 1.5 \text{ Hz}, 2\text{H}), 7.08 (\text{ddd}, J = 7.4, 2.4, 1.2 \text{ Hz}, 2\text{H}),$ 6.89 (d, J = 7.9 Hz, 1H), 6.82 (td, J = 7.4, 0.9 Hz, 1H), 6.79 (td, J = 7.5, 1.0 Hz, 1H), 6.52(d, J = 7.7 Hz, 1H), 5.77 (s, 1H), 5.65 (s, 1H), 4.60 (dd, J = 10.0, 8.1 Hz, 1H), 4.47 (d, J)= 8.7 Hz, 1H), 3.52 (d, J = 15.4 Hz, 1H), 3.31 (d, J = 15.4 Hz, 1H), 3.25 (d, J = 10.5 Hz, 1H), 2.96 (d, J = 12.6 Hz, 1H), 2.92 (s, 3H), 2.75 (dd, J = 13.4, 10.1 Hz, 1H), 2.49 (dd, J= 12.7, 8.8 Hz, 1H), 2.48 (s, 1H), 2.27 (dd, J = 13.4, 8.1 Hz, 1H), 2.17 (dd, J = 15.5, 10.5Hz, 1H), 1.99 (d, J = 15.6 Hz, 1H), 1.86 (s, 1H), 1.49 (s, 3H), 1.09 (s, 3H); ¹³C NMR $(126 \text{ MHz}, \text{CDCl}_3) \delta 171.9, 170.8, 149.3, 148.8, 134.5, 133.3, 128.6, 128.3, 121.5, 119.6, 119.0, 108.7, 108.2, 91.4, 89.4, 76.7, 69.5, 62.3, 60.2, 56.3, 50.6, 50.4, 42.7, 38.6, 35.5, 34.1, 20.7, 18.3; FTIR (NaCl, thin film): 3518, 3447, 3049, 3010, 2953, 2937, 2894, 2794, 1670, 1610, 1481, 1448, 1425, 1391, 1349, 1312, 1299, 1274, 1209, 1194, 1167, 1123, 1091, 1064, 1039, 1021, 1001, 975, 940, 909, 893, 862, 832, 804, 789, 780, 752, 746, 718 cm⁻¹; HRMS (MM) calc'd for C₂₉H₃₃N₄O₄ [M+H]⁺ 501.2496, found 501.2508.$

Preparation of mono-mesylate A-5



To a flame-dried 0.5-dram vial was added diol **279** (6.9 mg, 0.014 mmol, 1.0 equiv) and THF (0.2 mL). The reaction flask was cooled to 0 °C. Mesyl chloride (MsCl, 5.5 μ L, 0.069 mmol, 5.0 equiv) was added into the reaction solution, followed by Et₃N (11.5 μ L, 0.083 mmol, 6.0 equiv). After 40 minutes, the reaction was quenched with saturated NaHCO₃ (4 mL). The mixture was extracted with EtOAc (3 x 4 mL). Combined organic layers were washed with brine (8 mL), dried over Na₂SO₄, filtered, and concentrated down to give a yellow liquid. Preparative TLC chromatography (60% EtOAc in hexanes) afforded mono-mesylate **A-5** as a white solid (5.8 mg, 0.10 mmol, 75% yield). [α]_D²⁵ = +67° (*c* = 0.45, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.16 (td, *J* = 7.7, 1.2 Hz, 1H), 7.14 (td, *J* = 7.9, 1.3 Hz, 1H), 7.07 (ddd, *J* = 8.8, 7.4, 1.3 Hz, 2H), 7.00 (d, *J* = 7.9 Hz, 1H), 6.85 (td, *J* = 7.4, 1.0 Hz, 1H), 6.79 (td, *J* = 7.5, 1.0 Hz, 1H), 6.53 (d, *J* = 7.8 Hz, 1H), 5.83 (s, 1H), 5.62 (s, 1H), 4.61 (dd, *J* = 10.2, 8.0 Hz, 1H), 4.58 (d, *J* = 10.7 Hz, 1H), 4.46 (d, *J* = 8.5 Hz, 1H), 3.52 (d, *J* = 15.5 Hz, 1H), 3.33 (d, *J* = 15.5 Hz, 1H), 3.52 (d, *J* = 15.5 Hz, 1H), 3.33 (d, *J* = 15.5 Hz, 1H), 3.52 (d, *J* = 15.5 Hz, 1H), 3.33 (d, *J* = 15.5 Hz, 1H), 3.52 (d, *J* = 15.5 Hz, 1H), 3.53 (d, *J* = 15.5 Hz, 1H), 3.52 (d, *J* = 15.5 Hz, 1H), 3.53 (d, *J* = 15.5 Hz, 1H), 3.55 (d, *J* = 15.5 Hz, 1Hz), 3.55 (d, *J* = 15.5 Hz, 1Hz), 3.55 (d, *J* = 15.5 Hz), 3.55 Hz, 1Hz), 3.55 (d, *J* = 15.5 Hz),

1H), 2.96 (s, 3H), 2.94 (d, J = 12.7 Hz, 1H), 2.83 (dd, J = 13.4, 10.2 Hz, 1H), 2.74 (s, 3H), 2.53 (dd, J = 12.7, 8.6 Hz, 1H), 2.49 (dd, J = 16.8, 10.8 Hz, 1H), 2.40 (s, 1H), 2.30 (dd, J = 13.4, 7.9 Hz, 1H), 2.13 (d, J = 16.8 Hz, 1H), 1.48 (s, 3H), 1.16 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 171.8, 171.7, 149.5, 149.2, 133.3, 132.7, 128.7, 128.6, 121.5, 121.3, 120.0, 118.8, 109.8, 108.4, 90.7, 89.7, 83.5, 76.6, 62.1, 60.5, 57.9, 50.5, 50.3, 42.8, 38.9, 38.6, 34.1, 33.1, 20.6, 18.8; FTIR (NaCl, thin film): 3541, 3390, 3024, 2954, 2925, 2855, 2798, 1694, 1674, 1610, 1482, 1447, 1427, 1379, 1347, 1337, 1301, 1273, 1198, 1171, 1124, 1091, 1062, 1028, 1000, 974, 957, 944, 933, 916, 895, 851, 835, 806, 781, 752 cm⁻¹; HRMS (MM) calc'd for C₃₀H₃₅N₄O₆S [M+H]⁺ 579.2272, found 579.2278.

Preparation of epi-(C2")-nocardioazine A (280)



To a flame-dried 1-dram vial was added mono-mesylate **A-5** (4.0 mg, 0.007 mmol, 1.0 equiv) and K₂CO₃ (12.6 mg, 0.091 mmol, 13.0 equiv). Methanol (0.9 mL) was added at last. The vial was sealed using a Teflon cap and heated to 50 °C for 90 minutes. The reaction was cooled to room temperature and quenched with saturated NaHCO₃ (4 mL). The mixture was extracted with EtOAc (3 x 4 mL). Combined organic layers were washed with brine (8 mL), dried over Na₂SO₄, filtered, and concentrated down to give a white liquid. Flash chromatography (10% to 50% EtOAc in hexanes) afforded *epi*-(C2")-nocardioazine A (**280**) as a white solid, which was contaminated with an unknown side product as a 10 : 1 mixture detected by ¹H NMR, (corrected yield: 2.9 mg, 0.0060 mmol, 87% yield). $[\alpha]_D^{25} = +36^\circ$ (c = 0.33, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.20 (td, J =

7.7, 1.3 Hz, 1H), 7.10 (td, J = 7.7, 1.2 Hz, 1H), 7.11 (dd, J = 7.5, 1.3 Hz, 1H), 7.06 (dd, J = 7.3, 1.3 Hz, 1H), 6.79 (td, J = 7.5, 1.0 Hz, 1H), 6.66 (td, J = 7.4, 0.9 Hz, 1H), 6.53 (d, J = 7.8 Hz, 1H), 6.49 (d, J = 7.8 Hz, 1H), 5.75 (s, 1H), 5.73 (s, 1H), 4.51 (dd, J = 10.6, 7.6 Hz, 1H), 4.40 (d, J = 8.6 Hz, 1H), 3.59 (d, J = 15.6 Hz, 1H), 3.37 (d, J = 15.7 Hz, 1H), 2.95 (s, 3H), 2.91 (d, J = 12.6 Hz, 1H), 2.83 (dd, J = 11.6, 3.7 Hz, 1H), 2.77 (dd, J = 13.2, 10.7 Hz, 1H), 2.66 (dd, J = 16.0, 3.7 Hz, 1H), 2.45 (dd, J = 12.7, 8.7 Hz, 1H), 2.25 (dd, J = 13.1, 7.6 Hz, 1H), 2.00 (dd, J = 16.0, 11.6 Hz, 1H), 1.45 (s, 3H), 1.39 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) & 172.5, 171.4, 149.7, 147.1, 132.9, 132.1, 128.8, 128.3, 121.7, 121.5, 118.3, 116.9, 108.0, 105.7, 92.9, 86.8, 64.2, 62.2, 61.7, 60.0, 52.0, 50.7, 45.0, 42.1, 39.5, 33.9, 30.3, 26.1, 19.5; FTIR (NaCl, thin film): 3051, 3009, 2956, 2927, 2893, 2869, 2821, 2791, 1692, 1671, 1610, 1484, 1467, 1452, 1440, 1425, 1382, 1353, 1301, 1282, 1266, 1235, 1214, 1197, 1172, 1158, 1144, 1123, 1115, 1093, 1073, 1055, 1048, 1035, 1020, 991, 973, 958, 945, 924, 892, 881, 859, 847, 830, 801, 792, 780, 751, 742 cm⁻¹; HRMS (MM) calc'd for $C_{29}H_{11}N_AO_3$ [M+H]⁺ 483.2391, found 483.2387.

Preparation of epoxide 281



To a flame-dried 10 mL flask was added Ti(O'Pr)₄ (3.7 μ L, 0.012 mmol, 10 mol %), activated 4Å molecular sieves and DCM (2 mL). The reaction flask was cooled to – 20 °C (crushed ice mixed with NaCl at about 3 : 1 ratio). (+)-Diethyl-tartrate (2.5 μ L, 0.015 mmol, 12 mol %) was added. After stirring for 5 minutes, allylic alcohol **261** (60 mg, 0.124 mmol, 1.0 equiv) was added as a DCM solution (0.5 mL). After 30 minutes,

[']BuOOH (5.0-6.0 M decane solution, 68 μ L, 0.371 mmol, 3.0 equiv) was added. In 105 minutes, the flask was warmed to 0 °C using an ice water bath. The reaction was quenched with freshly prepared and ice-cold $FeSO_4$ /citric acid solution (0.66 g FeSO₄). 0.22 g citric acid monohydrate, 2 mL distilled water). The mixture was extracted with Et₂O (5 x 5 mL). Combined organic layers were cooled to 0 °C and then treated with precooled 30% NaOH (w/v) in saturated NaCl solution (prepared using 10 g NaOH, 1.7 g NaCl, 30 ml distilled water). The mixture was stirred vigorously for 1 hour. Then two layers were separated and the aqueous layer was extracted with Et₂O (2 x 30 mL). Combined organic layers were dried over MgSO₄, filtered, and concentrated down to give a colorless oil. Flash chromatography (20% to 95% EtOAc in hexanes) afforded epoxy alcohol 281 (10: 1 mixture of epoxide diastereomers by ¹H NMR), as a white foam (56.5 mg, 0.113 mmol, 90% yield). $[\alpha]_{D}^{25} = +74^{\circ}$ (c = 0.26, CHCl₂); ¹H NMR (400 MHz, $CDCl_3$ δ 7.14 (td, J = 7.6, 1.2 Hz, 1H), 7.07 (app dd, J = 8.0, 6.9 Hz, 3H), 6.79 - 6.74 (m, 1H), 6.72 (td, J = 7.5, 1.0 Hz, 1H), 6.57 (dt, J = 7.5, 1.0 Hz, 1H), 6.40 (d, J = 7.8 Hz, 1H), 5.59 (s, 1H), 5.34 (s, 1H), 5.28 (s, 1H), 4.44 (ddd, J = 9.9, 8.1, 1.9 Hz, 1H), 4.14 (ddd, J = 10.8, 6.3, 1.9 Hz, 1H), 3.41 (d, J = 12.2 Hz, 1H), 3.30 (d, J = 12.3 Hz, 1H), 3.04(s, 3H), 2.83 - 2.71 (m, 2H), 2.42 - 2.34 (m, 2H), 2.31 (dd, J = 12.8, 10.9 Hz, 1H), 2.11 $(dd, J = 14.4, 4.9 Hz, 1H), 1.87 (dd, J = 14.4, 7.0 Hz, 1H), 1.46 (s, 3H), 1.12 (s, 3H); {}^{13}C$ NMR (101 MHz, CDCl₃) δ 167.0, 165.7, 150.8, 147.0, 133.3, 130.2, 129.3, 128.4, 122.8, 122.3, 119.2, 118.1, 109.4, 106.2, 84.5, 83.7, 65.3, 60.2, 59.8, 59.2, 56.6, 53.1, 51.2, 41.0, 40.9, 37.1, 33.5, 23.3, 14.3; FTIR (NaCl, thin film): 3354, 3052, 3006, 2956, 2928, 2870, 1668, 1608, 1486, 1471, 1418, 1339, 1302, 1253, 1197, 1161, 1092, 1036, 1001, 978, 894, 748 cm⁻¹; HRMS (MM) calc'd for $C_{29}H_{33}N_4O_4$ [M+H]⁺ 501.2496, found 501.2500.

Preparation of mesylate 282



To a half-a-dram vial was added alcohol 281 (7 mg, 0.014 mmol, 1.0 equiv), which was co-evaporated with benzene (0.4 mL) and dried in vacuo. Under N2, alcohol **281** was dissolved in THF (0.1 mL) and cooled to 0 °C, when MsCl (1.2 μ L, 0.015 mmol, 1.1 equiv) and Et₃N (3.9 μ L, 0.028 mmol, 2.0 equiv) were added in sequence as a freshly prepared THF stock solution. The reaction mixture was allowed to stir at 0 °C for 40 minutes before filtering through a Kimwipe plug and concentrating down to give a colorless oil. Flash chromatography (5% to 70% EtOAc in hexanes) afforded epoxy mesylate **282**, as a colorless oil (6.8 mg, 0.012 mmol, 84% yield). $[\alpha]_{D}^{25} = +74^{\circ}$ (c = 0.735, CHCl₂); ¹H NMR (300 MHz, CDCl₂) δ 7.16 (td, J = 7.7, 1.3 Hz, 1H), 7.12 – 7.04 (m, 3H), 6.78 (td, J = 7.6, 1.1 Hz, 1H), 6.75 (td, J = 7.4, 0.9 Hz, 1H), 6.59 (d, J = 7.5 Hz, 1H), 6.41 (d, J = 7.8 Hz, 1H), 5.59 (s, 1H), 5.35 (s, 1H), 4.46 (td, J = 8.9, 1.8 Hz, 1H), 4.16 (ddd, J = 10.2, 5.9, 1.5 Hz, 1H), 4.02 (d, J = 11.5 Hz, 1H), 3.84 (d, J = 11.5 Hz, 1H),3.04 (s, 3H), 2.95 (s, 3H), 2.78 (dd, J = 12.7, 6.2 Hz, 1H), 2.65 (dd, J = 7.2, 4.7 Hz, 1H), 2.38 (d, J = 8.9 Hz, 2H), 2.28 (dd, J = 12.8, 11.0 Hz, 1H), 2.16 (dd, J = 14.4, 4.8 Hz, 1H), 1.86 (dd, J = 14.4, 7.2 Hz, 1H), 1.47 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 166.9, 165.8, 150.9, 147.0, 133.3, 129.7, 129.5, 128.5, 122.8, 122.4, 119.3, 118.2, 109.3, 106.3, 84.2, 83.7, 73.3, 59.8, 59.2, 57.6, 57.5, 53.0, 51.3, 41.3, 41.0, 37.7, 36.9, 33.4, 23.3, 14.1; FTIR (NaCl, thin film): 3364, 3011, 2958, 2932, 1668, 1608, 1486, 1471, 1445, 1418, 1354, 1300, 1253, 1197, 1175, 1092, 1018, 978, 961, 896, 817, 750, 667, 644 cm⁻¹; HRMS (MM) calc'd for C₃₀H₃₅N₄O₆S [M+H]⁺ 579.2272, found 579.2287.

Preparation of aldehyde 283



To a 50 mL flame-dried flask was added 3-allyl pyrroloindoline 265 (1.0 g, 2.7 mmol, 1.0 equiv) and DCM (20 mL), followed by methacrolein (95%, 2.36 mL, 27.1 mmol, 10 equiv). ortho-Pr-Hoveyda-Grubbs II catalyst (170 mg, 0.27 mmol, 10 mol %) was added as a DCM solution (4 mL) at last. The flask was equipped with a condenser and heated to 40 °C for 3 days. The reaction was then guenched with ethyl vinyl ether (1.5 mL) and filtered through a silica gel plug, eluting with EtOAc. The filtrate was concentrated down to give a brown oil. Flash chromatography (5% to 35% EtOAc in hexanes) afforded aldehyde 283 as a light brown thick oil (951 mg, 2.32 mmol, 86%) yield). $[\alpha]_D^{25} = +106^\circ$ (c = 1.27, CHCl₃); ¹H NMR (500 MHz, CDCl₃; compound exists as a 2.0:1 mixture of rotamers; the major rotamer is denoted by *, minor rotamer denoted by [§]) δ 9.26 (s, 1H[§]), 9.20 (s, 1H^{*}), 7.14 (t, J = 7.6 Hz, 1H^{*}, 1H[§]), 7.03 (d, J = 7.4 Hz, 1H^{*}, $1H^{\$}$, 6.79 (s, $1H^{\$}$), 6.73 (t, J = 7.4 Hz, $1H^{\ast}$), 6.60 – 6.51 (m, $1H^{\$}$), 6.48 (d, J = 8.0 Hz, 1H*), 6.33 - 6.17 (m, 1H[§]), 6.13 (t, J = 7.0 Hz, 1H*), 5.55 (s, 1H*), 5.38 (s, 1H[§]), 4.66 $(d, J = 7.5 Hz, 1H^*), 4.38 (s, 1H^{\$}), 3.77 (s, 3H^*), 3.71 (s, 3H^{\$}), 3.01 (s, 3H^*), 2.83 (s, 3H^{\$}), 3.71 (s, 3H^{\$}), 3.01 (s, 3H^{\$}), 3.83 (s, 3H^{\ast}), 3.83 (s,$ $3H^{\$}$), 2.74 (d, J = 7.7 Hz, $2H^{\$}$, $2H^{\$}$), 2.69 (d, J = 10.2 Hz, $1H^{\$}$), 2.57 (s, $1H^{\$}$), 2.44 (d, J= 13.0 Hz, 1H^{*}), 2.18 (s, 1H[§]), 1.66 (s, 3H^{*}, 3H[§]); ¹³C NMR (126 MHz, CDCl₃) δ

194.3*[§], 172.4*, 170.2[§], 158.6* (q, J = 37.3 Hz), 157.1[§] (q, J = 39.4 Hz), 149.7*, 149.5[§], 147.4*, 147.2[§], 141.5*[§], 130.9*, 130.5[§], 129.3[§], 129.1*, 121.7*[§], 119.9[§], 118.9*, 115.7* (q, J = 288.7 Hz), 109.5[§], 108.1*, 90.1*, 88.9[§], 60.5[§], 59.4*, 56.8[§], 53.1*, 52.9*, 52.3[§], 42.4*, 39.1[§], 36.2*, 35.5*, 34.6[§], 34.2[§], 9.2*[§]; FTIR (NaCl, thin film): 3421, 3052, 3026, 2955, 2827, 2717, 1751, 1688, 1609, 1490, 1437, 1358, 1302, 1204, 1155, 1061, 1021, 985, 932, 873, 850, 794, 754 cm⁻¹; HRMS (MM) calc'd for C₂₀H₂₂F₃N₂O₄ [M+H]⁺

411.1526, found 411.1531.

Preparation of allylic alcohol 284



To a 100 mL flask was added aldehyde **283** (636 mg, 1.55 mmol, 1.0 equiv) and methanol (31 mL). Then, cerium chloride heptahydrate (693 mg, 1.86 mmol, 1.2 equiv) was dissolved in methanol (2.5 mL), while NaBH₄ (59 mg, 1.55 mmol, 1.0 equiv) was mixed with methanol (1.2 mL). The reaction was cooled to 0 °C. The pre-generated methanol solution of cerium chloride was added into the reaction flask, quickly followed by the slow addition of NaBH₄ methanol solution. After reacting at 0 °C for 15 minutes, the reaction was quenched with saturated ammonium chloride solution (70 mL), followed by EtOAc (50 mL). The mixture was separated and aqueous layer was extracted with EtOAc (3 x 50 mL). Combined organic layers were washed with brine (120 mL), dried over Na₂SO₄, filtered, and concentrated down to give a grey oil. Flash chromatography (5% to 60% EtOAc in hexanes) afforded allylic alcohol **284** as a light brown thick oil

(567 mg, 1.37 mmol, 89% yield). $[\alpha]_{D}^{25} = +88^{\circ} (c = 1.16, CHCl_{3}); {}^{1}H NMR (500 MHz,$ CDCl₃; compound exists as a 1.6:1 mixture of rotamers; the major rotamer is denoted by *, minor rotamer denoted by §) δ 7.11 (t, J = 7.6 Hz, 1H*, 1H§), 7.01 (d, J = 7.5 Hz, 1H*, $1H^{\$}$), 6.80 – 6.76 (m, $1H^{\$}$), 6.71 (t, J = 7.4 Hz, $1H^{\ast}$), 6.53 (d, J = 7.9 Hz, $1H^{\$}$), 6.46 (d, J $= 7.9 \text{ Hz}, 1\text{H}^{\text{\$}}$, 5.52 (s, 1H^{*}), 5.37 (s, 1H[§]), 5.25 (t, $J = 7.2 \text{ Hz}, 1\text{H}^{\text{\$}}$), 5.13 (t, J = 7.4 Hz, 1H*), 4.63 (d, J = 7.5 Hz, 1H*), 4.30 (t, J = 8.0 Hz, 1H[§]), 3.85 (s, 2H[§]), 3.83 (s, 2H*), $3.77 (s, 3H^*), 3.69 (s, 3H^{\$}), 3.02 (s, 3H^*), 2.85 (s, 3H^{\$}), 2.61 (dd, J = 13.6, 9.3 Hz, 2H^*), 3.77 (s, 3H^{\$}), 3.69 (s, 3H^{\$}), 3.02 (s, 3H^{\$}), 3.85 (s, 3H^{\$}), 3.61 (dd, J = 13.6, 9.3 Hz), 3.61 (dd, J =$ $2H^{\$}$), 2.53 – 2.44 (m, 1H*), 2.41 (d, J = 3.9 Hz, 2H^{\\$}), 2.39 (d, J = 6.8 Hz, 2H*), 2.17 – 2.09 (m, 1H[§]), 1.55 (s, 3H^{*}, 3H[§]); ¹³C NMR (126 MHz, CDCl₃) δ 172.5^{*}, 170.6[§], 158.7^{*} $(q, J_{C-F} = 37.0 \text{ Hz}), 157.4^{\$} (q, J_{C-F} = 38.1 \text{ Hz}), 149.9^{\$}, 149.8^{\ast}, 138.6^{\ast\$}, 132.3^{\ast}, 132.1^{\$},$ $128.8^{\$}, 128.6^{\$}, 121.9^{\$}, 121.8^{\$}, 119.9^{\$}, 119.1^{\ast}, 118.6^{\ast\$}, 115.8^{\ast}$ (q, $J_{C-F} = 288.5$ Hz), 115.7[§] (app d, $J_{C-F} = 286.6 \text{ Hz}$), 109.8[§], 108.0^{*}, 90.2^{*}, 89.0[§], 67.6^{*§}, 60.5[§], 59.4^{*}, 57.6[§], 53.5*, 52.8*, 52.3[§], 41.9*, 38.4[§], 36.4*, 35.3[§], 34.3*, 34.1[§], 13.6*[§]; FTIR (NaCl, thin film): 3421, 3052, 2954, 2921, 2875, 1749, 1690, 1608, 1490, 1437, 1356, 1301, 1203, 1155, 1062, 1021, 994, 931, 852, 794, 746, 727 cm⁻¹; HRMS (MM) calc'd for $C_{20}H_{24}F_{3}N_{2}O_{4}$ [M+H]⁺ 413.1683, found 413.1690.

Preparation of epoxy alcohol 285



To a flame-dried 50 mL flask was added $Ti(O'Pr)_4$ (31 μ L, 0.105 mmol, 10 mol %), activated 4Å molecular sieves, and DCM (18 mL). The reaction flask was cooled to –

20 °C (crushed ice mixed with NaCl at about 3 : 1 ratio). (+)-Diethyl-tartrate (21.5 μ L, 0.126 mmol, 12 mol %) was added. After stirring for 5 minutes, allylic alcohol **284** (432 mg, 1.05 mmol, 1.0 equiv) was added as a DCM solution (2 mL). After 30 minutes, 'BuOOH (5.0-6.0 M decane solution, 0.57 mL, 3.14 mmol, 3.0 equiv) was added. In 90 minutes, the flask was warmed to 0 °C using an ice water bath. The reaction was quenched with freshly prepared FeSO₄/citric acid solution (4 g FeSO₄, 0.66 g citric acid monohydrate, 12 mL distilled water). The mixture was extracted with Et₂O (4 x 20 mL). Combined organic layers were cooled to 0 °C and then treated with precooled 30% NaOH (w/v) in saturated NaCl solution (prepared using 30 g NaOH, 5 g NaCl, 90 ml distilled water). The mixture was extracted with Et₂O (2 x 80 mL). Combined organic layers were dried over MgSO₄, filtered, and concentrated down to give a colorless oil. Flash chromatography (10% to 70% EtOAc in hexanes) afforded epoxy alcohol **285** (10 : 1 mixture of epoxide diastereomers by ¹H NMR), as a white foam (434 mg, 1.01 mmol,

97% yield). $[\alpha]_{D}^{25} = +104^{\circ}$ (c = 0.87, CHCl₃); ¹H NMR (500 MHz, CDCl₃; compound exists as a 1.7 : 1 mixture of rotamers; the major rotamer is denoted by *, minor rotamer denoted by [§]) δ 7.17 (td, J = 7.7, 1.2 Hz, 1H*, 1H[§]), 7.03 (d, J = 7.3 Hz, 1H*, 1H[§]), 6.80 (d, J = 8.4 Hz, 1H[§]), 6.77 (d, J = 7.2 Hz, 1H*), 6.56 (d, J = 8.4 Hz, 1H[§]), 6.52 (d, J = 8.7Hz, 1H*), 5.89 (s, 1H*), 5.82 (s, 1H[§]), 4.70 – 4.53 (m, 1H*), 4.33 (t, J = 8.1 Hz, 1H[§]), 3.77 (s, 3H*), 3.73 (s, 3H[§]), 3.55 – 3.43 (m, 1H*, 1H[§]), 3.42 – 3.26 (m, 1H*, 1H[§]), 3.12 (s, 3H*), 2.91 (s, 3H[§]), 2.85 – 2.78 (m, 1H[§]), 2.78 – 2.65 (m, 2H*), 2.61 – 2.50 (m, 1H[§]), 2.41 (dd, J = 13.4, 4.7 Hz, 1H[§]), 2.22 (d, J = 14.7 Hz, 1H[§]), 2.12 (d, J = 12.5 Hz, 1H*), 2.02 – 1.86 (m, 2H*), 1.78 (dd, J = 15.4, 8.6 Hz, 1H[§]), 1.23 (s, 3H[§]), 1.15 (s, 3H*); ¹³C NMR (126 MHz, CDCl₃) δ 172.4*, 170.6[§], 158.6* (q, $J_{C-F} = 37.1$ Hz), 157.6[§] (q, $J_{C-F} = 37.9$ Hz), 150.2*[§], 131.4*, 130.7[§], 129.2*[§], 122.0*[§], 119.9[§], 188.8*, 115.9* (q, $J_{C-F} = 288.3$ Hz), 109.5[§], 108.3*, 90.1*, 88.8[§], 65.0*[§], 60.9[§], 60.23*, 60.15*, 59.1*, 56.4*, 56.3[§], 52.9*[§], 52.6*[§], 42.9*, 40.4[§], 36.8*, 35.7*, 34.9[§], 34.8[§], 14.3*[§]; FTIR (NaCl, thin film): 3462, 3004, 2955, 1751, 1691, 1609, 1490, 1437, 1358, 1302, 1203, 1159, 1103, 1063, 1034, 985, 928, 848, 754 cm⁻¹; HRMS (MM) calc'd for C₂₀H₂₄F₃N₂O₅ [M+H]⁺ 429.1632, found 429.1643.

Preparation of epoxy mesylate 286



To a flame-dried 25 mL flask was added epoxy alcohol **285** (284 mg, 0.66 mmol, 1.0 equiv) and DCM (6.6 mL). The reaction flask was cooled to 0 °C. Methanesulfonyl chloride (MsCl, 57 μ L, 0.73 mmol, 1.1 equiv) was added, followed by Et₃N (185 μ L, 1.33 mmol, 2.0 equiv). After stirring for 1 hour, the reaction was quenched with saturated NaHCO₃ solution (15 mL). The aqueous layer was extracted with EtOAc (4 x 15 mL). Combined organic layers were washed with brine (30 mL), dried over Na₂SO₄, filtered, and concentrated down to give a colorless oil. Flash chromatography (5% to 60% EtOAc in hexanes) afforded epoxy mesylate **286** as a white foam (296 mg, 0.58 mmol, 89% yield; resulting epoxy mesylate diastereomers from previous step were readily separated at this stage). $[\alpha]_D^{25} = +89^\circ$ (c = 0.85, CHCl₃); ¹H (500 MHz, CDCl₃; compound exists as a 1.7 : 1 mixture of rotamers; the major rotamer is denoted by *, minor rotamer denoted

by [§]) δ 7.17 (t, J = 7.8 Hz, 1H^{*}, 1H[§]), 7.04 (d, J = 7.3 Hz, 1H^{*}, 1H[§]), 6.87 – 6.71 (m, 1H^{*}, 1H[§]), 6.65 – 6.47 (m, 1H^{*}, 1H[§]), 5.87 (s, 1H^{*}), 5.79 (s, 1H[§]), 4.60 (s, 1H^{*}), 4.33 (s, 1H[§]), 4.08 (d, J = 14.0 Hz, 1H[§]), 4.04 (d, J = 11.1 Hz, 1H^{*}), 3.89 (s, 1H[§]), 3.85 (d, J =10.6 Hz, 1H^{*}), 3.76 (s, 3H^{*}), 3.73 (s, 3H[§]), 3.10 (s, 3H^{*}), 2.94 (s, 3H^{*}, 3H[§]), 2.88 (s, 3H[§]), 2.72 (dt, J = 18.8, 9.4 Hz, 1H^{*}, 1H[§]), 2.68 – 2.60 (m, 1H^{*}), 2.55 (dd, J = 13.2, 8.1 Hz, 1H[§]), 2.39 (dd, J = 13.4, 4.6 Hz, 1H^{*}), 2.28 (d, J = 14.6 Hz, 1H[§]), 2.16 (d, J = 14.7Hz, 1H^{*}), 2.13 – 2.06 (m, 1H[§]), 1.95 (t, J = 11.7 Hz, 1H[§]), 1.76 (dt, J = 15.0, 5.7 Hz, 1H^{*}), 1.34 (s, 3H[§]), 1.25 (s, 3H^{*}); ¹³C NMR (126 MHz, CDCl₃) δ 172.4^{*}, 170.4[§], 158.5^{*} (q, $J_{C-F} = 37.3$ Hz), 157.4[§] (q, $J_{C-F} = 36.8$ Hz), 150.1^{*§}, 130.9^{*}, 130.1[§], 129.3^{*§}, 121.9^{*§}, 119.7[§], 118.8^{*}, 115.8[§] (q, $J_{C-F} = 288.7$ Hz), 109.3[§], 108.2^{*}, 90.0^{*}, 88.6[§], 73.2[§], 73.1^{*}, 60.2[§], 59.0^{*}, 57.4^{*§}, 57.4^{*}, 56.2[§], 52.9^{*§}, 52.4^{*§}, 42.9^{*}, 40.3[§], 37.4^{*§}, 36.7^{*}, 35.3^{*}, 34.5[§], 34.1[§], 14.0^{*§}; FTIR (NaCl, thin film): 3028, 2956, 1747, 1693, 1608, 1489, 1439, 1360, 1303, 1203, 1175, 1160, 1106, 1063, 1022, 982, 962, 897, 846, 817, 755 cm⁻¹; HRMS (MM) calc'd for C₂₁H₂₆F₃N_{2O7}S [M+H]^{*} 507.1407, found 507.1411.

Preparation of epoxy iodide 287



To a 10 mL flame-dried flask equipped with a condenser was added epoxy mesylate **286** (146 mg, 0.288 mmol, 1.0 equiv) and sodium iodide (432 mg, 2.88 mmol, 10.0 equiv). Acetone (2.8 mL) was then added and the reaction was heated to 60 °C, resulting in a yellow clear solution gradually turning blurry. After 90 minutes, the reaction was cooled to room temperature and the mixture was quenched with saturated

 NH_4Cl solution (10 mL) and extracted with EtOAc (3 x 10 mL). Combined organic layers were washed with saturated NaHCO₃ solution (50 mL) and brine (50 mL). It was dried over Na_2SO_4 , filtered and concentrated down to give an oil. Flash chromatography (1% to 25% EtOAc in hexanes) afforded epoxy iodide **287**, as white foam (136 mg, 0.253 mmol, 88% yield). $[\alpha]_{D}^{25} = +110^{\circ}$ (c = 0.545, CHCl₃); ¹H NMR (500 MHz, CDCl₃; compound exists as a 1.7 : 1 mixture of rotamers the major rotamer is denoted by *, minor rotamer denoted by §) δ 7.20 (t, J = 7.7 Hz, 1H*, 1H§), 7.06 (d, J = 7.2 Hz, 1H*, 1H§), 6.88 - 6.76 $(m, 1H^*, 1H^{\$}), 6.61 - 6.49 (m, 1H^*, 1H^{\$}), 5.88 (s, 1H^*), 5.78 (s, 1H^{\$}), 4.62 (s, 1H^{*}), 4.35$ $(s, 1H^{\$}), 3.79 (s, 3H^{\ast}), 3.76 (s, 3H^{\$}), 3.14 (s, 3H^{\ast}), 3.10 - 3.03 (m, 3H^{\$}), 2.93 (d, J = 10.7)$ Hz, $2H^{\$}$, $2H^{\$}$), 2.79 - 2.62 (m, $1H^{\$}$, $1H^{\$}$), 2.62 - 2.53 (m, $1H^{\$}$), 2.49 - 2.40 (m, $1H^{\ast}$), 2.35 - 2.21 (m, 1H[§]), 2.15 (d, J = 15.1 Hz, 1H^{*}), 2.02 - 1.87 (m, 1H[§]), 1.73 (dd, J = 14.6, 8.1 Hz, 1H*), 1.45 (s, 3H[§]), 1.37 (s, 3H*); ¹³C NMR (126 MHz, CDCl₃) δ 172.4*, $170.5^{\$}, 158.6^{\ast}$ (q, $J_{CF} = 36.2, 35.4$ Hz), $150.2^{\ast\$}, 131.3^{\ast}, 130.5^{\$}, 129.3^{\ast\$}, 122.0^{\ast\$}, 119.9^{\$},$ 118.9*, 115.9* (q, $J_{CF} = 288.9$ Hz), 109.5[§], 108.5*, 90.1*, 88.7[§], 62.5*, 60.3[§], 59.2*[§], 56.3[§], 53.0^{*}, 52.6[§], 52.4^{*}, 43.0^{*}, 40.5[§], 36.9^{*}, 36.4^{*}, 35.2[§], 34.7[§], 16.4^{*§}, 13.1^{*§}; FTIR (NaCl, thin film): 3444, 3054, 3022, 3005, 2956, 1747, 1699, 1608, 1489, 1435, 1386, 1360, 1303, 1203, 1158, 1023, 986, 929, 853, 809, 755 cm⁻¹; HRMS (MM) calc'd for $C_{20}H_{23}F_{3}N_{2}O_{4}I [M+H]^{+} 539.0649$, found 539.0633.

Preparation of amine 288



pyrroloindoline **264** (500 mg, 1.36 mmol, 1.0 equiv) and dimethylbibarturic acid (636 mg, 4.07 mmol, 3.0 equiv). The Schlenk flask was then evacuated and backfilled with argon three times. The solids were then dissolved in dry DCE (3.8 mL). In the meantime, in а 1-dram vial, $Pd_2(dba)_3$ (62 mg, 0.068 mmol, 5 mol %) and 1,4bis(diphenylphosphino)butane (dppb, 58 mg, 0.135 mmol, 10 mol %) were mixed in DCE (1.6 mL) and the mixture was allowed to stir at room temperature for 1 hour; then the resulting solution was added into Schlenk flask. The reaction was heated to 80 °C. After 4 days, the reaction was cooled to room temperature and quenched with saturated Na₂CO₃ aqueous solution (40 mL). The mixture was extracted with EtOAc (3 x 40 mL). Combined organic layers were washed with brine (100 mL). It was dried over Na_2SO_4 , filtered and concentrated down to give a brown oil. Flash chromatography (1% to 20% EtOAc in hexanes) afforded amine 288, which was contaminated with phosphine oxide formed from the dppb ligand. The mixture was then subjected to preparative reverse phase HPLC (t = 0 - 14 min, 65% to 75% CH₃CN in H₂O; t = 14 - 15 min, 75% to 95% CH₃CN in H₂O; t = 15 - 17 min, 95% to 100% CH₃CN in H₂O; t = 17 - 17.5 min, 100% to 65% CH₃CN in H₂O; t = 17.5 - 25 min, 65% CH₃CN in H₂O; $t_{R} = 16.5 - 20.0$ min), to give pure product **43** as a yellow oil (408 mg, 1.24 mmol, 92% yield). $[\alpha]_{D}^{25} = -228^{\circ}$ (c = 0.93, CHCl₃); ¹H NMR (500 MHz, CDCl₃; compound exists as a 3.4 : 1 mixture of rotamers; the major rotamer is denoted by *, minor rotamer denoted by δ 7.08 – 7.01 $(m, 1H^*, 2H^{\$}), 7.00 (ddd, J = 7.4, 1.3, 0.6 Hz, 1H^*), 6.75 (td, J = 7.4, 0.9 Hz, 1H^{\$}), 6.70$ $(td, J = 7.5, 0.9 Hz, 1H^*), 6.61 - 6.58 (m, 1H^{\$}), 6.58 (dt, J = 7.9, 0.7 Hz, 1H^*), 5.45 (tt, J)$ $= 1.9, 1.1 \text{ Hz}, 1\text{H}^{\$}$, 5.34 (s, 1H*), 5.21 (br s, 1H^{\\$}), 4.91 (dd, $J = 8.7, 2.3 \text{ Hz}, 1\text{H}^{\$}$), 4.74

(ddd, J = 8.9, 1.9, 1.0 Hz, 1H*), 3.24 (s, 3H[§]), 3.12 (s, 3H*), 2.86 (d, J = 13.2 Hz, 1H*), 2.70 (dd, J = 13.0, 2.3 Hz, 1H[§]), 2.50 (dd, J = 13.2, 8.5 Hz, 1H*), 2.33 (dd, J = 13.0, 8.7Hz, 1H[§]), 1.46 (s, 3H[§]), 1.42 (s, 3H*); ¹³C NMR (126 MHz, CDCl₃) & 170.0*, 169.5[§], 156.8* (q, $J_{CF} = 37.3$ Hz), 155.9[§] (q, $J_{CF} = 37.5$ Hz), 148.8*, 147.6[§], 131.3[§], 131.0*, 128.9*[§], 122.8*, 122.7[§], 119.4[§], 119.0*, 116.2[§] (q, $J_{CF} = 287.4$ Hz), 115.8* (q, $J_{CF} =$ 288.0 Hz), 108.9[§], 108.8*, 84.6*, 83.2[§], 60.7[§], 60.1* (q, $J_{CF} = 3.2$ Hz), 54.4[§], 52.4*, 52.2[§], 50.7*, 41.9*, 40.2[§], 24.4[§], 24.2*; FTIR (NaCl, thin film): 3401, 3055, 2957, 2929, 2871, 2121, 1738, 1687, 1612, 1521, 1485, 1470, 1455, 1408, 1354, 1334, 1315, 1302, 1260, 1204, 1148, 1104, 1065, 1034, 1018, 1000, 977, 939, 904, 865, 837, 748, 718 cm⁻¹; HRMS (MM) calc'd for C₁₅H₁₆F₃N₂O₃ [M+H]⁺ 329.1108, found 329.1113.

Preparation of bis(pyrroloindoline) 289



To a 0.5-dram vial was added amine **288** (76 mg, 0.23 mmol, 3.0 equiv), which was then co-evaporated with benzene (2 x 1 mL). Epoxy mesylate **286** (39 mg, 0.08 mmol, 1.0 equiv) was added as a solid, followed by tetra-*n*-butylammonium iodide (TBAI, 5.7 mg, 0.015 mmol, 0.2 equiv), and acetonitrile (90 μ L). DIPEA (20 μ L, 0.12 mmol, 1.5 equiv) was added at last. The vial was sealed using a Teflon cap and heated to 90 °C for 5 days. It was then cooled to room temperature and quenched with saturated NaHCO₃ aqueous solution (2 mL). The mixture was extracted with EtOAc (5 x 2 mL).

Combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered, and concentrated down to give a yellow liquid. Flash chromatography (1% to 28% EtOAc in hexanes) afforded bis(pyrroloindoline) **289** as a light yellow oil (41.9 mg, 0.057 mmol, 74% yield). Starting material **288** can be recovered. $[\alpha]_D^{25} = -21^\circ$ (c = 0.61, CHCl₃); ¹H NMR (500 MHz, CD₃CN; *half of proton peaks* in compound exist as a 1.6 : 1 mixture of rotamers; the major rotamer is denoted by *, minor rotamer denoted by [§]) δ 7.15 (td, J = 7.7, 1.2 Hz, 1H*, 1H[§]), 7.11 – 7.00 (m, 1H*, 1H[§], 1H), 6.92 (dd, J = 7.3, 1.2 Hz, 1H), 6.83 (t, J = 8.1 Hz, 1H[§]), 6.78 (t, J = 7.3 Hz, 1H*), 6.66 (t, J = 7.4 Hz, 1H), 6.56 – 6.48 (m, 1H*, 1H[§]), 6.47 (d, J = 8.1 Hz, 1H), 5.90 (s, 1H*), 5.79 (s, 1H[§]), 5.37 (s, 1H),

7.15 (td, J = 7.7, 1.2 Hz, 1H*, 1H[§]), 7.11 – 7.00 (m, 1H*, 1H[§], 1H), 6.92 (dd, J = 7.3, 1.2Hz, 1H), 6.83 (t, J = 8.1 Hz, 1H[§]), 6.78 (t, J = 7.3 Hz, 1H^{*}), 6.66 (t, J = 7.4 Hz, 1H), 6.56 -6.48 (m, 1H^{*}, 1H[§]), 6.47 (d, J = 8.1 Hz, 1H), 5.90 (s, 1H^{*}), 5.79 (s, 1H[§]), 5.37 (s, 1H), 4.70 (d, J = 8.2 Hz, 1H), 4.64 – 4.55 (m, 1H*), 4.29 (t, J = 8.2 Hz, 1H[§]), 3.75 (s, 3H*), $3.73 (s, 3H^{\$}), 3.59 - 3.35 (m, 2H^{\$}, 2H^{\$}), 3.13 (s, 3H), 3.05 (s, 3H^{\ast}), 2.81 (s, 3H^{\$}), 2.78$ $(d, J = 13.0 \text{ Hz}, 1\text{H}), 2.73 (dd, J = 13.8, 9.4 \text{ Hz}, 1\text{H}^{\$}), 2.67 - 2.59 (m, 1\text{H}^{*}), 2.42 (dd, J = 13.8 \text{ Hz}, 1\text{H}^{\$}), 2.67 - 2.59 (m, 10.8 \text{ Hz}), 2.42 (dd, J = 13.8 \text{ Hz}), 2.42 (dd, J = 13.8 \text{ Hz}), 3.43 (dd, J = 13.8 \text{ Hz})$ 13.5, 4.4 Hz, 1H*), 2.31 (dd, J = 13.0, 8.4 Hz, 1H), 2.33 – 2.27 (m, 1H⁸), 2.21 (d, J =14.3 Hz, 1H*), 2.17 – 2.10 (m, 1H[§]), 1.87 (dt, J = 16.5, 6.3 Hz, 1H[§]), 1.76 – 1.60 (m, 1H*), 1.30 (s, 3H[§]), 1.25 (s, 3H*, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 172.3*, 170.6[§], 169.6, 158.5* (q, $J_{C-F} = 37.4 \text{ Hz}$), 157.8[§] (app d, $J_{C-F} = 41.7 \text{ Hz}$), 156.9 (q, $J_{C-F} = 36.8 \text{ Hz}$), $150.8^{\$}, 150.5^{\ast}, 149.5, 131.7^{\ast}, 131.4, 131.0^{\$}, 129.3^{\$}, 129.1^{\ast}, 128.9^{\ast\$}, 122.3^{\ast\$}, 122.0,$ $120.1^{\$}$, 118.8*, 118.3, 116.1 (q, $J_{CF} = 288.5$ Hz), 116.0* (q, $J_{CF} = 288.6$ Hz), 115.8[§] (q, $J_{C-F} = 286.1 \text{ Hz}$, 110.0[§], 108.5^{*}, 107.3, 90.2^{*}, 88.9, 88.8[§], 60.2[§], 60.0^{*}, 60.0, 59.8[§], $59.5^{*}, 59.1^{*\$}, 57.6^{*}, 56.8^{\$}, 52.9^{*}, 52.8^{*}, 52.5^{\$}, 52.4, 52.1^{\$}, 50.6, 42.9^{*}, 42.4, 40.1^{\$},$ 37.0*, 36.2*, 35.8[§], 35.7[§], 25.8, 15.5[§], 15.4*; FTIR (NaCl, thin film): 2956, 2927, 1750, 1694, 1608, 1491, 1436, 1357, 1341, 1302, 1255, 1206, 1155, 1105, 1065, 1034, 998, 944, 861, 845, 845, 747 cm⁻¹; HRMS (MM) calc'd for $C_{35}H_{37}F_6N_4O_7$ [M+H]⁺ 739.2561, found 739.2570.

OMe CF₃ When epoxy iodide 287 was used instead of epoxy mesylate, a 42% yield of rearranged product **290** was isolated. $[\alpha]_D^{25} = -122^\circ$ (c = 0.475, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.17 (td, J = 7.6, 1.3Ĥ Me 290 Hz, 1H), 7.03 (ddd, J = 7.3, 1.3, 0.5 Hz, 1H), 6.75 (td, J = 7.4, 1.0 Hz, 1H), 6.60 (d, J =8.3 Hz, 1H), 6.43 (d, J = 7.9 Hz, 1H), 5.23 (s, 1H), 4.94 (dt, J = 1.9, 1.0 Hz, 1H), 4.86 -4.74 (m, 1H), 4.33 (td, J = 8.1, 4.8 Hz, 1H), 3.99 (dd, J = 11.1, 4.4 Hz, 1H), 3.64 (s, 3H),2.89 (s, 3H), 2.65 (dd, J = 14.7, 4.9 Hz, 1H), 2.37 – 2.19 (m, 2H), 1.91 (dd, J = 11.8, 11.1Hz, 1H), 1.68 (d, J = 1.2 Hz, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.8, 156.3 (q, $J_{C-F} =$ 37.6 Hz), 151.4, 143.3, 129.7, 129.4, 123.0, 118.0, 115.5 (q, $J_{C-F} = 287.9$ Hz), 111.8, 106.2, 101.7, 80.7, 55.3, 52.9, 50.9, 46.1, 39.2, 30.4, 17.9; FTIR (NaCl, thin film): 3307, 2953, 2924, 2853, 1747, 1713, 1608, 1557, 1495, 1442, 1290, 1262, 1208, 1179, 1033, 1021, 997, 959, 900, 743 cm⁻¹; HRMS (MM) calc'd for $C_{20}H_{24}F_3N_2O_4$ [M+H]⁺ 413.1683, found 413.1690.

Preparation of bis(amino acid) 293



A solution of lithium hydroxide (7.4 mg, 0.31 mmol, 5.0 equiv) in distilled water (200 μ L) was added dropwise to a solution of bis(pyrroloindoline) **289** (45.7 mg, 0.062

mmol, 1.0 equiv) in THF (350 μ L) and distilled water (150 μ L). After stirring at room temperature for 6 hours, the reaction was quenched with 1M HCl until pH reached 7 (210 μ L). The resulting solution was concentrated down using rotavap to get rid of THF, and then put under high vacuum to give a yellow oil. It was dissolved in methanol and subjected to reverse phase preparative HPLC (10% to 60% CH₃CN in H₂O over 12 min, $t_R = 6.8 - 8.0$ min), giving bis(amino acid) **293** as a white solid (22.3 mg, 0.043 mmol, 70% yield). $[\alpha]_{D}^{25} = +59^{\circ}$ (c = 0.59, MeOH); ¹H NMR (500 MHz, CD₃OD) δ 7.20 – 7.15 (m, 2H), 7.11 (dd, J = 7.6, 1.2 Hz, 1H), 7.09 (td, J = 8.0, 1.5 Hz, 1H), 6.79 (td, J = 7.4, 0.8 Hz, 1H), 6.77 (td, J = 7.5, 0.8 Hz, 1H), 6.55 (dd, J = 8.2, 0.9 Hz, 1H), 6.21 (d, J = 7.9Hz, 1H), 5.21 (s, 1H), 4.88 (s, 1H), 4.10 (dd, J = 8.6, 3.2 Hz, 1H), 3.67 (d, J = 16.2 Hz, 1H), 3.62 (d, J = 16.2 Hz, 1H), 3.51 (dd, J = 12.3, 5.9 Hz, 1H), 3.35 (dd, J = 8.2, 3.6 Hz, 13.0, 5.9 Hz, 1H), 2.46 (dd, J = 13.5, 8.6 Hz, 1H), 2.19 (dd, J = 15.1, 3.7 Hz, 1H), 2.06 $(dd, J = 15.1, 8.2 \text{ Hz}, 1\text{H}), 1.38 (s, 3\text{H}), 1.37 (s, 3\text{H}); {}^{13}\text{C} \text{ NMR} (126 \text{ MHz}, \text{CD}_3\text{OD}) \delta$ 174.3, 173.5, 151.2, 149.7, 134.3, 133.7, 130.3, 130.0, 124.1, 124.0, 121.0, 120.0, 107.8, 107.6, 93.4, 88.2, 62.2, 61.7, 61.3, 57.8, 57.7, 54.5, 54.4, 42.5, 42.4, 36.7, 33.1, 26.4, 15.6; FTIR (NaCl, thin film): 3049, 2957, 2930, 2603, 1631, 1607, 1490, 1462,1451, 1402, 1383, 1350, 1308, 1275, 1213, 1187, 1129, 1106, 1043, 1026, 921, 860, 741 cm⁻¹; HRMS (MM) calc'd for $C_{29}H_{35}N_4O_5$ [M+H]⁺ 519.2602, found 519.2615.

Preparation of (+)-nocardioazine A (171)



To a 0.5-dram vial was added bis(amino acid) 293 (2.9 mg, 0.006 mmol, 1.0 equiv). It was co-evaporated with benzene (1 mL). DMF (280 μ L) was added into the vial. At 0 °C, DIPEA (4.5 μ L, 0.026 mmol, 4.6 equiv) was added, followed by bromotripyrrolidinophosphonium hexafluorophosphate (PyBroP, 10.4 mg, 0.022 mmol, 4.0 equiv). After 5 minutes, the reaction was allowed to stir at room temperature. After 24 hours, the reaction was quenched with saturated NaHCO₃ solution (1 mL). The aqueous layer was extracted with EtOAc (5 x 1 mL). Combined organic layers were washed with brine (3 mL), dried over Na_2SO_4 , filtered and concentrated down to give a light yellow oil. Flash chromatography (5% to 40% EtOAc in hexanes) afforded (+)nocardioazine A (171) as a white solid (1.7 mg, 0.0035 mmol, 63% yield). $\left[\alpha\right]_{D}^{25} = +45^{\circ}$ $(c = 0.50, \text{CHCl}_3)$; ¹H NMR (500 MHz, CDCl₃) δ 7.18 (td, J = 7.7, 1.3 Hz, 1H), 7.16 (td, J = 7.7, 1.3 Hz, 1H), 7.10 (td, J = 7.5, 1.0 Hz, 2H), 6.79 (td, J = 7.5, 0.9 Hz, 1H), 6.74 (td, J = 7.4, 0.9 Hz, 1H), 6.49 (t, J = 7.3 Hz, 2H), 5.66 (s, 1H), 5.40 (s, 1H), 4.55 - 4.49(m, 2H), 3.73 (d, J = 15.3 Hz, 1H), 3.33 (dd, J = 11.0, 3.5 Hz, 1H), 3.28 (dd, J = 14.2, 1.8)Hz, 1H), 2.93 (s, 3H), 2.80 (dd, J = 15.0, 3.4 Hz, 1H), 2.76 (d, J = 15.4 Hz, 1H), 2.62 (dd, J = 13.7, 9.2 Hz, 1H), 2.40 (dd, J = 14.3, 11.2 Hz, 1H), 2.31 (dd, J = 13.7, 8.8 Hz, 1H), 1.53 (dd, J = 14.9, 10.7 Hz, 1H), 1.52 (s, 3H), 1.12 (s, 3H); ¹³C NMR (126 MHz, CDCl₃)

δ 169.8, 169.0, 149.0, 147.2, 133.7, 133.3, 128.9, 128.7, 121.7, 121.3, 118.7, 118.0, 107.6, 105.5, 91.6, 88.2, 62.7, 61.8, 61.6, 59.3, 53.4, 51.2, 51.1, 40.2, 36.5, 35.0, 34.3, 20.1, 14.2; FTIR (NaCl, thin film): 3051, 3011, 2956, 2923, 2871, 2821, 2793, 1681, 1608, 1483, 1453, 1428, 1390, 1359, 1345, 1303, 1278, 1245, 1216, 1190, 1158, 1146, 1119, 1095, 1068, 1053, 1038, 1024, 1001, 981, 966, 920, 909, 890, 874, 841, 829, 810, 788, 750, 703 cm⁻¹; HRMS (MM) calc'd for C₂₉H₃₁N₄O₃ [M+H]⁺ 483.2391, found 483.2409.

Table 3.5. Comparison of ¹H NMR data for natural vs. synthetic (+)-nocardioazine A (**171**)

-
This Work,
Synthetic
(+)-nocardioazine A
¹ H NMR, 500 MHz, CDCl ₃
δ 7.18 (td, J = 7.7, 1.3 Hz, 1H)
7.16 (td, <i>J</i> = 7.7, 1.3 Hz, 1H)
7.10 (td, $J = 7.5$, 1.0 Hz, 2H)
_
6.79 (td, <i>J</i> = 7.5, 0.9 Hz, 1H)
6.74 (td, <i>J</i> = 7.4, 0.9 Hz, 1H)
6.49 (t, <i>J</i> = 7.3 Hz, 2H)
_
5.66 (s, 1H)
5.40 (s, 1H)
4.55 – 4.49 (m, 2H)
_
3.73 (d, <i>J</i> = 15.3 Hz, 1H)
3.33 (dd, J = 11.0, 3.5 Hz, 1H)
3.28 (dd, J = 14.2, 1.8 Hz, 1H)
2.93 (s, 3H)
2.80 (dd, J = 15.0, 3.4 Hz, 1H)
2.76 (d, <i>J</i> = 15.4 Hz, 1H)
2.62 (dd, J = 13.7, 9.2 Hz, 1H)
2.40 (dd, <i>J</i> = 14.3, 11.2 Hz, 1H)
2.31 (dd, <i>J</i> = 13.7, 8.8 Hz, 1H)
1.53 (dd, J = 14.9, 10.7 Hz, 1H)
1.52 (s, 3H)
1.12 (s, 3H)

Raju et al. Report, ³	This Work,	Chemical Shift Difference, $\Delta\delta$
Natural	Synthetic	
(+)-nocardioazine A	(+)-nocardioazine A	
¹³ C NMR, 150 MHz, CDCl ₃	¹³ C NMR, 126 MHz, CDCl ₃	
δ 169.6	δ 169.8	0.2
168.8	169.0	0.2
148.8	149.0	0.2
146.9	147.2	0.3
133.6	133.7	0.1
133.0	133.3	0.3
128.8	128.9	0.1
128.4	128.7	0.3
121.5	121.7	0.2
121.1	121.3	0.2
118.4	118.7	0.3
117.8	118.0	0.2
107.4	107.6	0.2
105.4	105.5	0.1
91.5	91.6	0.1
88.0	88.2	0.2
62.4	62.7	0.3
61.7	61.8	0.1
61.4	61.6	0.2
59.2	59.3	0.1
53.3	53.4	0.1
51.0	51.2	0.2
50.9	51.1	0.2
40.1	40.2	0.1
36.4	36.5	0.1
34.9	35.0	0.1
34.2	34.3	0.1
19.9	20.1	0.2
14.1	14.2	0.1

Table 3.6. Comparison of ¹³C NMR data for natural vs. synthetic (+)-nocardioazine A (**171**)

3.6 NOTES AND REFERENCES

- (1) Repka, L. M.; Ni, J.; Reisman, S. E. J. Am. Chem. Soc. 2010, 132, 14418.
- (2) Ni, J.; Wang, H.; Reisman, S. E. *Tetrahedron* **2013**, *69*, 5622.
- (3) Raju, R.; Piggott, A. M.; Huang, X.-C.; Capon, R. J. Org. Lett. 2011, 13,

2770.

(4) Wang, M.; Feng, X.; Cai, L.; Xu, Z.; Ye, T. Chem. Commun. 2012, 48, 4344.

(5) Espejo, V. R.; Li, X.-B.; Rainier, J. D. J. Am. Chem. Soc. 2010, 132, 8282.

(6) Marsden, S. P.; Depew, K. M.; Danishefsky, S. J. J. Am. Chem. Soc. 1994,

116, 11143.

(7) Mari, M.; Lucarini, S.; Bartoccini, F.; Piersanti, G.; Spadoni, G. *Beilstein J. Org. Chem.* **2014**, *10*, 1991.

(8) Garro-Helion, F.; Merzouk, A.; Guibe, F. J. Org. Chem. 1993, 58, 6109.

(9) Chatterjee, A. K.; Sanders, D. P.; Grubbs, R. H. Org. Lett. 2002, 4, 1939.

(10) Chatterjee, A. K.; Morgan, J. P.; Scholl, M.; Grubbs, R. H. J. Am. Chem. Soc. 2000, 122, 3783.

(11) Eames, J.; J. Mitchell, H.; Nelson, A.; O'Brien, P.; Warren, S.; Wyatt, P. J. Chem. Soc., Perkin Trans. 1 1999, 1095.

(12) Gao, Y.; Klunder, J. M.; Hanson, R. M.; Masamune, H.; Ko, S. Y.; Sharpless, K. B. J. Am. Chem. Soc. **1987**, 109, 5765.

- (13) Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.
- (14) Usui, I.; Schmidt, S.; Keller, M.; Breit, B. Org. Lett. 2008, 10, 1207.
- (15) Odle, R.; Blevins, B.; Ratcliff, M.; Hegedus, L. S. J. Org. Chem. **1980**, 45, 2709.

(16) Liu, G.; Xin, Z.; Liang, H.; Abad-Zapatero, C.; Hajduk, P. J.; Janowick, D. A.; Szczepankiewicz, B. G.; Pei, Z.; Hutchins, C. W.; Ballaron, S. J.; Stashko, M. A.; Lubben, T. H.; Berg, C. E.; Rondinone, C. M.; Trevillyan, J. M.; Jirousek, M. R. *J. Med. Chem.* **2003**, *46*, 3437.

Appendix 2

Spectra Relevant to Chapter 3: Enantioselective Total Synthesis of (+)-Nocardioazines A and B
































•

÷

l

T

ī

T

I

I ı י ן

ł



Appendix 2 – Spectra Relevant to Chapter 3













































ω

6

- 2












I









WHX-5-179-F-Characterization INDY CDCL3

Ì

1





WHX-5-147-rec-characterization_INDY_CDCL3

ł

I

T

Т Ì

i i

I Т

| |

ł





WHX-5-243-F-Repurified_INDY_CDCL3

ł

|

ł

1

T







210









Appendix 3

X-Ray Crystallography Reports Relevant to Chapter 3: Enantioselective Total Synthesis of (+)-Nocardioazines A and B⁺

[†] The work disclosed in this appendix for the X-ray crystallographic analysis of **277** completed entirely by Larry Henling and Dr. Michael Day in the Caltech X-ray crystallography lab.

Figure A3.1. Macrocyclic alkene **277**. Crystallographic data have been deposited at the CCDC, 12 Union Road, Cambridge CB2 1EZ, UK and copies can be obtained on request, free of charge, by quoting the publication citation and the deposition number 997790.



Empirical formula	$C_{29}H_{30}N_4O_2$	
Formula weight	466.57	
Crystallization solvent	DCM/Pentane	
Crystal shape	blade	
Crystal color	colourless	
Crystal size	0.03 x 0.2 x 0.36 mm	
Data	Collection	
Preliminary photograph(s)	rotation	
Type of diffractometer	Bruker APEX-II CCD	
Wavelength	0.71073 Å MoK	
Data collection temperature	100.15 K	
Theta range for 5293 reflections used in lattice determination	2.40 to 20.69°	
Unit cell dimensions	a = 8.2481(3) Å b = 12.7097(5) Å c = 22.8106(8) Å	a= 90° b= 90° g = 90°
Volume	2391.26(15) Å ³	
Z	4	
Crystal system	orthorhombic	
Space group	P 21 21 21 (# 19)	
Density (calculated)	1.296 g/cm^3	
F(000)	992	
Theta range for data collection	2.4 to 29.4°	
Completeness to theta = 25.000°	99.9%	
Index ranges	-11 £ h £ 10, -16 £ k £ 1	.6, -30 £1£29
Data collection scan type	and scans	
Reflections collected	42025	
Independent reflections	5687 [R _{int} =0.1002]	
Reflections > 2s(I)	3486	
Average s(I)/(net I)	0.1114	
Absorption coefficient	0.08 mm^{-1}	

None

1.0000 and 0.8355

Absorption correction

Max. and min. transmission

Table A3.1. Crystal data and structure refinement for macrocyclic alkene 277(CCDC 997790).

Structure solution and Refinement

Table A3.1 (cont.)

Primary solution method	dual
Secondary solution method	?
Hydrogen placement	?
Refinement method	Full-matrix least-squares on F^2
Data / restraints / parameters	5687 / 0 / 437
Treatment of hydrogen atoms	refall
Goodness-of-fit on F ²	1.13
Final R indices [I>2s(I), 3486 reflections]	R1 = 0.0522, wR2 = 0.0632
R indices (all data)	R1 = 0.1217, wR2 = 0.0725
Type of weighting scheme used	calc
Weighting scheme used	
Max shift/error	0.000
Average shift/error	0.000
Absolute structure parameter	0.6(8)
Extinction coefficient	0.0112(8)
Largest diff. peak and hole	0.21 and -0.23 $e \cdot \text{\AA}^{-3}$

Programs Used

?
?
SAINT v8.27A (Bruker, 2012)

	X	у	Z	U _{eq}
O(1)	7309(2)	5733(2)	8607(1)	29(1)
O(2)	12123(2)	5018(2)	10081(1)	30(1)
N(1)	9738(3)	5862(2)	9901(1)	20(1)
N(3)	9952(3)	5296(2)	8768(1)	21(1)
N(2)	9195(3)	6507(2)	10884(1)	21(1)
N(4)	9753(3)	3417(2)	8592(1)	24(1)
C(26)	7924(3)	3412(2)	9447(1)	22(1)
C(13)	11173(4)	5437(2)	9738(1)	22(1)
C(6)	4946(4)	6119(2)	11133(1)	25(1)
C(10)	7760(3)	6589(2)	11204(1)	21(1)
C(11)	8986(3)	5648(2)	10462(1)	20(1)
C(5)	6497(3)	6100(2)	10906(1)	20(1)
C(22)	10876(4)	2697(2)	8370(1)	24(1)
C(24)	10142(3)	4459(2)	8346(1)	24(1)
C(1)	8540(4)	5774(2)	8907(1)	24(1)
C(27)	6821(3)	4127(2)	9606(1)	24(1)
C(8)	5939(4)	7100(3)	11959(2)	28(1)
C(9)	7532(4)	7080(2)	11738(1)	26(1)
C(16)	11970(3)	4392(2)	8235(1)	26(1)
C(28)	6452(4)	4540(2)	10204(1)	24(1)
C(25)	8138(4)	3156(3)	8800(1)	28(1)
C(4)	7146(3)	5638(2)	10344(1)	18(1)
C(3)	7000(4)	6423(2)	9821(1)	22(1)
C(17)	12209(4)	3228(2)	8137(1)	27(1)
C(2)	8613(3)	6375(2)	9487(1)	21(1)
C(14)	11466(3)	5529(3)	9087(1)	24(1)
C(7)	4685(4)	6635(2)	11664(1)	27(1)
C(18)	13463(4)	2675(3)	7887(1)	36(1)
C(12)	10752(4)	6581(3)	11188(2)	28(1)
C(29)	9013(4)	2825(3)	9858(2)	33(1)
C(15)	12677(4)	4735(3)	8837(2)	29(1)
C(21)	10792(4)	1611(3)	8356(1)	31(1)
C(23)	12541(5)	5104(3)	7738(2)	34(1)
C(20)	12072(5)	1067(3)	8094(1)	39(1)
C(19)	13375(5)	1583(3)	7862(2)	45(1)

Table A3.2. Atomic coordinates $(x \ 10^4)$ and equivalent isotropic displacement parameters $(\mathring{A}^2x \ 10^3)$ for macrocyclic alkene **277** (CCDC 997790). U(eq) is defined as one third of the trace of the orthogonalized U^{ij} tensor.

O(1)-C(1)	1.227(3)
O(2)-C(13)	1.228(3)
N(1)-C(13)	1.353(3)
N(1)-C(11)	1.447(3)
N(1)-C(2)	1.477(3)
N(3)-C(24)	1.445(3)
N(3)-C(1)	1 351(3)
N(3)-C(14)	1 475(4)
N(2) - C(10)	1 395(3)
N(2) - C(11)	1 466(3)
N(2) - C(12)	1.462(4)
N(2) - C(12) N(4) - C(22)	1 307(3)
N(4) - C(22) N(4) - C(24)	1.357(3)
N(4) - C(24) N(4) - C(25)	1.475(5) 1.452(4)
N(4)-C(23)	1.433(4)
C(20)-C(27)	1.530(4)
C(26)-C(25)	1.321(4)
C(20)-C(29)	1.498(4)
C(13)-C(14)	1.510(4)
C(6)-H(6)	0.92(2)
C(6)-C(5)	1.380(4)
C(6)-C(7)	1.396(4)
C(10)-C(5)	1.390(4)
C(10)-C(9)	1.381(4)
C(11)-H(11)	1.04(2)
C(11)-C(4)	1.541(4)
C(5)-C(4)	1.509(4)
C(22)-C(17)	1.396(4)
C(22)-C(21)	1.383(4)
C(24)-H(24)	1.03(3)
C(24)-C(16)	1.531(4)
C(1)-C(2)	1.529(4)
C(27)-H(27)	1.04(3)
C(27)-C(28)	1.493(4)
C(8)-H(8)	0.90(3)
C(8)-C(9)	1.407(4)
C(8)-C(7)	1.367(4)
C(9)-H(9)	1.01(3)
C(16)-C(17)	1.509(4)
C(16)-C(15)	1.554(4)
C(16)-C(23)	1.524(4)
C(28)-H(28A)	1.00(3)
C(28)-H(28B)	0.94(2)
C(28)-C(4)	1.541(4)
C(25)-H(25A)	1.05(3)
C(25)-H(25B)	1.02(3)
C(4)-C(3)	1.560(4)
C(3)-H(3A)	1.03(3)
C(3)-H(3B)	0.98(3)
C(3)-C(2)	1.534(4)

Table A3.3. Bond lengths [Å] and angles [°] for macrocyclic alkene **277** (CCDC 997790).

C(17)-C(18)	1.374(4)
C(2)-H(2)	1.10(3)
C(14)-H(14)	0.99(2)
C(14)-C(15)	1.530(4)
C(7)-H(7)	0.95(3)
C(18)-H(18)	0.94(3)
C(18)-C(19)	1.391(5)
C(12)-H(12A)	0.98(4)
C(12)-H(12B)	1.10(3)
C(12)-H(12C)	1.00(3)
C(29)-H(29A)	1.00(3)
C(29)-H(29B)	1.04(3)
C(29)-H(29C)	1.01(3)
C(15)-H(15A)	1.05(3)
C(15)-H(15B)	0.97(3)
С(21)-Н(21)	0.98(3)
C(21)- $C(20)$	1.397(5)
C(23)-H(23A)	1.05(3)
C(23)-H(23B)	1.03(3)
C(23)-H(23C)	1.05(3)
C(20)-H(20)	0.97(3)
C(20)- $C(19)$	1.366(5)
C(19)-H(19)	1.000(3)
	1110(0)
C(13)-N(1)-C(11)	122.9(2)
C(13)-N(1)-C(2)	123.4(2)
C(11)-N(1)-C(2)	112.3(2)
C(24)-N(3)-C(14)	112.6(2)
C(1)-N(3)-C(24)	125.5(2)
C(1)-N(3)-C(14)	121.6(2)
C(10)-N(2)-C(11)	107.5(2)
C(10)-N(2)-C(12)	119.6(2)
C(12)-N(2)-C(11)	117.6(3)
C(22)-N(4)-C(24)	107.9(2)
C(22)-N(4)-C(25)	125.2(2)
C(25)-N(4)-C(24)	122.0(2)
C(27)-C(26)-C(25)	119.2(3)
C(27)-C(26)-C(29)	125.2(3)
C(29)-C(26)-C(25)	115.6(3)
O(2)-C(13)-N(1)	123.8(3)
O(2)-C(13)-C(14)	123.8(3)
N(1)-C(13)-C(14)	112.3(2)
C(5)-C(6)-H(6)	121.4(15)
C(5)-C(6)-C(7)	118.5(3)
C(7)-C(6)-H(6)	120.0(15)
C(5)-C(10)-N(2)	110.2(2)
C(9)-C(10)-N(2)	127.6(3)
C(9)-C(10)-C(5)	122.1(3)
N(1)-C(11)-N(2)	113.0(2)
N(1)-C(11)-H(11)	107.5(13)
N(1)-C(11)-C(4)	105.6(2)
N(2)-C(11)-H(11)	113.3(13)
N(2)-C(11)-C(4)	103.7(2)

C(4)-C(11)-H(11)	113.4(13)
C(6)-C(5)-C(10)	120.2(3)
C(6)-C(5)-C(4)	130.8(3)
C(10)-C(5)-C(4)	108.9(2)
C(17)-C(22)-N(4)	110.0(3)
C(21)-C(22)-N(4)	129.0(3)
C(21)-C(22)-C(17)	120.9(3)
N(3)-C(24)-N(4)	112.6(2)
N(3)-C(24)-H(24)	110.4(15)
N(3)-C(24)-C(16)	1050(2)
N(4)-C(24)-H(24)	109.0(2) 110.2(15)
$N(4) - C(24) - \Pi(24)$	103.1(2)
C(16) C(24) - C(10)	105.1(2) 115 3(14)
O(1) C(1) N(3)	113.3(14) 124.3(3)
O(1) - C(1) - N(3)	124.3(3) 122.5(2)
V(1)-C(1)-C(2)	122.5(3)
N(3)-C(1)-C(2)	113.2(2)
C(26)-C(27)-H(27)	116.2(15)
C(26)-C(27)-C(28)	128.8(3)
C(28)-C(27)-H(27)	114.9(15)
C(9)-C(8)-H(8)	118(2)
C(7)-C(8)-H(8)	120(2)
C(7)-C(8)-C(9)	121.6(3)
C(10)-C(9)-C(8)	116.7(3)
C(10)-C(9)-H(9)	124.6(15)
C(8)-C(9)-H(9)	118.7(15)
C(24)-C(16)-C(15)	102.0(2)
C(17)-C(16)-C(24)	102.0(2)
C(17)-C(16)-C(15)	110.9(3)
C(17)-C(16)-C(23)	115.6(3)
C(23)-C(16)-C(24)	113.2(3)
C(23)-C(16)-C(15)	111.9(3)
C(27)-C(28)-H(28A)	111.3(15)
C(27)- $C(28)$ - $H(28B)$	107.9(14)
C(27)- $C(28)$ - $C(4)$	1155(2)
$H(28A)_{-}C(28)_{-}H(28B)$	105(2)
C(4) - C(28) - H(28A)	103(2) 108 9(15)
C(4) - C(28) + H(28R)	100.9(13) 107.4(14)
N(4) C(25) C(26)	107.4(14) 112.0(2)
N(4) - C(25) - C(20) N(4) - C(25) + U(25A)	112.0(2) 105 5(15)
$N(4) - C(25) - \Pi(25R)$	103.3(13)
N(4)-C(23)-H(23B)	110.0(13)
C(26)- $C(25)$ - $H(25A)$	110.1(15)
C(26)-C(25)-H(25B)	113.2(15)
H(25A)-C(25)-H(25B)	106(2)
C(11)-C(4)-C(3)	101.8(2)
C(5)-C(4)-C(11)	101.3(2)
C(5)-C(4)-C(28)	113.3(2)
C(5)-C(4)-C(3)	112.0(2)
C(28)-C(4)-C(11)	114.2(2)
C(28)-C(4)-C(3)	113.1(2)
C(4)-C(3)-H(3A)	112.4(14)
C(4)-C(3)-H(3B)	109.9(16)
H(3A)-C(3)-H(3B)	105(2)
C(2)-C(3)-C(4)	106.7(2)

C(2)-C(3)-H(3A)	112.7(14)
C(2)-C(3)-H(3B)	109.9(16)
C(22)-C(17)-C(16)	108.4(2)
C(18)-C(17)-C(22)	120.2(3)
C(18)-C(17)-C(16)	131.4(3)
N(1)-C(2)-C(1)	111.0(2)
N(1)-C(2)-C(3)	1042(2)
N(1)-C(2)-H(2)	107.6(12)
C(1)-C(2)-C(3)	1145(2)
C(1) C(2) H(2)	107.6(12)
C(1)-C(2)-H(2)	107.0(12) 111.8(12)
$V(2) - C(2) - \Pi(2)$	111.0(12)
N(3) - C(14) - C(13)	109.3(2)
N(3)-C(14)-H(14)	109.1(13)
N(3)-C(14)-C(15)	103.7(2)
C(13)-C(14)-H(14)	108.5(13)
C(13)-C(14)-C(15)	114.9(3)
C(15)-C(14)-H(14)	110.9(13)
C(6)-C(7)-H(7)	121.6(16)
C(8)-C(7)-C(6)	120.8(3)
C(8)-C(7)-H(7)	117.6(16)
C(17)-C(18)-H(18)	119.5(17)
C(17)-C(18)-C(19)	119.2(3)
C(19)-C(18)-H(18)	121.3(17)
N(2)-C(12)-H(12A)	106(2)
N(2)-C(12)-H(12B)	109.3(16)
N(2)-C(12)-H(12C)	110.4(15)
H(12A)-C(12)-H(12B)	114(3)
H(12A)-C(12)-H(12C)	108(2)
H(12R) = C(12) - H(12C)	100(2) 109(2)
C(26) C(20) H(204)	109(2) 112 3(18)
C(26) - C(29) - H(29R) C(26) - C(20) - H(29R)	100 6(16)
C(26) - C(29) - H(29D)	107.0(10)
$U(20)-U(29)-\Pi(29U)$	107.2(10) 110(2)
H(29A)-C(29)-H(29B)	110(3)
H(29A)-C(29)-H(29C)	113(3)
H(29B)-C(29)-H(29C)	104(2)
C(16)-C(15)-H(15A)	112.7(15)
C(16)-C(15)-H(15B)	110.2(17)
C(14)-C(15)-C(16)	105.7(2)
C(14)-C(15)-H(15A)	105.3(15)
C(14)-C(15)-H(15B)	107.0(17)
H(15A)-C(15)-H(15B)	115(2)
C(22)-C(21)-H(21)	127.2(16)
C(22)-C(21)-C(20)	117.7(3)
C(20)-C(21)-H(21)	114.9(16)
C(16)-C(23)-H(23A)	108.3(17)
C(16)-C(23)-H(23B)	109.8(17)
C(16)-C(23)-H(23C)	112.1(16)
H(23A)-C(23)-H(23B)	106(2)
H(23A)-C(23)-H(23C)	115(2)
$H(23R)_{C}(23)_{H}(23C)$	105(2)
C(21) C(20) H(20)	103(2) 110 2(18)
$C(21)$ - $C(20)$ - $\Pi(20)$ C(10) $C(20)$ $C(21)$	117.2(10)
C(19)-C(20)-C(21)	121.0(4)
C(19)-C(20)-H(20)	119.2(18)

C(18)-C(19)-H(19)	120.2(16)
C(20)-C(19)-C(18)	120.3(3)
C(20)-C(19)-H(19)	119.4(16)

Symmetry transformations used to generate equivalent atoms.

Table A3.4. Anisotropic displacement parameters ($Å^2x \ 10^4$) for for macrocyclic alkene **277** (CCDC 997790). The anisotropic displacement factor exponent takes the form: $-2p^2[h^2a^{*2}U^{11} + ... + 2h \ k \ a^* \ b^* \ U^{12}]$

	U ¹¹	U ²²	U ³³	U ²³	U ¹³	U ¹²
O(1)	299(12)	311(13)	263(12)	14(10)	-58(10)	52(10)
O(2)	204(11)	433(14)	277(12)	-44(11)	-10(10)	68(10)
N(1)	188(13)	226(14)	175(13)	3(11)	42(11)	-1(11)
N(3)	205(14)	224(15)	209(14)	-27(11)	-13(12)	16(12)
N(2)	171(14)	250(15)	209(13)	-43(12)	34(11)	-26(11)
N(4)	232(15)	191(14)	288(14)	-7(12)	66(11)	-5(12)
C(26)	220(16)	170(16)	266(16)	-8(14)	1(14)	-16(15)
C(13)	168(17)	233(18)	259(18)	-42(15)	2(14)	-13(14)
C(6)	229(19)	238(18)	283(19)	29(15)	-12(17)	11(15)
C(10)	249(17)	163(15)	218(16)	34(15)	12(15)	19(14)
C(11)	224(16)	187(18)	203(17)	0(15)	-36(14)	29(14)
C(5)	179(17)	186(18)	231(17)	13(13)	27(14)	-2(13)
C(22)	315(19)	251(19)	169(16)	-32(15)	-37(15)	77(16)
C(24)	285(18)	239(18)	200(17)	-45(15)	-3(15)	37(15)
C(1)	257(18)	196(18)	252(18)	13(15)	13(15)	7(15)
C(27)	185(17)	237(19)	282(19)	-3(15)	-24(15)	-66(14)
C(8)	320(20)	283(19)	236(19)	-29(16)	66(16)	16(17)
C(9)	297(19)	230(18)	254(18)	-18(15)	7(15)	-29(15)
C(16)	288(18)	266(18)	217(16)	-27(15)	52(14)	22(15)
C(28)	164(19)	239(19)	320(20)	8(16)	1(15)	-10(14)
C(25)	266(19)	230(20)	330(20)	-47(16)	-38(16)	-4(15)
C(4)	173(15)	180(16)	202(16)	3(13)	5(12)	-6(14)
C(3)	210(18)	194(18)	243(17)	0(15)	24(15)	47(15)
C(17)	331(19)	260(20)	208(17)	9(14)	9(15)	46(16)
C(2)	222(17)	203(19)	206(16)	32(14)	8(14)	36(13)
C(14)	221(17)	250(20)	253(18)	-28(16)	11(14)	-4(15)
C(7)	270(20)	252(18)	296(19)	20(16)	95(17)	53(15)
C(18)	390(20)	350(20)	330(20)	-13(18)	129(18)	69(19)
C(12)	222(19)	370(20)	246(18)	-38(19)	-22(16)	6(17)
C(29)	380(20)	290(20)	320(20)	18(19)	14(18)	99(19)
C(15)	223(19)	360(20)	278(19)	-79(17)	54(16)	11(16)
C(21)	480(20)	220(20)	229(18)	-13(16)	2(17)	52(19)
C(23)	400(30)	290(20)	320(20)	-24(17)	108(18)	-16(17)
C(20)	620(30)	260(20)	290(20)	5(17)	109(19)	140(20)
C(19)	530(30)	440(30)	380(20)	-10(20)	159(19)	230(20)

	X	у	Z	U _{iso}
H(6)	408(3)	584(2)	1093(1)	11(7)
H(11)	943(3)	493(2)	1061(1)	14(7)
H(24)	944(3)	460(2)	798(1)	31(8)
H(27)	618(3)	448(2)	927(1)	34(9)
H(8)	580(3)	733(2)	1233(1)	39(10)
H(9)	842(3)	743(2)	1197(1)	32(9)
H(28A)	681(3)	404(2)	1051(1)	25(8)
H(28B)	532(3)	458(2)	1024(1)	8(7)
H(25A)	801(3)	235(2)	873(1)	29(8)
H(25B)	729(3)	350(2)	854(1)	31(8)
H(3A)	601(3)	626(2)	956(1)	20(7)
H(3B)	682(3)	714(2)	997(1)	31(8)
H(2)	909(3)	716(2)	939(1)	20(7)
H(14)	1181(3)	626(2)	900(1)	6(7)
H(7)	364(3)	667(2)	1184(1)	22(8)
H(18)	1437(3)	304(2)	774(1)	26(9)
H(12A)	1073(4)	724(3)	1141(2)	73(13)
H(12B)	1174(4)	654(2)	1086(1)	56(10)
H(12C)	1087(3)	599(2)	1148(1)	17(7)
H(29A)	891(4)	308(3)	1027(2)	55(11)
H(29B)	1021(4)	289(2)	972(1)	48(10)
H(29C)	876(3)	205(3)	981(1)	50(10)
H(15A)	1271(3)	412(2)	914(1)	30(8)
H(15B)	1370(4)	511(2)	878(1)	37(9)
H(21)	990(3)	117(2)	849(1)	31(9)
H(23A)	1381(4)	506(2)	772(1)	39(9)
H(23B)	1227(4)	587(3)	784(1)	50(10)
H(23C)	1192(3)	495(2)	734(1)	42(9)
H(20)	1204(3)	31(2)	808(1)	40(10)
H(19)	1440(4)	112(2)	768(1)	50(10)

Table A3.5. Hydrogen coordinates ($x \ 10^3$) and isotropic displacement parameters (Å² $x \ 10^3$) for macrocyclic alkene **277** (CCDC 997790).

Table A3.6. Hydrogen bonds for macrocyclic alkene **277** [Å and °]. (CCDC 997790).

D-HA	d(D-H)	d(HA)	d(DA)	<(DHA)
C(12)-H(12B)O(2)	1.10(3)	2.65(3)	3.406(4)	125(2)

Symmetry transformations used to generate equivalent atoms.

Chapter 4

Enantioselective Total Synthesis of Epidithiodiketopiperazine Natural Product (–)-Acetylapoaranotin⁺

4.1 INTRODUCTION

Polysulfide bridge-containing natural products, especially the epipolythiodiketopiperazine (ETP) family members, have become an important class of molecules at the interface between organic chemistry and chemical biology due to their activities in either redox-cycling to generate reactive oxygen species (ROS) or covalent modification of cysteine residues.¹ These complex molecules share a common polysulfide linkage, yet a wide range of biological activity, including antiproliferative and cytotoxic activities against various human cancer cell lines, have been identified within the ETP family members, indicating the importance of their diverse peripheral structural features (**294** to **302**, Figure 4.1).^{2,3} Thus, the development of a modular synthetic strategy to

[†] The research discussed in this chapter was completed in collaboration with Clinton J. Regan (graduate student) and Dr. Paola Romanato (postdoctoral fellow) in the Reisman Laboratory.

access these related natural products could facilitate the corresponding structure-activity relationship (SAR) studies.

Among these compounds, our laboratory has accomplished the first asymmetric total synthesis of dihydrooxepine-containing natural product (–)-acetylaranotin (**294**),⁴ which commenced our ongoing synthetic program to access other dihydrooxepine subfamily members such as (–)-emethallicin C (**295**) and (+)-MPC1001B (**296**). A related subfamily that has attracted our attention is the *cyclohexadienol*-containing natural products (motif highlighted in red) including C_2 -symmetric (–)-emethallicin E (**298**) and (–)-haematocin (**299**), as well as the heterodimer natural product between those two subfamilies, namely (–)-acetylapoaranotin (**300**).

Figure 4.1. Selected ETP natural products



4.1.1 Biological Origins

Among the cyclohexadienol ETP subfamily, the biosynthesis of (–)-gliotoxin (**297**, Figure 4.1) has been intensely investigated.⁵⁻⁸ Utilizing gene-mutagenesis and mass spectroscopy techniques, the entire biosynthetic pathway of **297** has been well mapped (Scheme 4.1).

Scheme 4.1. A brief picture of (-)-gliotoxin biosynthesis



Starting with cyclization of L-phenylalanine (**303**) and L-serine (**304**) mediated by peptide synthetase GliP, the resulting DKP **305** is oxidized by a hydroxylase (GliC) to provide diol **306**. Subsequent elimination of hydroxyl groups in **306** followed by thiol addition of glutathiones (GSH) furnishes the key sulfur-transfer intermediate **307**, where the C-S bonds are cleaved by the enzyme sequence GliK/GliJ/GliI to produce free dithiol **308**. *N*-Methylation followed by a P450 enzyme (GliC or GliF)-mediated epoxidation

produces epoxide **310**, which undergoes intramolecular epoxide opening to furnish the core of gliotoxin. The final step includes oxidation of the free thiol groups to disulfide bridge via GliT enzyme and O_2 . This biosynthetic pathway is likely related to other cyclohexadienol subfamily members (**297-300**).

4.1.2 Previous Synthetic Efforts

Due to the intriguing biological properties of these ETP natural products, a number of synthetic efforts toward them have been reported in the past few decades.⁹ The simplest cyclohexadienol ETP family member, (–)-gliotoxin (**297**), was successfully synthesized by Kishi and coworkers in 1976 (Scheme 4.2).¹⁰

Scheme 4.2. Total synthesis of gliotoxin by Kishi



Beginning with glycine-derived diketopiperazine (DKP) **312**, dithioacetal **314** was prepared in six steps (including a kinetic resolution step). Deprotonation at the DKP nitrogen followed by nucleophilic addition to oxepine **315** provided cyclohexadienol **316** in 3 : 1 dr. Subsequent functional group manipulation in nine steps advanced **316** to diol **317**, which possesses the core of gliotoxin (**297**). Diol **317** was then subjected to

deprotection of the dithioacetal using *m*-CPBA and acidic workup to accomplish the synthesis of gliotoxin.

For a long period of time, the Kishi synthesis of gliotoxin utilizing the dithiol acetal-protecting strategy represented the state of the art for the preparation of ETP natural products. Since the early 2000s, a new wave of ETP synthesis has emerged featuring a late-stage sulfenylation strategy pioneered by Movassaghi,¹¹ Nicolaou,¹² and Reisman⁴ groups.





Based on the initial work by Sundberg and coworkers,¹³ Nicolaou and coworkers began with enantiopure *N*-Boc-L-tyrosine **318** (Scheme 4.3), which was subjected to oxidative intramolecular dearomatization conditions followed by lactone opening with

methoxide and subsequent cyclization to yield hydroxyl enone¹⁴ **319**.² Luche reduction and acetylation provided allylic acetate **320**, which was converted to diene **321** under palladium catalyzed elimination conditions. In order to install the correct oxidation states, diene **321** was subjected under photooxygenation conditions to form endoperoxide **322**, which was reduced with thiourea to afford triol **323**. Subsequent silylation, Corey-Winter olefination, and desilylation provided the cyclohexadienol core in **325**. DKP formation with L-serine derivative **326** and sulfenylation using LiHMDS and elemental sulfur accomplished the synthesis of gliotoxin (**297**), which represents a mild methodology to incorporate the sulfur bridge in DKP substrates.¹⁵

The cyclohexadienol intermediate **325** was used as the key intermediate to access C_2 -symmetric ETP natural products (–)-emethallicin E (**298**) and (–)-haematocin (**299**), **Scheme 4.4.** Total synthesis of (–)-emethallicin E and (–)-haematocin by Nicolaou



illustrated by Nicolaou and coworkers.² The Boc protecting group in **329** was switched to allyl carbamate in **330** in two steps, which was hydrolyzed and coupled with secondary amine **331** to provide dipeptide **332**. Subsequent palladium-catalyzed deprotection of Alloc group triggered *in situ* DKP formation, which was followed by the sulfenylation step to form tetrasulfide **333**. Ester formation of diol **333** with phenylacetic acid or acetic acid afforded esters **334a** and **334b**, respectively. **334a** was then subjected to 1,3-propane dithiol-mediated reduction followed by aerobic oxidation to provide (–)-emethallicin E (**298**). On the other hand, **334b** was subjected to NaBH₄ reduction/methylation sequence to produce (–)-haematocin (**299**).

An alternative strategy to access the cyclohexadienol fragment was reported by Bräse and coworkers (Scheme 4.5).¹⁶ L-Pyroglutamic acid (**335**) was converted to enamine **336** in a three-step sequence. The following key reaction involves a diastereoselective [2 + 2] ketene cycloaddition to provide bicyclic cyclobutanone **338**, which was subjected to the Baeyer-Villiger ring expansion to afford **339**. Ruthenium hydride catalyzed alkene isomerization and vinyl Grignard addition yielded lactol **340**, which was converted to hydroxyl enone **341** via a ring-closing metathesis. Enone **341** was then converted to allylic acetate **342** in three steps, which was subsequently treated under palladium-catalyzed elimination conditions to provide the cyclohexadienol building block **343**. However, Bräse and coworkers did not advance this key building block **343** to related cyclohexadienol ETP natural products in the report.



Scheme 4.5. Preparation of cyclohexadienol fragment by Bräse

4.2 SYNTHETIC EFFORTS TOWARD CYCLOHEXADIENOL ETP

4.2.1 Retrosynthetic Analysis

Both strategies reported by Nicolaou and Bräse groups rely on starting materials from the chiral pool. As our ongoing project to access various ETP family members, especially the *cyclohexadienol* subfamily, a strategy involving a catalytic *asymmetric* stereocenters-assembling step is proposed to access the key cyclohexadienol fragment **344** (Scheme 4.6).

Retrosynthetically, this common cyclohexadienol building block **344** was envisioned to be prepared using an asymmetric (1,3)-dipolar cycloaddition to assemble the central pyrrolidine core, followed by chemo-selective allyl addition to a Weinreb amide to provide a ring-closing metathesis (RCM) substrate **347**. Subsequent RCM/epoxidation/rearrangement would give access to enone **345**, which could then be converted to cyclohexadiene **344** through vinyl triflate formation and reduction.





4.2.2 Preparation of Cyclohexadienol Fragment and Formal Synthesis

of (-)-Emethallicin E and (-)-Haematocin

In the forward sense, copper/brucin-OL-catalyzed (1,3)-dipolar cycloaddition between Weinreb amide **348**, cinnamaldehyde **349**, and glycinate **350** provided pyrrolidine **351** in 32% yield and 95% ee (Scheme 4.7),¹⁷ which was subsequently protected as its (trimethylsilyl)ethyl carbamate (Teoc) **352**. The following allyl Grignard addition proved to be challenging due to competitive addition to the ethyl ester. Nevertheless, with careful control of reagent stoichiometry, mono-addition product **347** could be isolated in 51% yield on a multi-gram scale.

Treatment of non-conjugated diene **347** with Hoveyda-Grubbs II catalyst yielded ring-closing product **346** in good yield. In order to install the allylic hydroxyl moiety, alkene **346** was oxidized with dimethyldioxirane (DMDO) and the resulting epoxide was


Scheme 4.7. Asymmetric route accessing cyclohexadienol 344

directly heated with silica gel in toluene to effect isomerization, providing the enone product as a 6.5 : 1 inseparable mixture of diastereomers. Protection of alcohol **353** as its TBS ether **354** allowed facile separation of the two diastereomers using silica gel chromatography. Subsequent formation of vinyl triflate followed by palladium-catalyzed reduction¹⁸ provided the key divergent intermediate **344**.

In order to access C_2 -symmetric emethallicin E (298) and haematocin (299), diene 344 was first globally deprotected with excess TBAF (Scheme 4.8), followed by hydrolysis, to afford amino acid 356. Successful dimerization using peptide coupling reagent PyBroP furnished DKP 357, which was then epimerized to form the thermodynamically more favored diastereomer 358 using cesium carbonate in MeOH. Dimeric intermediate 358 has been prepared by Nicolaou and coworkers to access both (–)-298 and (–)-299 in short sequences (Scheme 4.4)². Thus, a formal total synthesis of these natural products is completed. In comparison, our current synthetic route shortens their synthesis by three steps.





4.2.3 Attempts to Prepare (–)-Acetylapoaranotin

Having established an efficient route to prepare C_2 -symmetric cyclohexadienolcontaining ETP natural products, we next turned our attention to the hybrid natural product between the dihydrooxepine/cyclohexadiene subfamilies, (–)-acetylapoaranotin (**300**, Figure 4.1). It was recognized that the sequential peptide coupling strategy was preferred for the selective synthesis of heterodimeric diketopiperazines, such as **300**.

Starting from the key diene intermediate **344**, treatment with trimethyltinhydroxide afforded carboxylic acid **359**,¹⁹ which was successfully coupled with amine **360** (prepared according to reference 4) in excellent yield. The resulting dipeptide **361** was subjected to the TBAF•('BuOH)₄ conditions reported in the total synthesis of acetylaranotin (**294**, Figure 4.1) by our group.⁴ Unfortunately, undesired

aromatized product **363** was isolated. It is hypothesized that following the desired removal of the Teoc and TBS groups, cyclization and epimerization proceeded smoothly; however, the resulting allylic secondary alcohol on the cyclohexadienol fragment (**362**) was not stable under the reaction conditions and was further eliminated, giving rise to aromatized product **363**. Interestingly, this side product mapped well onto another ETP family member, deoxyapoaranotin, which shows direct cytotoxic effects toward HCT116 colon cancer cell lines.²⁰ A more expedient route toward deoxyapoaranotin could be accomplished starting from (*R*)-indoline carboxylic acid.





4.2.4 Total Synthesis of (–)-Acetylapoaranotin

Aware that the cyclohexadiene alcohol moiety readily undergoes both elimination and oxidation, a mild and *stepwise* DKP formation strategy was investigated.

Cyclohexadienol **344** was transformed to TBS-ether **364** by global desilylation and reprotection of the more reactive secondary alcohol group (Scheme 4.10). Secondary amine **364** was then coupled with carboxylic acid **365** (prepared according to reference 4)



Scheme 4.10. Completion of (–)-acetylapoaranotin total synthesis

to provide dipeptide **366**. Interestingly, it was found that the Teoc group as well as the TBS group on the cyclohexadienol fragment could be selectively removed using TBAF, while the TBS group on the dihydrooxepine fragment remained intact. The resulting ethyl ester was then hydrolyzed and subjected to peptide coupling reagent PyBroP to provide DKP **368** without any sign of aromatized product. DKP **368** was then epimerized using Cs_2CO_3 and removal of the last TBS group was effected under mildly acidic conditions. Notably, attempts to employ TBAF for desilylation gave exclusively aromatized side product. Diol **369** was subjected to LiHMDS/S₈ to afford tetrasulfide **370**, accompanied with a small amount of aromatized side product. Nevertheless, tetrasulfide **370** could be advanced to (–)-acetylapoaranotin (**300**) following the previously established two-step protocol.⁴ Thus, (–)-**300** was successfully prepared for the first time in 22 steps starting

from commercially available starting materials. Ongoing efforts focus on optimization of the current synthetic route.

4.3 CONCLUDING REMARKS

In summary, we have developed an efficient asymmetric synthetic route allowing access to a series of natural products in the cyclohexadienol ETP subfamily including (–)emethallicin E (**298**), (–)-haematocin (**299**), (–)-acetylapoaranotin (**300**). Through this endeavor, it was found that the labile nature of the allylic alcohol cyclohexadienol fragment required a mild and eventually stepwise DKP formation strategy to prepare the core of (–)-acetylapoaranotin (**300**). By employing this strategy, the first enantioselective total synthesis of (–)-**300** was accomplished in 22 steps (longest linear sequence).

Intermediates in this synthetic route could be intercepted to synthesize other related 6,5-bicyclic ETP subfamilies, for example, (–)-epicorazine A (**301**, Figure 4.1) and (–)-epiccocin C (**302**). Synthetic studies directed toward realizing this goal are ongoing in our laboratory.

4.4 EXPERIMENTAL SECTION

4.4.1 Materials and Methods

Unless otherwise stated, reactions were performed under a nitrogen atmosphere using freshly dried solvents. Tetrahydrofuran (THF), methylene chloride (CH_2Cl_2), acetonitrile (MeCN), dimethylformamide (DMF), and toluene (PhMe) were dried by passing through activated alumina columns. Unless otherwise stated, chemicals and

prior to use. All reactions were monitored by thin-layer chromatography using EMD/Merck silica gel 60 F254 pre-coated plates (0.25 mm) and were visualized by UV, *p*-anisaldehyde, or KMnO₄ staining. Flash column chromatography was performed either as described by Still et al.²¹ using silica gel (particle size 0.032-0.063) purchased from Silicycle or using pre-packaged RediSep[®]Rf columns on a CombiFlash Rf system (Teledyne ISCO Inc.). Optical rotations were measured on a Jasco P-2000 polarimeter using a 100 mm path-length cell at 589 nm. ¹H and ¹³C NMR spectra were recorded on a Varian 400 MR (at 400 MHz and 101 MHz, respectively), a Bruker 400 equipped with a cryoprobe (at 400 MHz and 101 MHz, respectively), a Varian Inova 500 (at 500 MHz and 126 MHz, respectively), or a Varian Inova 600 (at 600 MHz and 150 MHz, respectively), and are reported relative to internal CHCl₃ (¹H, $\delta = 7.26$), CHDCl₃ (¹H, $\delta =$ 5.32), CD₂HOD (¹H, $\delta = 3.31$), MeCN-d2 (¹H, $\delta = 1.94$), or DMSO-d5 (¹H, $\delta = 2.50$), and CDCl₃ (¹³C, $\delta = 77.0$), CD₂Cl₂ (¹³C, $\delta = 54.0$), CD₃OD (¹³C, $\delta = 49.0$), MeCN-d3 $({}^{13}C, \delta = 118.3)$, or DMSO-d6 $({}^{13}C, \delta = 40.0)$. Data for ¹H NMR spectra are reported as follows: chemical shift (δ ppm) (multiplicity, coupling constant (Hz), integration). Multiplicity and qualifier abbreviations are as follows: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, app = apparent. IR spectra were recorded on a Perkin Elmer Paragon 1000 spectrometer and are reported in frequency of absorption (cm⁻¹). HRMS were acquired using an Agilent 6200 Series TOF with an Agilent G1978A Multimode source in electrospray ionization (ESI), atmospheric pressure chemical ionization (APCI), or mixed (MM) ionization mode. Analytical chiral HPLC was performed with an Agilent 1100 Series HPLC utilizing Chiralpak AD or Chiralcel OD-H

columns (4.6 mm x 25 cm) obtained from Daicel Chemical Industries, Ltd with visualization at 254 nm. Preparative HPLC was performed with an Agilent 1100 Series HPLC utilizing an Agilent Eclipse XDB-C18 5 μ m column (9.4 x 250 mm) or an Agilent Zorbax RX-SIL 5 μ m column (9.4 x 250 mm). Melting points were determined using a Büchi B-545 capillary melting point apparatus and the values reported are uncorrected.

4.4.2 Preparative Procedures and Spectroscopic Data

Preparation of pyrrolidine 351



(Isolation of ethyl glycinate) The ethyl glycinate HCl salt (5.1 g, 36.5 mmol) was freebased by first being taken up in DCM (10 mL) then washed with 3.56M KOH (10 mL). The layers were separated and the aqueous phase was further extracted with DCM (2 x 10 mL), and the combined organic layers were dried over MgSO₄, filtered, and concentrated down by rotary evaporation to yield 3.14 g of glycinate ethyl ester **350** (83% recovery).

(*Formation of imime*) The free amine **350** (3.14 g, 30.5 mmol, 1.0 equiv) was taken up in $CHCl_3$ (61 mL) with silica gel (9.1 g, 0.3 g/mmol) and cooled to 0 °C under air. Cinnamaldehyde **349** (3.8 mL, 30.5 mmol, 1.0 equiv) was added dropwise, and the solution was kept at 0 °C for 7 hours while capped. The silica gel was filtered off and rinsed with more $CHCl_3$. The resulting imine was used immediately.

(Dipolar cycloaddition reaction) A round-bottom flask was charged with brucin-OL (1.31 g, 3.05 mmol, 10 mol %), CuI (580 mg, 3.05 mmol, 10 mol %) and CHCl₃ (61 mL) then cooled to 0 °C. After 5 minutes, DBU (0.46 mL, 3.05 mmol, 10 mol %) was added and the solution went from cream to deep jade-green over the next twenty minutes. Weinreb amide acrylamide 348 (3.88 g, 33.7 mmol, 1.1 equiv) was added followed by the filtered imine slowly over 10 minutes. The solution was kept at 0 °C for 5.5 hours before being warmed up to room temperature and stirred for another 23 hours. The crude reaction was concentrated down to roughly half the volume, and directly subjected to silica gel column chromatography using a gradient of 20 to 100% EtOAc in hexanes (with 1% Et₃N) to yield 3.21 g (32% yield, 9.7 mmol) of pyrrolidine **351** as a thick light brown oil. The enantiomeric excess of 351 was determined to be 95% by chiral HPLC analysis (OD, 1 mL/min, 15% IPA in hexanes, $\lambda = 254$ nm): $t_{\rm R}$ (major) = 24.2 min, $t_{\rm R}({\rm minor}) = 14.2 {\rm min.} [\alpha]_{\rm D}^{25} = +152^{\circ} (c = 0.90, {\rm CHCl}_3); {}^{1}{\rm H} {\rm NMR} (500 {\rm MHz}, {\rm CDCl}_3) \delta$ 7.32 - 7.29 (m, 2H), 7.29 - 7.22 (m, 2H), 7.21 - 7.16 (m, 1H), 6.53 (d, J = 15.7 Hz, 1H), 6.10 (dd, J = 15.7, 8.3 Hz, 1H), 4.22 (qd, J = 7.1, 3.2 Hz, 2H), 4.12 (t, J = 7.9 Hz, 1H), 3.86 (t, J = 8.4 Hz, 1H), 3.65 (s, 3H), 3.59 (q, J = 7.7 Hz, 1H), 3.05 (s, 3H), 2.56 (s, 1H), 2.45 – 2.28 (m, 2H), 1.28 (t, J = 7.1 Hz, 3H); ¹³C (126 MHz, CDCl₃) δ 173.7, 173.4, 136.6, 131.9, 128.3, 127.5, 127.4, 126.4, 63.6, 61.3, 61.0, 59.8, 45.3, 33.2, 32.2, 14.1; FTIR (NaCl/thin film) 3340, 3298, 3057, 3024, 2979, 2937, 2902, 1955, 1882, 1735, 1654, 1599, 1493, 1448, 1388, 1321, 1255, 1197, 1108, 1073, 1056, 1028, 1008, 969, 901, 861, 834, 786, 754 cm⁻¹; HRMS (MM) calc'd for $C_{18}H_{24}N_2O_4$ [M+H]⁺ 333.1809, found 333.1817.

Preparation of Teoc-pyrrolidine 352



Pyrrolidine **351** (1.77 g, 5.31 mmol, 1.0 equiv) was suspended in H₂O (14 mL) and 1,4-dioxane (14 mL). Triethylamine (1.48 mL, 10.62 mmol, 2.0 equiv) was added followed by Teoc-OSu (2.06 g, 7.96 mmol, 1.5 equiv). The resulting solution was allowed to stir for 20 hours at room temperature. The solution was acidified with 36 mL 1M HCl then extracted with DCM (3 x 20 mL). The combined organic extracts were dried over $MgSO_4$ and concentrated to yield a light orange oil. Flash chromatography (50% to 60% EtOAc in hexanes) afforded Teoc-pyrrolidine 352, as a thick yellow oil (2.03 g, 4.26 mmol, 80% yield). $[\alpha]_{D}^{25} = +101^{\circ} (c = 0.64, \text{CHCl}_{3})$; ¹H NMR (400 MHz, CD_3CN , 60 °C) δ 7.38 – 7.29 (m, 4H), 7.29 – 7.21 (m, 1H), 6.70 (dd, J = 15.8, 1.1 Hz, 1H), 6.05 (dd, J = 15.8, 7.6 Hz, 1H), 4.92 (t, J = 7.8 Hz, 1H), 4.30 (dd, J = 10.3, 7.6 Hz, 1H), 4.21 (qd, *J* = 7.1, 1.0 Hz, 2H), 4.18 – 4.12 (m, 2H), 3.75 (s, 3H), 3.61 (dt, *J* = 12.2, 7.4 Hz, 1H), 3.08 (s, 3H), 2.46 (q, J = 12.0 Hz, 1H), 2.33 (dt, J = 13.0, 7.2 Hz, 1H), 1.28 $(t, J = 7.1 \text{ Hz}, 3\text{H}), 0.97 \text{ (dd}, J = 8.8, 7.5 \text{ Hz}, 2\text{H}), 0.03 \text{ (s}, 9\text{H}); {}^{13}\text{C} \text{ NMR}$ (101 MHz, CD_3CN , compound exists as a 1:1 mixture of rotamers) δ 173.8, 173.5, 171.3, 155.8, 155.0, 137.8, 132.8, 129.6, 128.6, 127.7, 127.3, 127.2, 64.3, 64.2, 62.3, 62.0, 61.8, 61.7, 61.2, 59.7, 59.4, 46.6, 45.9, 32.8, 31.6, 30.6, 18.4, 18.3, 14.6, -1.4, -1.5; FTIR (NaCl, thin film): 2953, 2900, 1747, 1700, 1668, 1404, 1345, 1282, 1250, 1186, 1112, 1038, 1012, 961, 860, 838, 756, 694 cm⁻¹; HRMS (MM) calc'd for C₂₂H₃₃N₂O₆Si [M-C₂H₄+H]⁺ 449.2102, found 449.2110 (detected fragment has undergone elimination of ethylene from the Teoc protecting group).

Preparation of diene 347



Weinreb amide 352 (2.37 g, 4.97 mmol, 1.0 equiv) was dissolved in dry THF (42 mL) under N_2 and the solution was brought to -78 °C. A solution of allyl Grignard (0.85M in THF, diluted two times with THF from commercially available reagent; 8.2 mL, 6.96 mmol, 1.4 equiv) was added slowly over the course of 4 hours using a syringe pump at -78 °C. When the addition was done, the reaction was allowed to stir for another 10 minutes before being quenched with 30 mL of AcOH/THF/H₂O (1:1:1) and warmed to room temperature. The reaction was then carefully basified with saturated NaHCO₃ solution until no more bubbles occurred. The aqueous layer was then extracted with EtOAc (3 x 150 mL). Combined organic layer was washed with brine (200 mL). It was then dried over Na₂SO₄, filtered, and concentrated down to give a yellow oil. Flash chromatography (5% to 30% EtOAc in hexanes) afforded diene 347, as a yellow oil (1.15 g, 2.51 mmol, 51% yield). $[\alpha]_{D}^{25} = -8^{\circ} (c = 0.495, CHCl_{3}); {}^{1}H NMR (400 MHz, CD_{3}CN, CHCl_{3}); {}^{1}H NMR (400 MLZ, CD_{3}CN, CHCL_{3}); {}^{1}H NMZ (400 MLZ, CD_{3}CN, CHCL_{$ 60 °C) $\delta 7.39 - 7.29 \text{ (m, 4H)}$, 7.29 - 7.21 (m, 1H), 6.77 (dd, J = 15.9, 0.9 Hz, 1H), 6.01 C(ddd, J = 15.7, 8.1, 0.8 Hz, 1H), 5.95 - 5.77 (m, 1H), 5.16 - 5.10 (m, 1H), 5.12 - 5.07(m, 1H), 4.97 (t, J = 8.0 Hz, 1H), 4.30 (dd, J = 9.8, 8.0 Hz, 1H), 4.20 (qt, J = 7.2, 1.2 Hz, 2H), 4.17 - 4.10 (m, 2H), 3.55 (dt, J = 11.6, 7.5 Hz, 1H), 3.26 (dt, J = 6.9, 1.3 Hz, 2H), 2.48 - 2.23 (m, 2H), 1.27 (td, J = 7.1, 0.7 Hz, 3H), 1.06 - 0.88 (m, 2H), 0.03 (d, J = 0.8Hz, 9H); ¹³C NMR (101 MHz, CD₃CN, compound exists as a 1:1 mixture of rotamers) δ 205.5, 205.4, 173.6, 173.3, 155.6, 154.8, 137.5, 133.74, 133.68, 131.6, 129.7, 128.9,

128.8, 127.3, 126.6, 126.5, 119.1, 64.4, 64.3, 62.1, 62.0, 61.9, 61.7, 59.8, 59.5, 54.7, 54.1, 48.2, 30.5, 29.5, 18.4, 14.6, -1.47, -1.52; FTIR (NaCl, thin film): 3082, 3060, 3024, 2981, 2952, 2899, 1749, 1702, 1450, 1408, 1371, 1344, 1285, 1250, 1185, 1168, 1110, 1038, 962, 924, 860, 837, 751, 694 cm⁻¹; HRMS (MM) calc'd for C₂₃H₃₂NO₅Si [M–C₂H₄+H]⁺ 430.2044, found 430.2053 (detected fragment has undergone elimination of ethylene from the Teoc protecting group).

Preparation of ketone 346



To a 500 mL flame-dried flask was added diene **347** (1.15 g, 2.51 mmol, 1.0 equiv) and DCM (250 mL). Hoveyda-Grubbs II catalyst (63 mg, 0.10 mmol, 4 mol %) was added and the resulting light green solution was allowed to stir at room temperature for 4 hours. The reaction was then quenched with DMSO (380 μ L, 50 equiv) and stirred for another 22 hours. It was filtered through a silica gel plug, eluting with EtOAc, and the filtrate was concentrated down to give a light brown oil. Flash chromatography (5% to 25% EtOAc in hexanes) afforded ketone **346**, as a light brown oil (761 mg, 2.15 mmol, 86% yield). [α]_D²⁵ = -117° (*c* = 0.63, CHCl₃); ¹H NMR (400 MHz, CD₃CN, 65 °C) δ 6.04 (dq, *J* = 10.2, 2.5 Hz, 1H), 5.80 (dtd, *J* = 10.2, 3.7, 1.6 Hz, 1H), 4.79 (dt, *J* = 7.6, 2.3 Hz, 1H), 4.32 (dd, *J* = 8.3, 7.1 Hz, 1H), 4.24 – 4.15 (m, 2H), 4.12 (qd, *J* = 7.1, 1.1 Hz, 2H), 3.05 (q, *J* = 8.0 Hz, 1H), 2.99 – 2.80 (m, 2H), 2.45 – 2.26 (m, 2H), 1.23 (t, *J* = 7.1 Hz, 3H), 1.00 (t, *J* = 8.3 Hz, 2H), 0.05 (s, 9H); ¹³C NMR (101 MHz, CD₃CN, 65 °C) δ 207.5, 173.3, 155.8, 128.1, 124.4, 64.7, 62.2, 61.2, 60.2, 51.0, 38.2, 32.8, 19.0, 14.8, -1.0; FTIR

(NaCl, thin film): 3042, 2953, 2899, 1749, 1703, 1454, 1412, 1350, 1249, 1186, 1112, 1033, 988, 964, 946, 860, 838, 769, 695 cm⁻¹; HRMS (MM) calc'd for $C_{15}H_{24}NO_5Si$ [M– C_2H_4+H]⁺ 326.1418, found 326.1419 (detected fragment has undergone elimination of ethylene from the Teoc protecting group).

Preparation of enone 353



To ketone **346** (761 mg, 2.15 mmol, 1.0 equiv) in a 200 mL round-bottom flask was added freshly prepared DMDO acetone solution (0.0905 M, 48 mL, 4.30 mmol, 2.0 equiv) and the resulting solution was allowed to stir at room temperature for 90 minutes (the reaction was monitored by taking ¹H NMR spectra of aliquot of the reaction solution). The reaction was then concentrated down and put under high vacuum for 90 minutes to get rid of residue solvent. The crude material was then dissolved in toluene (215 mL) and mixed with silica gel (17.2 g). The resulting mixture was heated to 50 °C for 1 hour and cooled down to room temperature. It was filtered through a silica gel plug, eluting with EtOAc, and the filtrate was concentrated down to give a light brown oil. Flash chromatography (5% to 40% EtOAc in hexanes) afforded enone **353**, (6.5 : 1 mixture of diastereomers by ¹H NMR), as a thick colorless oil (630 mg, 1.71 mmol, 80% yield). The mixture of diastereomers was carried to the next reaction. Analytically pure products were isolated using preparative reverse phase HPLC (50% to 60% CH₃CN in H₂O over 10 minutes, t_R (**353**) = 8.0-8.7 min, t_R (**A-6**) = 9.5-10.0 min).

Major diastereomer **353**. $[\alpha]_D^{25} = -23^\circ$ (c = 1.925, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 6.85 (dd, J = 10.4, 2.1 Hz, 1H), 6.00 (dd, J = 10.4, 2.5 Hz, 1H), 4.91 (s, 1H), 4.78 (dt, J = 7.2, 2.3 Hz, 1H), 4.38 (dd, J = 8.6, 7.3 Hz, 1H), 4.33 (dd, J = 9.8, 7.6 Hz, 1H), 4.25 – 4.12 (m, 4H), 3.04 (dt, J = 12.8, 8.2 Hz, 1H), 2.65 (dt, J = 12.7, 7.6 Hz, 1H), 1.95 (td, J = 12.8, 9.7 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H), 1.01 – 0.88 (m, 2H), 0.02 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 195.4, 171.7, 156.8, 150.5, 126.9, 70.0, 65.2, 65.1, 61.6, 59.2, 45.6, 32.8, 17.7, 14.1, -1.6; FTIR (NaCl, thin film): 3413, 2953, 2899, 1744, 1676, 1457, 1420, 1374, 1350, 1304, 1250, 1215, 1188, 1166, 1118, 1069, 1032, 960, 861, 839, 770, 695 cm⁻¹; HRMS (MM) calc'd for C₁₅H₂₄NO₆Si [M–C₂H₄+H]⁺ 342.1367, found 342.1378 (detected fragment has undergone elimination of ethylene from the Teoc protecting group).

Minor diastereomer **A-6**. $[\alpha]_{D}^{25} = -58^{\circ}$ (c = 0.405, CHCl₃); ¹H NMR (400 MHz, CD₃CN, 60 °C) δ 7.08 (dd, J = 10.0, 5.9 Hz, 1H), 6.10 (d, J = 10.0 Hz, 1H), 4.70 – 4.56 (m, 1H), 4.39 (dd, J = 9.5, 7.9 Hz, 1H), 4.37 – 4.32 (m, 1H), 4.27 – 4.15 (m, 5H), 3.08 (dt, J = 12.0, 8.3 Hz, 1H), 2.62 (dt, J = 12.2, 8.2 Hz, 1H), 2.13 (app q, J = 11.6 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H), 1.10 – 0.90 (m, 2H), 0.06 (s, 9H); ¹³C NMR (101 MHz, CD₃CN, compound exists as a mixture of rotamers) δ 198.7, 175.2, 155.7, 148.0, 147.2, 132.3, 131.9, 64.9, 63.2, 62.7, 61.6, 60.8, 60.4, 47.1, 46.7, 34.5, 33.9, 18.3, 14.4, -1.5; FTIR (NaCl, thin film): 3445, 2953, 2900, 1698, 1404, 1377, 1348, 1303, 1251, 1203, 1177, 1114, 1065, 1030, 999, 975, 942, 899, 853, 838, 769, 696 cm⁻¹; HRMS (MM) calc'd for C₁₅H₂₄NO₆Si [M–C₂H₄+H]⁺ 342.1367, found 342.1376 (detected fragment has undergone elimination of ethylene from the Teoc protecting group).

Preparation of TBS ether 354



To enone **353** (462 mg, 1.25 mmol, 1.0 equiv; as a 6.5 : 1 mixture of diastereomers) in a flame-dried 50 mL round-bottom flask was added dry DCM (12 mL), which was brought to -78 °C. 2,6-Lutidine (0.72 mL, 6.25 mmol, 5.0 equiv) was added, followed by slow addition of TBSOTf (0.57 mL, 2.50 mmol, 2.0 equiv). The resulting clear solution was allow to stir at -78 °C for 90 minutes. It was quenched with pH7 buffer (15 mL) and warmed to room temperature. The mixture was then separated and the aqueous layer was then extracted with EtOAc (3 x 20 mL). Combined organic layer was washed with brine (50 mL). It was then dried over Na₂SO₄, filtered and concentrated down to give a colorless oil (extra time under high vacuum could remove the residue 2.6lutidine and help the subsequent purification step). Flash chromatography (1% to 18% EtOAc in hexanes) afforded TBS ether 354 as a single diastereomer, as a colorless oil (425 mg, 0.825 mmol, 71% yield). $[\alpha]_{D}^{25} = +49^{\circ} (c = 0.650, \text{CHCl}_{3})$; ¹H NMR (400 MHz, CD_3CN , 60 °C) δ 6.79 (dd, J = 10.3, 2.8 Hz, 1H), 6.13 – 5.74 (m, 1H), 4.86 (br s, 1H), 4.43 - 4.37 (m, 2H), 4.22 (app q, J = 8.8 Hz, 1H), 4.18 - 4.04 (m, 3H), 2.96 (dt, J = 10.1, 7.5 Hz, 1H), 2.52 (dt, J = 12.9, 8.2 Hz, 1H), 2.11 (q, J = 10.5 Hz, 1H), 1.23 (t, J = 7.1 Hz, 3H), 1.00 (t, J = 8.5 Hz, 2H), 0.95 (s, 9H), 0.18 (s, 3H), 0.17 (s, 3H), 0.04 (s, 9H); ¹³C NMR (101 MHz, CD₃CN, 60 °C) & 197.7, 173.6, 156.8, 151.9, 129.0, 69.4, 66.3, 64.8, 62.3, 61.3, 48.1, 33.4, 26.6, 19.0, 18.9, 14.9, -1.1, -4.0, -4.2; FTIR (NaCl, thin film): 2953, 2929, 2896, 2856, 1748, 1701, 1682, 1462, 1405, 1375, 1340, 1319, 1289, 1250, 1211, 1187, 1155, 1099, 1058, 985, 956, 939, 862, 829, 779 cm⁻¹; HRMS (MM) calc'd

for $C_{21}H_{38}NO_6Si_2$ [M– C_2H_4 +H]⁺ 456.2232, found 456.2231 (detected fragment has undergone elimination of ethylene from the Teoc protecting group).

Preparation of vinyl triflate A-7



A flame-dried 50 mL round-bottom flask was charged with TBS ether 354 (200 mg, 0.41 mmol, 1.0 equiv), which was dissolved in dry THF (7.4 mL) and cooled to -78 °C. A solution of KHMDS (0.5M in toluene, 0.9 mL, 0.45 mmol, 1.1 equiv) was added slowly. The reaction solution turned dark red upon addition and was stirred for 5 minutes before the addition of a THF solution of PhNTf₂ (162 mg, 0.45 mmol, 1.1 equiv; prepared by dissolving 180 mg in 1 mL THF and used 0.9 mL). It was reacted for another 2 hours before quenching with 1% NaOH solution (10 mL) and warmed to room temperature. The mixture was then separated and the organic layer was washed with 1% NaOH solution (10 mL). The aqueous layer was then extracted with ether (3 x 20 mL). Combined organic layer was washed with brine (50 mL). It was then dried over Na_2SO_4 , filtered and concentrated down to give a light yellow oil. Flash chromatography (1% to 8% EtOAc in hexanes) afforded vinyl triflate A-7, as a colorless oil (191 mg, 0.31 mmol, 75% yield; A-7 was labile and it is recommended to carry to the next reaction as soon as possible). $[\alpha]_{D}^{25} = +14^{\circ} (c = 0.69, CH_{2}Cl_{2}); {}^{1}H NMR (400 MHz, CD_{3}CN, 60 {}^{\circ}C) \delta 5.96$ (d, J = 10.2 Hz, 1H), 5.87 (dd, J = 10.2, 2.3 Hz, 1H), 5.06 - 4.90 (m, 3H), 4.28 (ddd, J = 10.2 Hz, 1Hz), 5.06 - 4.90 (m, 3Hz), 5.06 (10.9, 9.3, 7.4 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 4.09 (ddd, J = 10.8, 9.2, 7.1 Hz, 1H), 3.00 - 2.76 (m, 2H), 1.27 (t, J = 7.1 Hz, 3H), 1.03 (ddd, J = 9.3, 7.0, 1.8 Hz, 2H), 0.93 (s, 9H), 0.09 (s, 3H), 0.07 (s, 3H), 0.05 (s, 9H); ¹³C NMR (101 MHz, CD₃CN, 60 °C) δ 172.8, 157.1, 140.7, 138.6, 132.1, <u>124.6</u>, 121.7, <u>121.5</u>, <u>115.1</u>, 75.6, 67.8, 65.2, 64.6, 62.7, 31.9, 26.7, 19.1, 18.8, 14.8, -1.1, -4.0, -4.4 (one of the quartet of -CF₃ carbons is masked under the solvent peak and the rest of the three peaks are underlined); FTIR (NaCl, thin film): 3426, 2954, 2930, 2898, 2857, 1750, 1722, 1709, 1423, 1403, 1361, 1334, 1295, 1251, 1213, 1142, 1104, 1037, 973, 943, 894, 839, 779, 769, 693, 619 cm⁻¹; HRMS (MM) calc'd for C₂₂H₃₇F₃NO₈SSi₂ [M–C₂H₄+H]⁺ 588.1725, found 588.1744 (detected fragment has undergone elimination of ethylene from the Teoc protecting group).

Preparation of diene 344



To a flame-dried 50 mL round-bottom flask was added vinyl triflate A-7 (260 mg, 0.42 mmol, 1.0 equiv), Pd(OAc)₂ (19 mg, 0.084 mmol, 20 mol %), and PPh₃ (44 mg, 0.169 mmol, 40 mol %). The system was purged with N₂ and charged with dry DMF (8 mL), "Bu₃N (0.50 mL, 2.11 mmol, 5.0 equiv), and HCOOH (48 μ L, 1.27 mmol, 3.0 equiv). The resulting yellow clear solution was then heated to 65 °C for 15 minutes, at which point the reaction turned black. It was then diluted with EtOAc (25 mL) and washed with 1M HCl (25 mL), H₂O (25 mL) and brine (25 mL). The aqueous layers were each extracted with ether (20 mL). Combined organic layer was then dried over Na₂SO₄, filtered and concentrated down to give a brown oil. Flash chromatography (1% to 10% EtOAc in hexanes) afforded diene **344**, as a light yellow oil (165 mg, 0.35 mmol, 84% yield). [α]_D²⁵ = +55° (*c* = 1.43, CHCl₃); ¹H NMR (400 MHz, CD₃CN, 60 °C) δ 5.88 –

5.81 (m, 1H), 5.81 – 5.73 (m, 1H), 5.65 (d, J = 9.6 Hz, 1H), 4.87 – 4.76 (m, 2H), 4.74 – 4.64 (m, 1H), 4.33 – 4.23 (m, 1H), 4.17 (qd, J = 7.1, 1.0 Hz, 2H), 4.07 (ddd, J = 10.8, 9.0, 7.3 Hz, 1H), 2.93 – 2.80 (m, 1H), 2.63 (d, J = 15.9 Hz, 1H), 1.26 (t, J = 7.2 Hz, 3H), 1.02 (ddd, J = 8.8, 7.1, 1.1 Hz, 2H), 0.93 (s, 9H), 0.08 (s, 3H), 0.07 (s, 3H), 0.05 (s, 9H); ¹³C NMR (101 MHz, CD₃CN, 60 °C) δ 173.5, 157.6, 142.0, 135.3, 125.6, 119.1, 76.7, 66.7, 64.7, 64.3, 62.3, 35.1, 26.8, 19.2, 18.9, 15.0, -1.0, -3.8, -4.3; FTIR (NaCl, thin film): 3049, 2954, 2928, 2897, 2855, 1750, 1722, 1699, 1472, 1398, 1361, 1329, 1290, 1250, 1204, 1180, 1105, 1031, 958, 839, 776, 701, 670 cm⁻¹; HRMS (MM) calc'd for C₂₁H₃₈NO₅Si₂ [M–C₂H₄+H]⁺ 440.2283, found 440.2298 (detected fragment has undergone elimination of ethylene from the Teoc protecting group).

Preparation of dienol 355



Diene **344** (28.6 mg, 0.061 mmol, 1.0 equiv) was dissolved in dry THF (1.1 mL) in a 1-dram vial. TBAF (1M in THF, 0.18 mL, 0.18 mmol, 3 equiv) was added and the resulting light brown solution was allowed to stir at room temperature for 2 hours and 20 minutes before being quenched with saturated Na₂SO₄ solution (2 mL). The mixture was then further diluted with brine (1 mL) and extracted with EtOAc (12 x 5 mL). Each of the EtOAc extractions was filtered through a short silica gel plug. Combined organic layer was concentrated down to give a light brown oil. Flash chromatography (60% to 100% EtOAc in hexanes) afforded dienol **355**, as a light brown oil (12.9 mg, 0.06 mmol, 95% calculated yield, accompanied by 5% aromatized side product). $[\alpha]_D^{25} = +190^\circ$ (c = 0.60, CH₂Cl₂); ¹H NMR (500 MHz, CDCl₃) δ 5.84 (ddd, J = 9.7, 4.8, 2.8 Hz, 1H), 5.71 (dt, J =

4.9, 2.5 Hz, 1H), 5.65 (d, J = 9.8 Hz, 1H), 4.58 (d, J = 15.1 Hz, 1H), 4.21 (qd, J = 7.1, 2.5 Hz, 2H), 3.86 (t, J = 8.0 Hz, 1H), 3.82 (dd, J = 14.2, 2.8 Hz, 1H), 3.04 (br s, 2H), 2.90 (dd, J = 17.7, 8.3 Hz, 1H), 2.66 (dd, J = 17.6, 7.6 Hz, 1H), 1.29 (t, J = 7.1 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 173.2, 141.1, 130.3, 124.7, 115.9, 74.8, 66.4, 61.2, 59.3, 33.9, 14.2; FTIR (NaCl, thin film): 3337, 3043, 2980, 2928, 2853, 1738, 1553, 1446, 1377, 1329, 1200, 1082, 1061, 1033, 862, 750, 711 cm⁻¹; HRMS (MM) calc'd for C₁₁H₁₆NO₃ [M+H]⁺ 210.1125, found 210.1125.

Preparation of syn-diol 357



In a half-a-dram vial, dienol **355** (1.2 mg, 0.006 mmol, 1.0 equiv) was dissolved in THF (50 μ L) and MeOH (50 μ L). A solution of LiOH (1.4 mg, 0.060 mmol, 10 equiv) in water (50 μ L) was added into the vial and the reaction was allowed to stir at room temperature for 10 minutes. It was then quenched with 1M HCl (57 μ L) and all the solvents were removed under vacuum to provide a brown oil/solid crude material. It was subjected to the next reaction *directly*. Due to the high polarity of amino acid **A-8**, analytical pure sample could be obtained by preparative reverse phase HPLC (0% to 5% CH₃CN in H₂O over 10 minutes, t_R = 3.0-7.0 min). [α]_D²⁵ = +254° (*c* = 0.33, MeOH); ¹H NMR (400 MHz, CD₃OD) δ 5.91 (ddd, *J* = 9.7, 4.9, 2.7 Hz, 1H), 5.84 (dt, *J* = 5.0, 2.6 Hz, 1H), 5.68 (dd, *J* = 9.7, 1.8 Hz, 1H), 4.81 (d, *J* = 14.9 Hz, 1H), 4.10 (d, *J* = 15.5 Hz, 1H), 4.03 (dd, *J* = 9.1, 7.4 Hz, 1H), 3.05 (dd, *J* = 17.9, 9.0 Hz, 1H), 2.81 (dd, *J* = 17.7, 7.3 Hz, 1H); ¹³C NMR (101 MHz, CD₃OD) δ 174.7, 138.1, 131.3, 125.7, 118.7, 72.3, 67.8, 62.9, 33.8; FTIR (NaCl, thin film): 3380, 3044, 2916, 2849, 1624, 1417, 1380, 1314, 1253, 1145, 1068, 987, 875, 833, 794, 762, 712, 624 cm⁻¹; HRMS (MM) calc'd for C₉H₁₂NO₃ [M+H]⁺ 182.0812, found 182.0815.

The crude material was first dissolved in small amount of MeOH (ca. 0.1 mL) and co-evaporated with benzene to further get rid of water. It was then dissolved in DMF (0.3 mL). Under N₂, DIPEA (6μ L, 0.034 mmol, 6 equiv), and PyBroP (10.7 mg, 0.023 mmol, 4 equiv) were added in sequence. The resulting light brown solution was allowed to stir at room temperature for 22 hours. It was then quenched with saturated NaHCO₃ (1 mL). The mixture was separated and the aqueous layer was then extracted with DCM (5 x 1 mL). Combined organic layer was washed with brine (5 mL). It was then dried over Na₂SO₄, filtered, and concentrated down to give a light brown oil. Preparative TLC (80%) EtOAc in hexanes) afforded syn-diol 357, as a white solid (0.4 mg, 0.0012 mmol, 43%) yield over 2 steps). $[\alpha]_{D}^{25} = +230^{\circ} (c = 0.06, CHCl_3); {}^{1}H NMR (400 MHz, CDCl_3) \delta 6.41$ (d, J = 1.3 Hz, 1H), 5.93 (ddd, J = 9.5, 5.0, 2.8 Hz, 1H), 5.89 - 5.82 (m, 1H), 5.75 (ddt, J = 9.6, 2.0, 1.0 Hz, 1H, 4.75 - 4.65 (m, 1H), 4.48 (dd, J = 13.2, 3.0 Hz, 1H), 4.41 (dd, J = 13.2, 3.0 Hz, 1H)10.2, 6.6 Hz, 1H), 3.34 – 3.18 (m, 1H), 3.16 – 2.93 (m, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 168.4, 133.4, 129.5, 123.6, 118.7, 71.8, 68.9, 60.5, 29.3; FTIR (NaCl, thin film): 3281, 2922, 2853, 1651, 1423, 1381, 1351, 1336, 1295, 1273, 1255, 1230, 1192, 1147, 1083, 1061, 721, 671 cm⁻¹; HRMS (MM) calc'd for $C_{18}H_{19}N_2O_4$ [M+H]⁺ 327.1339, found 327.1342.

Preparation of *anti*-diol 358



A 1-dram vial was charged with syn-diol 357 (1.2 mg, 0.0037 mmol, 1.0 equiv) and Cs₂CO₃ (48 mg, 0.147 mmol, 40 equiv). In the meantime, dry MeOH (0.75 mL) was fully degassed by bubbling N₂ through and was added to the vial under N₂. The resulting mixture gradually turned into a clear yellow solution and was stirred for 30 minutes. It was then quenched with saturated NaHCO₃ (3 mL) and the mixture was extracted with EtOAc (5 x 3 mL). Combined organic layer was washed with brine (15 mL). It was then dried over Na₂SO₄, filtered, and concentrated down to give a white solid. Flash chromatography (20% to 100% EtOAc in hexanes) afforded anti-diol 358, as a white solid (0.8 mg, 0.0024 mmol, 67% yield). $[\alpha]_{D}^{25} = -159^{\circ}$ (c = 0.075, CHCl₃); ¹H NMR $(500 \text{ MHz}, \text{CDCl}_3) \delta 6.00 \text{ (s, 1H)}, 5.96 - 5.86 \text{ (m, 2H)}, 5.76 \text{ (dt, } J = 9.5, 1.4 \text{ Hz}, 1\text{H}),$ 4.78 - 4.63 (m, 3H), 2.99 (dd, J = 15.5, 7.2 Hz, 1H), 2.88 (t, J = 13.5 Hz, 1H); ¹³C NMR (126 MHz, CDCl₃) & 168.2, 132.7, 130.0, 123.0, 119.0, 73.6, 68.1, 62.5, 32.2; FTIR (NaCl, thin film): 3305, 3039, 2924, 2853, 2713, 1626, 1553, 1447, 1381, 1354, 1330, 1290, 1265, 1237, 1201, 1139, 1087, 1057, 767, 710 cm⁻¹; HRMS (MM) calc'd for $C_{18}H_{19}N_2O_4$ [M+H]⁺ 327.1339, found 327.1336.

Preparation of carboxylic acid 359



Diene **344** (9.1 mg, 0.019 mmol, 1.0 equiv) was transferred to a 0.5-dram vial, to which was added Me₃SnOH (35.2 mg, 0.195 mmol, 10 equiv) and dry DCE (0.4 mL).

The vial was then sealed with a Teflon cap and heated to 80 °C for 22 hours. It was then cooled to room temperature and quenched with pH2.5 buffer (0.5 mL). The mixture was separated and the aqueous layer was then extracted with EtOAc (5 x 1 mL). Combined organic layer was washed with brine (5 mL). It was then dried over Na_2SO_4 , filtered, and concentrated down to give a light brown oil. Flash chromatography (1% to 6% MeOH in DCM) afforded carboxylic acid **359**, as a light brown oil (7.9 mg, 0.018 mmol, 93%) yield). $[\alpha]_{D}^{25} = +44^{\circ}$ (c = 0.59, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 5.87 – 5.77 (m, 2H), 5.69 (d, J = 9.5 Hz, 1H), 4.93 – 4.79 (m, 1H), 4.72 (d, J = 14.4 Hz, 1H), 4.58 (d, J = 14.4 Hz, 14.4 Hz, 1H), 4.38 (d, J = 10.3 Hz, 1H), 4.09 (q, J = 9.5 Hz, 1H), 2.99 - 2.77 (m, 2H), 1.07 (dd, J = 9.6, 7.9 Hz, 2H), 0.90 (s, 9H), 0.04 (s, 3H), 0.04 (s, 12H); ¹³C NMR (101 MHz, CDCl₃, 45 °C) & 175.1, 157.6, 139.4, 134.6, 124.3, 118.7, 75.4, 65.0, 64.6, 62.8, 32.8, 26.0, 18.2, 18.0, -1.5, -4.6, -5.1; FTIR (NaCl, thin film): 3121, 3051, 2954, 2928, 2897, 2856, 1747, 1699, 1471, 1418, 1360, 1335, 1250, 1178, 1107, 1042, 1020, 970, 957, 862, 838, 776, 700, 667, 627 cm⁻¹; HRMS (MM) calc'd for C₁₉H₃₄NO₅Si₂ [M- $C_{2}H_{4}+H^{+}$ 412.1970, found 412.1977 (detected fragment has undergone elimination of ethylene from the Teoc protecting group).

Preparation of dipeptide 361



To a 1-dram vial was transferred carboxylic acid **359** (7.9 mg, 0.018 mmol, 1.0 equiv) and amine **360** (6.7 mg, 0.020 mmol, 1.1 equiv), using DCM, and the mixture of starting materials was co-evaporated with benzene (1 mL). It was then dissolved in dry

DCM (0.35 mL), followed by the addition of Et₃N (25 μ L, 0.18 mmol, 10 equiv) and BOP-Cl (22.9 mg, 0.09 mmol, 5 equiv). The mixture was allowed to stir at room temperature for 25 hours and quenched with saturated NaHCO₃ (1 mL). Then the mixture was extracted with EtOAc (5 x 1 mL). Combined organic layer was washed with brine (5 mL). It was then dried over Na_2SO_4 , filtered, and concentrated down to give a mixture of white solid and light brown oil. Flash chromatography (2% to 8% EtOAc in hexanes) afforded dipeptide **361**, as a colorless oil (13.4 mg, 0.018 mmol, 99% yield). $[\alpha]_{D}^{25} =$ +38° (c = 0.865, CHCl₃); ¹H NMR δ (400 MHz, CD₃CN) 6.48 (td, J = 2.5, 1.2 Hz, 1H), 6.23 (dd, J = 8.2, 2.2 Hz, 1H), 5.87 - 5.80 (m, 1H), 5.72 (gd, J = 2.2, 1.3 Hz, 1H), 5.67(br s, 1H), 5.57 (d, J = 9.6 Hz, 1H), 5.47 (dd, J = 5.7, 3.0 Hz, 1H), 4.83 (dd, J = 10.1, 1.8 Hz, 1H), 4.79 (dd, J = 8.2, 1.9 Hz, 1H), 4.75 – 4.72 (m, 2H), 4.46 (dt, J = 7.9, 2.1 Hz, 1H), 4.28 - 4.18 (m, 1H), 4.13 (qd, J = 7.1, 0.7 Hz, 2H), 3.98 (dt, J = 16.4, 8.5 Hz, 1H), 2.87 (dddd, J = 15.8, 10.1, 2.6, 1.6 Hz, 1H), 2.68 (dq, J = 15.8, 1.6 Hz, 1H), 2.65 – 2.60 (m, 2H), 1.23 (t, J = 7.1 Hz, 3H), 1.03 - 0.98 (m, 2H), 0.93 (s, 9H), 0.85 (s, 9H), 0.15 (s, 9H),3H), 0.06 (s, 3H), 0.02 (s, 9H), -0.08 (s, 3H), -0.10 (s, 3H); ¹³C NMR δ (101 MHz, CD₃CN, 50 °C) 173.5, 173.3, 158.1, 145.7, 139.8, 137.3, 134.5, 126.2, 117.4, 116.9, 112.0, 75.8, 72.4, 67.7, 65.1, 64.2, 62.4, 61.7, 58.8, 35.4, 33.2, 26.8, 26.6, 19.1, 19.1, 19.0, 14.8, -1.2, -2.8, -4.1, -4.6, -5.1; FTIR (NaCl, thin film): 3049, 3014, 2954, 2929, 2895, 2856, 1747, 1717, 1694, 1652, 1472, 1463, 1428, 1393, 1348, 1329, 1315, 1250, 1213, 1179, 1139, 1094, 1039, 974, 949, 860, 837, 780, 756, 701, 667, 632 cm⁻¹; HRMS (MM) calc'd for $C_{38}H_{64}N_2O_8Si_3Na [M+Na]^+ 783.3863$, found 783.3866.

Preparation of DKP 363 (undesired reaction pathway)



A 5 mL Schlenk tube was added TBAF•($^{t}BuOH$)₄ (4.8 mg, 0.009 mmol, 6 equiv), followed by addition of dipeptide 361 (1.1 mg, 0.0014 mmol, 1.0 equiv) as a CH₃CN solution (0.16 mL). The resulting solution was degassed using the freeze-pump-thaw technique. The vessel was sealed and the solution frozen by submersion in a bath of liquid N₂. The vessel was then placed under vacuum for ca. five minutes before once again being sealed and allowed to thaw under static vacuum by removal from the liquid N_2 bath. This procedure was repeated three times before the head-space was finally backfilled with N₂, the vessel sealed, and the solution heated to 70 °C with stirring. After 1 h and 30 min, the reaction mixture was cooled to room temperature, was diluted with saturated Na₂SO₄ solution, and extracted with EtOAc (5 x 0.5 mL). Each organic fraction was passed individually through a plug of SiO₂, which was then rinsed with excess EtOAc. The combined organic filtrates were then concentrated *in vacuo* to provide the crude product, which was purified by preparative TLC (50% EtOAc in hexanes) afforded alcohol **363**, as a white solid (0.2 mg, 0.0006 mmol, 43% yield). $[\alpha]_D^{25} = -331^\circ$ (c = 0.355, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, J = 7.9 Hz, 1H), 7.27 (t, J = 8.0Hz, 2H), 7.13 (td, J = 7.5, 1.1 Hz, 1H), 6.53 (q, J = 2.0 Hz, 1H), 6.20 (dd, J = 8.2, 2.3 Hz, 1H), 5.41 (d, J = 4.5 Hz, 1H), 5.07 – 4.98 (m, 1H), 4.92 (dd, J = 8.0, 2.1 Hz, 1H), 4.87 (dd, J = 8.2, 2.0 Hz, 1H), 4.50 (td, J = 9.0, 1.7 Hz, 1H), 4.40 (ddt, J = 8.2, 4.3, 2.1 Hz)1H), 3.61 (ddt, J = 16.6, 10.0, 1.2 Hz, 1H), 3.41 (dd, J = 16.5, 10.1 Hz, 1H), 3.06 (dt, J =

9.0, 1.7 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 168.3, 163.6, 140.4, 138.5, 137.7, 129.7, 128.0, 125.4, 125.0, 116.2, 110.4, 110.3, 71.5, 64.4, 61.0, 58.8, 33.2, 30.7; FTIR (NaCl, thin film): 3338, 3013, 2928, 2859, 1668, 1602, 1486, 1464, 1418, 1328, 1287, 1248, 1192, 1129, 1077, 1047, 978, 916, 860, 821, 755, 665, 625 cm⁻¹; HRMS (MM) calc'd for C₁₈H₁₅N₂O₃ [M–OH]⁺ 307.1077, found 307.1081 (detected fragment has undergone loss of hydroxyl anion).

Preparation of amine 364



A 1-dram vial of diene **344** (24.7 mg, 0.053 mmol, 1.0 equiv) was dissolved in dry THF (0.85 mL), followed by addition of a THF solution of TBAF (1M in THF, 160 μ L, 0.16 mmol, 3 equiv). The reaction solution was allowed to stir at room temperature for 2 hours and quenched with saturated Na₂SO₄ solution (5 mL). The solution was extracted using EtOAc (20 x 4 mL) and each EtOAc extraction was filtered through a short silica gel plug. Combined organic layer was concentrated down to give a brown oil, which was subjected to the next reaction immediately.

The crude material was dissolved in DCM (0.5 mL) and the solution was brought down to -78 °C. 2,6-Lutidine (31 μ L, 0.265 mmol, 5 equiv) was added, followed by TBSOTF (24 μ L, 0.106 mmol, 2 equiv). After stirring for 50 minutes, a second portion of TBSOTF (12 μ L, 0.053 mmol, 1 equiv) was added, which was allowed to react for another 40 minutes. It was quenched with saturated NH₄Cl solution (2 mL) and extracted with EtOAc (3 x 3 mL). Combined organic layer was washed with saturated NaHCO₃ solution (10 mL) and brine (10 mL). It was then dried over Na₂SO₄, filtered, and concentrated down to give a colorless oil. Flash chromatography (1% to 16% EtOAc in hexanes) afforded amine **364**, as a colorless oil (14.9 mg, 0.046 mmol, 88% yield). $[\alpha]_{\rm D}^{25}$ = +181° (*c* = 0.745, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 5.79 (ddt, *J* = 9.6, 4.8, 2.1 Hz, 1H), 5.66 (dt, *J* = 5.0, 2.5 Hz, 1H), 5.55 (d, *J* = 9.6 Hz, 1H), 4.61 (d, *J* = 14.0 Hz, 1H), 4.20 (qd, *J* = 7.2, 1.8 Hz, 2H), 3.90 – 3.63 (m, 2H), 2.85 (dd, *J* = 17.7, 8.2 Hz, 1H), 2.68 (dd, *J* = 17.5, 6.8 Hz, 1H), 1.28 (td, *J* = 7.2, 1.9 Hz, 3H), 0.92 (s, 9H), 0.13 (s, 3H), 0.11 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 173.4, 141.4, 131.4, 124.3, 115.4, 76.2, 65.9, 60.9, 59.2, 33.4, 25.9, 18.1, 14.2, -4.38, -4.40; FTIR (NaCl, thin film): 3366, 3045, 2955, 2929, 2896, 2856, 1739, 1472, 1464, 1384, 1330, 1253, 1198, 1156, 1097, 1035, 1006, 983, 921, 892, 859, 837, 777, 705 cm⁻¹; HRMS (MM) calc'd for C₁₇H₃₀NO₃Si [M+H]⁺ 324.1989, found 324.1980.

Preparation of bisTBS-dipeptide 366



To a 1-dram vial was transferred amine **364** (14.5 mg, 0.045 mmol, 1.0 equiv) and carboxylic acid **365** (21.5 mg, 0.047 mmol, 1.05 equiv), using DCM, and the mixture of starting materials was co-evaporated with benzene (1 mL). It was then dissolved in dry DCM (0.9 mL), followed by the addition of Et₃N (63 μ L, 0.45 mmol, 10 equiv) and BOP-Cl (57 mg, 0.224 mmol, 5 equiv). The mixture was allowed to stir at room temperature for 25 hours and quenched with saturated NaHCO₃ (2 mL). The mixture was extracted with EtOAc (5 x 2 mL). Combined organic layer was washed with brine (10

mL). It was then dried over Na_2SO_4 , filtered, and concentrated down to give a mixture of white solid and light brown oil. Flash chromatography (1% to 8% EtOAc in hexanes) afforded dipeptide **366**, as a colorless oil (35 mg, 0.046 mmol, quantitative yield). $[\alpha]_D^{25}$ $= +42^{\circ}$ (c = 0.865, CHCl₂); ¹H NMR (400 MHz, CD₂CN, 60 °C) δ 6.50 – 6.39 (m, 1H), 6.21 (dt, J = 8.2, 1.1 Hz, 1H), 5.91 (ddd, J = 9.6, 4.5, 1.8 Hz, 1H), 5.88 - 5.81 (m, 2H),5.78 (d, J = 9.7 Hz, 1H), 5.55 (dd, J = 8.7, 1.1 Hz, 1H), 5.16 (t, J = 5.2 Hz, 1H), 4.90 (d, J = 14.6 Hz, 1H), 4.68 (d, J = 8.3 Hz, 1H), 4.50 (s, 2H), 4.29 - 4.13 (m, 3H), 4.05 (q, J = 10014.9 Hz, 1H), 1.26 (t, J = 7.1 Hz, 3H), 1.07 - 1.01 (m, 1H), 0.97 (s, 9H), 0.87 (s, 9H), 0.12 (s, 6H), 0.04 (s, 3H), 0.04 (s, 9H), -0.09 (s, 3H); ¹³C NMR (101 MHz, CD₃CN, 60 °C) 8 174.8, 172.9, 142.8, 139.5, 135.7, 135.5, 126.3, 119.5, 111.9, 76.4, 72.0, 65.9, 65.5, 65.1, 62.9, 62.6, 56.9, 35.8, 34.3, 27.2, 26.9, 26.6, 19.3, 19.2, 18.9, 14.9, -1.1, -2.7, -3.8, -4.3, -4.4; FTIR (NaCl, thin film): 3052, 2954, 2928, 2897, 2856, 1745, 1715, 1686, 1655, 1473, 1463, 1431, 1359, 1331, 1304, 1290, 1251, 1208, 1188, 1176, 1143, 1102, 1063, 1029, 929, 837, 779, 701, 666 cm⁻¹; HRMS (MM) calc'd for C₂₆H₃₃N₂O₆Si [M- $C_6H_{16}OSi-C_6H_{15}OSi$ ⁺ 497.2101, found 497.2110 (detected fragment has undergone elimination of *tert*-butyldimethylsilanol, as well as loss of *tert*-butyldimethylsilanolate anion).

Preparation of dipeptide 367



A 2-dram vial of bisTBS dieptide 366 (11.3 mg, 0.015 mmol, 1.0 equiv) was dissolved in dry THF (1.4 mL), followed by addition of a THF solution of TBAF (1M in THF, 90 μ L, 0.09 mmol, 6 equiv). The reaction solution was allowed to stir at room temperature for 2 hours and quenched with saturated Na_2SO_4 solution (3 mL). The solution was extracted with EtOAc (4 x 3 mL) and each EtOAc extraction was filtered through a short silica gel plug. Combined organic layer was washed with brine (15 mL) and concentrated down to give a brown oil. Flash chromatography (10% to 60% EtOAc in hexanes) afforded dipeptide 367, as a colorless oil (5.5 mg, 0.011 mmol, 74% yield). $[\alpha]_{D}^{25} = +37^{\circ} (c = 0.40, \text{CHCl}_{3}); ^{1}\text{H NMR} (400 \text{ MHz}, \text{CDCl}_{3}) \delta 6.35 - 6.28 (m, 2\text{H}), 6.09$ (dd, J = 8.2, 2.3 Hz, 1H), 5.84 - 5.75 (m, 2H), 5.75 - 5.67 (m, 1H), 4.96 (d, J = 8.6 Hz)1H), 4.84 (dq, J = 13.0, 1.6 Hz, 1H), 4.80 – 4.72 (m, 1H), 4.66 (dd, J = 8.2, 1.9 Hz, 1H), 4.41 (dt, J = 7.3, 2.1 Hz, 1H), 4.31 – 4.13 (m, 2H), 3.94 (dd, J = 8.1, 5.3 Hz, 1H), 3.85 – 3.80 (m, 1H), 2.99 (ddt, J = 14.9, 8.1, 1.8 Hz, 1H), 2.88 (ddd, J = 13.6, 9.2, 3.0, 1.7 Hz,1H), 2.84 - 2.70 (m, 1H), 2.48 (ddt, J = 14.9, 5.5, 1.8 Hz, 1H), 1.27 (t, J = 7.1 Hz, 3H), 0.93 (s, 9H), 0.19 (s, 3H), 0.16 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 176.1, 170.6, 138.4, 135.0, 132.8, 130.9, 122.1, 118.8, 115.4, 110.9, 73.8, 71.4, 68.4, 65.3, 62.2, 61.0, 58.7, 34.64, 34.57, 25.9, 18.0, 14.1, -4.48, -4.52; FTIR (NaCl, thin film): 3345, 2955, 2927, 2885, 2855, 1740, 1685, 1639, 1437, 1370, 1327, 1297, 1253, 1206, 1181, 1087, 1065, 1025, 878, 838, 778 cm⁻¹; HRMS (MM) calc'd for $C_{26}H_{39}N_2O_6Si [M+H]^+$ 503.2572, found 503.2585.

Preparation of TBS-DKP 368



In a 1-dram vial, bisTBS-dipeptide **367** (5.5 mg, 0.011 mmol, 1.0 equiv) was dissolved in THF (180 μ L) and MeOH (180 μ L). A solution of LiOH (1.3 mg, 0.055 mmol, 5 equiv) in water (180 μ L) was added into the vial and the reaction was allowed to stir at room temperature for 30 minutes. It was then quenched with pH7 buffer (3 mL)/brine (0.2 mL) and extracted with EtOAc (10 x 2 mL). The combined organic layer was concentrated under vacuum to provide a light yellow oil crude material. It was subjected to the next reaction directly.

The crude material was first dissolved in small amount of DCM (ca. 0.1 mL) and co-evaporated with benzene (1 mL). It was then dissolved in DCM (2.2 mL). Under N₂, DIPEA (5.7 μ L, 0.033 mmol, 3 equiv) and PyBroP (10.2 mg, 0.022 mmol, 2 equiv) were added in sequence. The resulting light yellow solution was allowed to stir at room temperature for 18 hours. It was then quenched with saturated NaHCO₃ (4 mL). The mixture was separated and the aqueous layer was then extracted with EtOAc (5 x 4 mL). Combined organic layer was washed with brine (25 mL). It was then dried over Na₂SO₄, filtered, and concentrated down to give a light yellow solid. Flash chromatography (10% to 90% EtOAc in hexanes) afforded TBS-DKP **368**, as a white solid (4.4 mg, 0.010 mmol, 88% yield over 2 steps). $[\alpha]_D^{25} = +38^\circ$ (c = 0.29, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 6.54 (s, 1H), 6.48 (s, 1H), 6.22 (dd, J = 8.2, 1.9 Hz, 1H), 5.91 (ddd, J = 9.8, 5.0, 2.8 Hz, 1H), 5.83 (dq, J = 5.3, 2.8 Hz, 1H), 5.74 (d, J = 9.7 Hz, 1H), 4.81 – 4.63 (m, 3H),

4.47 (dd, J = 13.3, 3.0 Hz, 1H), 4.39 (dd, J = 11.8, 8.3 Hz, 1H), 4.35 (dd, J = 11.7, 7.1 Hz, 1H), 4.02 (dt, J = 8.2, 1.7 Hz, 1H), 3.30 – 3.19 (m, 1H), 3.08 (dd, J = 19.1, 11.0 Hz, 1H), 2.90 (ddt, J = 16.0, 7.5, 0.9 Hz, 1H), 2.81 (ddt, J = 16.0, 11.0, 2.5 Hz, 1H), 0.88 (s, 9H), 0.01 (s, 3H), -0.01 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 169.2, 169.0, 140.9, 138.0, 133.9, 129.2, 123.5, 118.2, 117.8, 109.4, 71.6, 71.3, 68.7, 64.2, 61.9, 61.5, 29.8, 27.9, 25.9, 18.4, -4.5, -4.9; FTIR (NaCl, thin film): 3260, 2949, 2926, 2892, 2855, 1693, 1646, 1471, 1460, 1428, 1388, 1355, 1329, 1289, 1249, 1232, 1155, 1133, 1101, 1066, 981, 940, 898, 837, 775, 721, 670, 630 cm⁻¹; HRMS (MM) calc'd for C₁₈H₁₇N₂O₄ [M–C₆H₁₅OSi]⁺ 325.1183, found 325.1191 (detected fragment has undergone loss of *tert*-butyldimethylsilanolate anion).

Preparation of anti-DKP A-9



A flame-dried 15 mL round-bottom flask was charged with TBS-DKP **368** (5.8 mg, 0.013 mmol, 1.0 equiv) and Cs₂CO₃ (166 mg, 0.508 mmol, 40 equiv). In the meantime, dry MeOH (2.6 mL) was fully degassed by bubbling N₂ through and was added to the flask under N₂. The resulting mixture gradually turned into a clear yellow solution and was stirred for 50 minutes. It was then quenched with saturated NaHCO₃ (20 mL) and the mixture was extracted with EtOAc (5 x 10 mL). Combined organic layer was washed with brine (50 mL). It was then dried over Na₂SO₄, filtered, and concentrated down to give a white solid. Flash chromatography (10% to 50% EtOAc in hexanes) afforded *anti*-DKP **A-9**, as a white solid (5.4 mg, 0.012 mmol, 94% yield). [α]_D²⁵ = -305°

 $(c = 0.27, CHCl_3)$; ¹H NMR (400 MHz, CDCl₃) δ 6.50 (td, J = 2.5, 1.0 Hz, 1H), 6.15 (dd, J = 8.2, 2.2 Hz, 1H), 6.00 (s, 1H), 5.93 – 5.83 (m, 2H), 5.81 – 5.71 (m, 1H), 5.06 (dd, J = 7.8, 2.1 Hz, 1H), 4.91 – 4.64 (m, 3H), 4.52 (ddd, J = 11.1, 6.9, 2.0 Hz, 1H), 4.35 (ddd, J = 11.1, 7.0, 1.9 Hz, 1H), 4.22 (dt, J = 7.9, 2.0 Hz, 1H), 3.05 – 2.78 (m, 4H), 0.90 (s, 9H), 0.08 (s, 3H), 0.03 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 167.9, 163.3, 138.7, 137.3, 133.3, 130.1, 123.0, 118.8, 112.1, 110.1, 73.5, 69.8, 68.3, 62.7, 62.7, 57.8, 34.6, 32.9, 25.7, 18.0, -4.6, -4.8; FTIR (NaCl, thin film): 3304, 2947, 2928, 2884, 2855, 1671, 1634, 1423, 1342, 1290, 1248, 1230, 1197, 1128, 1103, 1051, 1033, 1003, 904, 883, 870, 838, 809, 777, 750, 717 cm⁻¹; HRMS (MM) calc'd for C₁₈H₁₇N₂O₄ [M–C₆H₁₅OSi]⁺ 325.1183, found 325.1194 (detected fragment has undergone loss of *tert*-butyldimethylsilanolate anion).

Preparation of diol 369



A 15 mL round-bottom flask was charged with *anti*-DKP A-9 (5.4 mg, 0.012 mmol, 1.0 equiv). It was then dissolved in a mixed solvent including THF (1.44 mL), H_2O (0.24 mL), and HCOOH (0.72 mL). The resulting light yellow clear solution was allowed to stir at room temperature for 8 hours before being carefully quenched with saturated NaHCO₃ (15 mL); and the mixture was extracted with EtOAc (5 x 10 mL). Combined organic layer was washed with brine (30 mL). It was then dried over Na₂SO₄, filtered, and concentrated down to give a white solid. Flash chromatography (10% to 95% EtOAc in hexanes) afforded diol **369**, as a white solid (3.4 mg, 0.010 mmol, 84%)

yield). $[\alpha]_{D}^{25} = -456^{\circ}$ (c = 0.17, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 6.53 (td, J = 2.5, 1.1 Hz, 1H), 6.19 (dd, J = 8.2, 2.3 Hz, 1H), 5.93 (s, 1H), 5.92 – 5.84 (m, 2H), 5.79 – 5.72 (m, 1H), 5.20 (d, J = 4.6 Hz, 1H), 4.90 (dd, J = 7.9, 2.1 Hz, 1H), 4.87 (dd, J = 8.2, 1.9 Hz, 1H), 4.81 – 4.73 (m, 1H), 4.73 – 4.63 (m, 2H), 4.45 (ddd, J = 10.2, 7.5, 2.2 Hz, 1H), 4.41 – 4.34 (m, 1H), 3.05 – 2.96 (m, 2H), 2.92 (ddt, J = 15.2, 10.7, 2.2 Hz, 1H), 2.81 (dddt, J = 17.8, 12.1, 2.5, 1.3 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 167.8, 167.7, 138.4, 137.8, 132.6, 130.2, 123.0, 119.1, 110.4, 109.6, 73.5, 71.3, 68.2, 64.2, 62.3, 58.0, 33.5, 32.6; FTIR (NaCl, thin film): 3253, 3048, 2923, 2851, 2787, 1667, 1622, 1441, 1386, 1350, 1284, 1267, 1250, 1236, 1206, 1187, 1132, 1084, 1047, 1002, 852, 823, 750, 736, 708, 629 cm⁻¹; HRMS (MM) calc'd for C₁₈H₁₇N₂O₄ [M–OH]⁺ 325.1183, found 325.1194 (detected fragment has undergone loss of hydroxyl anion).

Preparation of tetrasulfide 370



To a suspension of S₈ (9 mg, 0.035 mmol, 5 equiv) in THF (3 mL) at 0 °C under argon was added LiHMDS (1 M in THF, 420 μ L, 0.42 mol, 60 equiv) dropwise over 2 min. This solution was stirred for an additional 1 min, and DKP **369** (2.4 mg, 0.007 mmol, 1.0 equiv) dissolved in THF (1 mL) was added dropwise at room temperature over 2 min and rinsed with 0.3 mL THF. The reaction mixture was allowed to stir for 50 minutes and quenched with saturated NaHCO₃ (5 mL), and then the mixture was extracted with EtOAc (4 x 5 mL). Combined organic layer was washed with brine (20 mL). It was then dried over Na₂SO₄, filtered, and concentrated down to give a yellow solid. Preparative TLC (60% EtOAc in hexanes) afforded tetrasulfide **370**, as a yellow solid (0.8 mg, 0.0017 mmol, 25% yield). $[\alpha]_D^{25} = -375^\circ$ (c = 0.045, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 6.54 (t, J = 2.3 Hz, 1H), 6.21 (dd, J = 8.2, 2.4 Hz, 1H), 5.98 – 5.91 (m, 1H), 5.92 – 5.86 (m, 1H), 5.79 (d, J = 9.8 Hz, 1H), 5.33 (s, 1H), 5.08 – 4.98 (m, 2H), 4.93 (dd, J = 8.3, 2.0 Hz, 1H), 4.78 (d, J = 13.3 Hz, 1H), 4.60 (d, J = 4.5 Hz, 1H), 4.46 (td, J = 4.9, 2.3 Hz, 1H), 3.30 – 3.19 (m, 2H), 3.03 (dd, J = 16.1, 3.1 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 170.3, 169.4, 138.9, 138.0, 131.0, 129.5, 122.9, 121.2, 110.4, 106.4, 78.1, 74.5, 72.7, 71.5, 70.1, 65.3, 41.5, 40.4; FTIR (NaCl, thin film): 3407, 2924, 2852, 1644, 1379, 1289, 1262, 1234, 1188, 1132, 1082, 1053, 971, 902, 861, 819, 744, 722, 622 cm⁻¹; HRMS (MM) calc'd for C₁₈H₁₆N₂O₅S₄Cl [M+Cl]⁻ 502.9636, found 502.9633.

Preparation of diacetate A-10



To a stirred solution of diol **370** (0.9 mg, 1.9 μ mol, 1.0 equiv) and DMAP (5.9 mg, 48 μ mol, 25 equiv) in DCM (0.2 mL) at 0 °C was added acetyl chloride (2.0 μ L, 29 μ mol). After 10 min, the ice bath was removed and the reaction mixture was allowed to warm to room temperature. After an additional 30 min, the reaction mixture was quenched with saturated NaHCO₃ (0.5 mL) and extracted five times with a mixture of hexanes and EtOAc (1 : 1). Each organic fraction was passed individually through a plug of SiO₂, which was subsequently rinsed with excess hexanes/EtOAc. The combined filtrates were concentrated *in vacuo* to provide the crude product, which was purified by preparative TLC (60% EtOAc in hexanes) to afford diacetate **A-10**, as a yellow solid (0.6

mg, 1.1 μ mol, 57% yield). [α]_D²⁵ = -327° (*c* = 0.03, CHCl₃); ¹H NMR (600 MHz, CDCl₃) δ 6.56 (t, *J* = 2.5 Hz, 1H), 6.26 (dd, *J* = 8.2, 2.3 Hz, 1H), 6.00 – 5.91 (m, 2H), 5.83 (d, *J* = 14.2 Hz, 1H), 5.68 – 5.59 (m, 1H), 5.37 (d, *J* = 14.4 Hz, 1H), 5.29 (d, *J* = 8.2 Hz, 1H), 5.22 (dt, *J* = 8.4, 2.1 Hz, 1H), 4.70 (dd, *J* = 8.2, 1.9 Hz, 1H), 3.31 – 3.21 (m, 2H), 3.04 (dd, *J* = 16.5, 6.4 Hz, 2H), 2.19 (s, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 170.4, 170.4, 166.6, 165.8, 139.6, 138.6, 131.9, 128.8, 124.9, 120.9, 108.1, 106.0, 79.4, 75.4, 74.2, 71.1, 64.2, 60.7, 41.8, 41.2, 21.5, 21.4; FTIR (NaCl, thin film): 2923, 2854, 1734, 1685, 1369, 1293, 1236, 1187, 1135, 1046, 753, 710 cm⁻¹; HRMS (LC-MM) calc'd for C₂₀H₁₇N₂O₅S₄ [M–C₂H₃O₂]⁺ 493.0026, found 493.0015 (detected fragment has undergone loss of acetate anion).

Preparation of (-)-acetylapoaranotin (300)



A solution of tetrasulfide **A-10** (0.6 mg, 1.1 μ mol) in DCM (0.12 mL) was diluted with MeCN (3.6 mL), then treated with a solution of Et₃N in MeCN (0.05 μ L, 0.36 μ mol in 10 μ L of MeCN), followed by 1,3-propanedithiol (11 μ L, 0.11 mmol). The resulting mixture was allowed to stand for 20 min, and was then washed with hexanes (5 x 4 mL, the final hexanes wash was back-extracted once with MeCN to ensure material recovery), and concentrated *in vacuo*. The resulting residue was dissolved in DCM/PhMe and loaded onto a short plug of SiO₂. Residual propanedithiol and other nonpolar impurities were eluted with 4 : 1 hexanes–EtOAc before the presumed dithiol intermediate was

[M+Na]⁺511.0610, found 511.0621.

eluted with 50 to 100% EtOAc in hexanes. Collected the fractions and concentrated *in vacuo*. The resulting material was taken up in EtOAc (12 mL) and MeOH (12 mL). The resulting solution was sparged with O₂ for 1 hour and allowed to stir for another 4 hours. The solution was then concentrated *in vacuo*, and purified by preparative TLC (60% EtOAc in hexanes) to provide (–)-acetylapoaranotin (**300**) as a yellow solid (0.3 mg, 0.6 μ mol, 57% yield). [α]_D²⁵ = –281° (*c* = 0.015, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 6.60 (d, *J* = 2.4 Hz, 1H), 6.30 (dd, *J* = 8.3, 2.1 Hz, 1H), 6.04 (d, *J* = 12.7 Hz, 1H), 6.00-5.95 (m, 2H), 5.69 (d, *J* = 8.6 Hz, 1H), 5.55 (d, *J* = 8.2 Hz, 1H), 5.14-5.06 (m, 1H), 5.00 (d, *J* = 13.1 Hz, 1H), 4.60 (dd, *J* = 8.2, 1.7 Hz, 1H), 4.01 (d, *J* = 18.3 Hz, 1H), 3.80 (d, *J* = 18.1 Hz, 1H), 2.99 (d, *J* = 18.2 Hz, 1H), 2.87 (d, *J* = 17.9 Hz, 1H), 2.14 (s, 3H), 2.03 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 170.5, 169.9, 163.1, 162.2, 141.1, 139.2, 132.2, 127.8, 124.5, 119.9, 113.4, 105.3, <u>100.0</u>, 78.2, 75.9, 73.9, 69.8, 64.5, 62.8, 36.1, 34.5, 21.3, 20.9; FTIR (NaCl, thin film): 2919, 2850, 1737, 1706, 1552, 1435, 1367, 1302, 1279, 1233, 1143, 1041, 962, 752, 720, 655 cm⁻¹; HRMS (ESI) calc'd for C₂₂H₂₀N₂O₇S₂Na

Yang et al. Report, ²⁰	This Work,
Natural (–)-acetylapoaranotin	Synthetic (–)-acetylapoaranotin
¹ H NMR, 500 MHz, CDCl ₃	¹ H NMR, 400 MHz, CDCl ₃
δ 6.61 (br ddd, J = 2.5, 2.0, 2.0 Hz, 1H)	δ 6.60 (d, J = 2.4 Hz, 1H)
6.31 (dd, J = 8.5, 2.0 Hz, 1H)	6.30 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H)
6.05 (br dm, $J = 13.2$ Hz, 1H)	6.04 (d, J = 12.7 Hz, 1H)
5.99 (m, 1H)	6.00-5.95 (m, 2H)
5.96 (m, 1H)	
5.70 (ddd, <i>J</i> =8.5, 2.0, 2.0 Hz, 1H)	5.69 (d, J = 8.6 Hz, 1H)
5.56 (br dm, $J = 13.2$ Hz, 1H)	5.55 (d, J = 8.2 Hz, 1H)
5.10 (br dddd, J = 8.5, 2.0, 2.0, 1.5, 1H)	5.14-5.06 (m, 1H)
5.00 (br dm, $J = 13.2$ Hz, 1H)	5.00 (d, J = 13.1 Hz, 1H)
4.61 (dd, J = 8.5, 2.0 Hz, 1H)	4.60 (dd, J = 8.2, 1.7 Hz, 1H)
4.02 (br ddd, $J = 18.0, 2.5, 1.5$ Hz, 1H)	4.01 (d, <i>J</i> = 18.3 Hz, 1H)
3.81 (dm, J = 18.5 Hz, 1H)	3.80 (d, J = 18.1 Hz, 1H)
2.99 (ddd, J = 18.0, 2.0, 2.0 Hz, 1H)	2.99 (d, J = 18.2 Hz, 1H)
2.88(br dd, J = 18.5, 1.5)	2.87 (d, J = 17.9 Hz, 1H)
2.15 (s, 3H)	2.14 (s, 3H)
2.03 (s, 3H)	2.03 (s, 3H)

Table 4.1. Comparison of ¹H NMR data for natural vs. synthetic (–)-acetylapoaranotin (**300**)

Table	4.2.	Comparison	of	¹³ C	NMR	data	for	natural	VS.	synthetic	(—)-
acetyla	ipoara	notin (300)									

Yang et al. Report, ²⁰	This Work,	Chemical Shift Difference,
Natural (–)-	Synthetic (–)-	$\Delta\delta$
acetylapoaranotin	acetylapoaranotin	
13 C NMR, 126 MHz, CDCl ₃	13 C NMR, 101 MHz, CDCl ₃	
δ 170.5	δ 170.5	0.0
170.0	169.9	0.1
163.1	163.1	0.0
162.2	162.2	0.0
141.2	141.1	0.1
139.2	139.2	0.0
132.2	132.2	0.0
127.8	127.8	0.0
124.5	124.5	0.0
119.9	119.9	0.0
113.4	113.4	0.0
105.3	105.3	0.0
78.2	78.2	0.0
75.9	75.9	0.0
73.9	73.9	0.0
69.8	69.8	0.0
64.5	64.5	0.0
62.9	62.8	0.1
36.1	36.1	0.0
34.5	34.5	0.0
21.3	21.3	0.0
21.0	20.9	0.1
4.5 NOTES AND REFERENCES

(1) Gardiner, D. M.; Waring, P.; Howlett, B. J. *Microbiology* **2005**, *151*, 1021.

(2) Nicolaou, K. C.; Lu, M.; Totokotsopoulos, S.; Heretsch, P.; Giguère, D.; Sun, Y.-P.; Sarlah, D.; Nguyen, T. H.; Wolf, I. C.; Smee, D. F.; Day, C. W.; Bopp, S.; Winzeler, E. A. J. Am. Chem. Soc. **2012**, *134*, 17320.

(3) Boyer, N.; Morrison, K. C.; Kim, J.; Hergenrother, P. J.; Movassaghi, M. *Chem. Sci.* **2013**, *4*, 1646.

(4) Codelli, J. A.; Puchlopek, A. L. A.; Reisman, S. E. J. Am. Chem. Soc. **2011**, *134*, 1930.

(5) Scharf, D. H.; Remme, N.; Habel, A.; Chankhamjon, P.; Scherlach, K.; Heinekamp, T.; Hortschansky, P.; Brakhage, A. A.; Hertweck, C. *J. Am. Chem. Soc.* **2011**, *133*, 12322.

(6) Scharf, D. H.; Chankhamjon, P.; Scherlach, K.; Heinekamp, T.; Willing, K.; Brakhage, A. A.; Hertweck, C. *Angew. Chem. Int. Ed.* **2013**, *52*, 11092.

(7) Scharf, D. H.; Groll, M.; Habel, A.; Heinekamp, T.; Hertweck, C.; Brakhage, A. A.; Huber, E. M. *Angew. Chem. Int. Ed.* **2014**, *53*, 2221.

(8) Davis, C.; Carberry, S.; Schrettl, M.; Singh, I.; Stephens, John C.; Barry, Sarah M.; Kavanagh, K.; Challis, Gregory L.; Brougham, D.; Doyle, S. *Chem. Biol.* **2011**, *18*, 542.

(9) Welch, T. R.; Williams, R. M. Nat. Prod. Rep. 2014, 31, 1376.

(10) Fukuyama, T.; Kishi, Y. J. Am. Chem. Soc. 1976, 98, 6723.

(11) Kim, J.; Ashenhurst, J. A.; Movassaghi, M. Science 2009, 324, 238.

(12) Nicolaou, K. C.; Totokotsopoulos, S.; Giguère, D.; Sun, Y.-P.; Sarlah, D. J. Am. Chem. Soc. 2011, 133, 8150.

(13) Henninger, T. C.; Sabat, M.; Sundberg, R. J. *Tetrahedron* **1996**, *52*, 14403.

(14) Wipf, P.; Kim, Y. Tetrahedron Lett. 1992, 33, 5477.

(15) Nicolaou, K. C.; Giguère, D.; Totokotsopoulos, S.; Sun, Y.-P. Angew. Chem. Int. Ed. 2012, 51, 728.

(16) Gross, U.; Nieger, M.; Bräse, S. Chem. Eur. J. 2010, 16, 11624.

(17) Kim, H. Y.; Shih, H.-J.; Knabe, W. E.; Oh, K. Angew. Chem. Int. Ed. **2009**, *48*, 7420.

(18) Fujiwara, H.; Kurogi, T.; Okaya, S.; Okano, K.; Tokuyama, H. Angew. Chem. Int. Ed. 2012, 51, 13062.

(19) Nicolaou, K. C.; Estrada, A. A.; Zak, M.; Lee, S. H.; Safina, B. S. Angew. Chem. Int. Ed. 2005, 44, 1378.

(20) Choi, E. J.; Park, J. S.; Kim, Y. J.; Jung, J. H.; Lee, J. K.; Kwon, H. C.; Yang, H. O. *J. Appl. Microbiol.* **2011**, *110*, 304.

(21) Still, W. C.; Kahn, M.; Mitra, A. J. Org. Chem. 1978, 43, 2923.

Appendix 4

Spectra Relevant to Chapter 4: Enantioselective Total Synthesis of Epidithiodiketopiperazine Natural Product (–)-Acetylapoaranotin



















WHX-7-177-F-Siena-CD3CN


















































































mdd

9.72 **0**

_ <u>60.6</u>



























ABOUT THE AUTHOR

Haoxuan Wang was born on November 27th, 1988, the year of the dragon, to Jian Wang and Nili Li in Huangshaping, a small town located in southern China, where his family still lives.

His interest in chemistry was first embarked upon when he decided to study science subjects in high school in China, which seemed to be the easiest course for him compared to math and physics. After high school, he got admitted to Fudan University as a chemistry major. Though he enjoyed learning chemistry, his first option when applying for undergraduate school was actually to become a doctor, something upon which his family insisted.

He got introduced to research in the laboratory of Professor Zhengwen Fu, where he studied the electrochemical properties of thin-film electrode materials. He later had the chance to join the laboratory of Professor Neil K. Garg for the summer of 2009, where he learned a lot about organic chemistry research by carrying through first nine steps of the synthetic route toward the natural product (–)-*N*-methylwelwitindolinone C isothiocyanate. It is this experience that got him captivated with organic chemistry, and he decided to pursue graduate school to learn more about this area.

After his experience at Fudan University, he moved across the Pacific and started his PhD studies under the guidance of Professor Sarah E. Reisman at the California Institute of Technology. He has been studying the total synthesis of several diketopiperazine-containing natural products. In the summer of 2015, he chooses to "abandon" the wonderful weather in California and move eastward to the Buchwald laboratory at the Massachusetts Institute of Technology as a postdoctoral fellow.